US20090253654A1 - Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment - Google Patents
Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment Download PDFInfo
- Publication number
- US20090253654A1 US20090253654A1 US12/422,901 US42290109A US2009253654A1 US 20090253654 A1 US20090253654 A1 US 20090253654A1 US 42290109 A US42290109 A US 42290109A US 2009253654 A1 US2009253654 A1 US 2009253654A1
- Authority
- US
- United States
- Prior art keywords
- alkyl
- oco
- galantamine
- bond
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 230000008499 blood brain barrier function Effects 0.000 title claims abstract description 65
- 210000001218 blood-brain barrier Anatomy 0.000 title claims abstract description 65
- 230000035699 permeability Effects 0.000 title claims abstract description 15
- 238000011282 treatment Methods 0.000 title claims description 35
- 230000001713 cholinergic effect Effects 0.000 title claims description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims description 17
- 201000010099 disease Diseases 0.000 title claims description 16
- 239000003623 enhancer Substances 0.000 title claims description 14
- 230000001976 improved effect Effects 0.000 title claims description 9
- 208000010877 cognitive disease Diseases 0.000 title description 6
- 208000028698 Cognitive impairment Diseases 0.000 title description 2
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims abstract description 332
- 150000001875 compounds Chemical class 0.000 claims abstract description 206
- 229960003980 galantamine Drugs 0.000 claims abstract description 186
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims abstract description 154
- 239000003814 drug Substances 0.000 claims abstract description 68
- 239000000651 prodrug Substances 0.000 claims abstract description 53
- 229940002612 prodrug Drugs 0.000 claims abstract description 53
- 239000000544 cholinesterase inhibitor Substances 0.000 claims abstract description 17
- QENVUHCAYXAROT-UHFFFAOYSA-N Galanthaminon Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(=O)C=C2 QENVUHCAYXAROT-UHFFFAOYSA-N 0.000 claims abstract description 15
- QENVUHCAYXAROT-YOEHRIQHSA-N Narwedine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1CC(=O)C=C2 QENVUHCAYXAROT-YOEHRIQHSA-N 0.000 claims abstract description 14
- WCRYNEMFWLZAAZ-WMLDXEAASA-N Narwedine Natural products COc1ccc2CCCC[C@@]34C=CC(=O)C[C@@H]3Oc1c24 WCRYNEMFWLZAAZ-WMLDXEAASA-N 0.000 claims abstract description 14
- GJRMHIXYLGOZSE-JDFRZJQESA-N 1,2-Dihydrogalanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)CC2 GJRMHIXYLGOZSE-JDFRZJQESA-N 0.000 claims abstract description 12
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 claims abstract description 12
- 239000004090 neuroprotective agent Substances 0.000 claims abstract description 6
- 210000004556 brain Anatomy 0.000 claims description 95
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 50
- 229940079593 drug Drugs 0.000 claims description 49
- -1 3-dihydropyridyl Chemical group 0.000 claims description 41
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 29
- 208000024827 Alzheimer disease Diseases 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 24
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical group OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 20
- AIXQQSTVOSFSMO-RBOXIYTFSA-N Norgalanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CNCC[C@]23[C@@H]1C[C@@H](O)C=C2 AIXQQSTVOSFSMO-RBOXIYTFSA-N 0.000 claims description 20
- 235000000346 sugar Nutrition 0.000 claims description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 18
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 18
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 230000006735 deficit Effects 0.000 claims description 14
- 229910052757 nitrogen Inorganic materials 0.000 claims description 14
- 229940122041 Cholinesterase inhibitor Drugs 0.000 claims description 11
- PFRVZQKEOAYKSC-DXJCSPRDSA-N Leucotamine Natural products O=C(O[C@H]1C=C[C@]23[C@@H](Oc4c(O)ccc(c24)CN(C)CC3)C1)C[C@@H](O)C PFRVZQKEOAYKSC-DXJCSPRDSA-N 0.000 claims description 11
- OYSGWKOGUVOGFQ-RBOXIYTFSA-N Sanguinine Chemical compound O1C(C(=CC=2)O)=C3C=2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 OYSGWKOGUVOGFQ-RBOXIYTFSA-N 0.000 claims description 11
- 206010002091 Anaesthesia Diseases 0.000 claims description 10
- 206010012218 Delirium Diseases 0.000 claims description 10
- OYSGWKOGUVOGFQ-UHFFFAOYSA-N O-demethylgalanthamine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(O)C=C2 OYSGWKOGUVOGFQ-UHFFFAOYSA-N 0.000 claims description 10
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical class C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 10
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical class C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 10
- 230000037005 anaesthesia Effects 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 10
- 235000001968 nicotinic acid Nutrition 0.000 claims description 10
- 229960003512 nicotinic acid Drugs 0.000 claims description 10
- 239000011664 nicotinic acid Substances 0.000 claims description 10
- 230000002980 postoperative effect Effects 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 9
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 9
- 229910002651 NO3 Inorganic materials 0.000 claims description 9
- 208000018737 Parkinson disease Diseases 0.000 claims description 9
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 9
- 150000001413 amino acids Chemical class 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 9
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 150000003839 salts Chemical class 0.000 claims description 9
- 229920006395 saturated elastomer Polymers 0.000 claims description 9
- 201000000980 schizophrenia Diseases 0.000 claims description 9
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical class O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 claims description 8
- 206010021143 Hypoxia Diseases 0.000 claims description 8
- UAJBMQOTHJIJOI-UHFFFAOYSA-N N-desmethylsanguinine Natural products O1C(C(=CC=2)O)=C3C=2CNCCC23C1CC(O)C=C2 UAJBMQOTHJIJOI-UHFFFAOYSA-N 0.000 claims description 8
- UAJBMQOTHJIJOI-WBIUFABUSA-N Norsanguinine Chemical compound O1C(C(=CC=2)O)=C3C=2CNCC[C@]23[C@@H]1C[C@@H](O)C=C2 UAJBMQOTHJIJOI-WBIUFABUSA-N 0.000 claims description 8
- 206010015037 epilepsy Diseases 0.000 claims description 8
- 125000001072 heteroaryl group Chemical group 0.000 claims description 8
- 208000020016 psychiatric disease Diseases 0.000 claims description 8
- 125000001424 substituent group Chemical group 0.000 claims description 8
- 208000012902 Nervous system disease Diseases 0.000 claims description 7
- 208000025966 Neurological disease Diseases 0.000 claims description 7
- SPGYGGXZMAHIKN-UHFFFAOYSA-N O-Demethyllycoramine Natural products CN1CCC23CCC(O)CC2Oc4c(O)ccc(C1)c34 SPGYGGXZMAHIKN-UHFFFAOYSA-N 0.000 claims description 7
- 125000003545 alkoxy group Chemical group 0.000 claims description 7
- 229910052794 bromium Inorganic materials 0.000 claims description 7
- 238000009826 distribution Methods 0.000 claims description 7
- 229910052731 fluorine Inorganic materials 0.000 claims description 7
- PWKNBLFSJAVFAB-UHFFFAOYSA-N 1-fluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC=CC=C1F PWKNBLFSJAVFAB-UHFFFAOYSA-N 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 6
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical class C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 150000001555 benzenes Chemical class 0.000 claims description 6
- 230000004048 modification Effects 0.000 claims description 6
- 238000012986 modification Methods 0.000 claims description 6
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical group FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 claims description 6
- 230000004770 neurodegeneration Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 230000000626 neurodegenerative effect Effects 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 231100000572 poisoning Toxicity 0.000 claims description 6
- 230000000607 poisoning effect Effects 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 208000007848 Alcoholism Diseases 0.000 claims description 5
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
- 206010057852 Nicotine dependence Diseases 0.000 claims description 5
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical class C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 claims description 5
- 229910019142 PO4 Inorganic materials 0.000 claims description 5
- 208000000474 Poliomyelitis Diseases 0.000 claims description 5
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 claims description 5
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical class C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 5
- 125000003282 alkyl amino group Chemical group 0.000 claims description 5
- 229910052801 chlorine Inorganic materials 0.000 claims description 5
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 claims description 5
- 229910052740 iodine Inorganic materials 0.000 claims description 5
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- 239000003176 neuroleptic agent Substances 0.000 claims description 5
- 230000000701 neuroleptic effect Effects 0.000 claims description 5
- 239000001301 oxygen Substances 0.000 claims description 5
- 238000001959 radiotherapy Methods 0.000 claims description 5
- 229930192474 thiophene Chemical class 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- WZRJTRPJURQBRM-UHFFFAOYSA-N 4-amino-n-(5-methyl-1,2-oxazol-3-yl)benzenesulfonamide;5-[(3,4,5-trimethoxyphenyl)methyl]pyrimidine-2,4-diamine Chemical group O1C(C)=CC(NS(=O)(=O)C=2C=CC(N)=CC=2)=N1.COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 WZRJTRPJURQBRM-UHFFFAOYSA-N 0.000 claims description 4
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims description 4
- 206010002660 Anoxia Diseases 0.000 claims description 4
- 241000976983 Anoxia Species 0.000 claims description 4
- 206010003497 Asphyxia Diseases 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 4
- 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 claims description 4
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical group NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 claims description 4
- 208000010496 Heart Arrest Diseases 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 4
- 229910003204 NH2 Inorganic materials 0.000 claims description 4
- 206010029240 Neuritis Diseases 0.000 claims description 4
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 claims description 4
- 208000029033 Spinal Cord disease Diseases 0.000 claims description 4
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 150000001450 anions Chemical class 0.000 claims description 4
- 230000007953 anoxia Effects 0.000 claims description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 4
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 claims description 4
- 125000004925 dihydropyridyl group Chemical group N1(CC=CC=C1)* 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 4
- 230000007954 hypoxia Effects 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 208000004296 neuralgia Diseases 0.000 claims description 4
- 208000021722 neuropathic pain Diseases 0.000 claims description 4
- JCXJVPUVTGWSNB-UHFFFAOYSA-N nitrogen dioxide Inorganic materials O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 4
- 235000018343 nutrient deficiency Nutrition 0.000 claims description 4
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 claims description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims description 4
- 239000010452 phosphate Substances 0.000 claims description 4
- LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 claims description 4
- 125000004076 pyridyl group Chemical group 0.000 claims description 4
- 102220067365 rs143592561 Human genes 0.000 claims description 4
- 102220012898 rs397516346 Human genes 0.000 claims description 4
- 229910021653 sulphate ion Inorganic materials 0.000 claims description 4
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 claims description 3
- 208000021642 Muscular disease Diseases 0.000 claims description 3
- 201000009623 Myopathy Diseases 0.000 claims description 3
- YDTYNIAJZIKMST-BBRMVZONSA-N N-Demethylnarwedine Chemical compound O1C(=C23)C(OC)=CC=C2CNCC[C@]23[C@@H]1CC(=O)C=C2 YDTYNIAJZIKMST-BBRMVZONSA-N 0.000 claims description 3
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 claims description 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 2
- 206010003805 Autism Diseases 0.000 claims description 2
- 208000020706 Autistic disease Diseases 0.000 claims description 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 2
- 229910052736 halogen Inorganic materials 0.000 claims description 2
- 150000002367 halogens Chemical class 0.000 claims description 2
- 125000003107 substituted aryl group Chemical group 0.000 claims description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical group O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 claims 8
- 239000000064 cholinergic agonist Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000001650 transport into the brain Effects 0.000 claims 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 14
- 108010009685 Cholinergic Receptors Proteins 0.000 abstract description 13
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 abstract description 11
- 229960004373 acetylcholine Drugs 0.000 abstract description 11
- 239000000126 substance Substances 0.000 abstract description 10
- 230000002255 enzymatic effect Effects 0.000 abstract description 9
- 230000001537 neural effect Effects 0.000 abstract description 7
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 239000002207 metabolite Substances 0.000 abstract description 6
- 229930013930 alkaloid Natural products 0.000 abstract description 4
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 abstract description 4
- 229960001231 choline Drugs 0.000 abstract description 4
- 241000234270 Amaryllidaceae Species 0.000 abstract description 3
- 239000000556 agonist Substances 0.000 abstract description 3
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 3
- 230000007062 hydrolysis Effects 0.000 abstract description 2
- 229930014626 natural product Natural products 0.000 abstract description 2
- 230000035945 sensitivity Effects 0.000 abstract description 2
- 102000034337 acetylcholine receptors Human genes 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 97
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 72
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 58
- 230000000694 effects Effects 0.000 description 54
- 239000000243 solution Substances 0.000 description 46
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 44
- 239000002585 base Substances 0.000 description 37
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- 239000000047 product Substances 0.000 description 33
- 241001465754 Metazoa Species 0.000 description 31
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 29
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 29
- 239000003795 chemical substances by application Substances 0.000 description 29
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 27
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 27
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 26
- 239000008280 blood Substances 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 25
- 102000003914 Cholinesterases Human genes 0.000 description 25
- 108090000322 Cholinesterases Proteins 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 25
- 238000012360 testing method Methods 0.000 description 25
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 24
- JKVNJTYHRABHIY-WXVUKLJWSA-N [(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-yl] benzoate Chemical compound O([C@H]1C=C[C@]23CCN(C)CC4=CC=C(C(O[C@H]2C1)=C43)OC)C(=O)C1=CC=CC=C1 JKVNJTYHRABHIY-WXVUKLJWSA-N 0.000 description 24
- 229940126321 benzgalantamine Drugs 0.000 description 24
- 150000002148 esters Chemical class 0.000 description 24
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 23
- 230000035515 penetration Effects 0.000 description 23
- 239000000203 mixture Substances 0.000 description 22
- 210000004369 blood Anatomy 0.000 description 21
- 241000282414 Homo sapiens Species 0.000 description 19
- 239000002904 solvent Substances 0.000 description 18
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 238000004128 high performance liquid chromatography Methods 0.000 description 17
- 230000002829 reductive effect Effects 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 16
- 239000011541 reaction mixture Substances 0.000 description 16
- 0 *N1([4*])CCC23CC[C@@H]([1*])CC2OC2=C3C(=C([3*])C=C2O[2*])C1 Chemical compound *N1([4*])CCC23CC[C@@H]([1*])CC2OC2=C3C(=C([3*])C=C2O[2*])C1 0.000 description 15
- 239000011780 sodium chloride Substances 0.000 description 14
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 13
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 13
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 13
- 230000015572 biosynthetic process Effects 0.000 description 13
- 239000012043 crude product Substances 0.000 description 13
- 239000007787 solid Substances 0.000 description 13
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 12
- 102000009660 Cholinergic Receptors Human genes 0.000 description 12
- 241000699670 Mus sp. Species 0.000 description 12
- 230000001965 increasing effect Effects 0.000 description 12
- 239000000377 silicon dioxide Substances 0.000 description 12
- 230000001225 therapeutic effect Effects 0.000 description 12
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 11
- 208000014644 Brain disease Diseases 0.000 description 11
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 11
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 11
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 11
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 11
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 11
- 229910021529 ammonia Inorganic materials 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 11
- 229960002646 scopolamine Drugs 0.000 description 11
- 239000000725 suspension Substances 0.000 description 11
- ZWCQCWGXEZSYBY-UHFFFAOYSA-N 2-fluoro-5-hydroxy-4-methoxybenzaldehyde Chemical compound COC1=CC(F)=C(C=O)C=C1O ZWCQCWGXEZSYBY-UHFFFAOYSA-N 0.000 description 10
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 10
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 10
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 10
- 239000000872 buffer Substances 0.000 description 10
- 210000003169 central nervous system Anatomy 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 238000007912 intraperitoneal administration Methods 0.000 description 10
- 239000003921 oil Substances 0.000 description 10
- 238000011084 recovery Methods 0.000 description 10
- 229910052938 sodium sulfate Inorganic materials 0.000 description 10
- 241000700159 Rattus Species 0.000 description 9
- 230000002411 adverse Effects 0.000 description 9
- 230000003281 allosteric effect Effects 0.000 description 9
- 210000004027 cell Anatomy 0.000 description 9
- 238000007385 chemical modification Methods 0.000 description 9
- 239000003112 inhibitor Substances 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical group OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 241000906446 Theraps Species 0.000 description 8
- 230000009471 action Effects 0.000 description 8
- 239000013078 crystal Substances 0.000 description 8
- 229940088598 enzyme Drugs 0.000 description 8
- 230000003389 potentiating effect Effects 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000001235 sensitizing effect Effects 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 241000282339 Mustela Species 0.000 description 7
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 7
- 229940024606 amino acid Drugs 0.000 description 7
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000008346 aqueous phase Substances 0.000 description 7
- 230000006399 behavior Effects 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000001914 filtration Methods 0.000 description 7
- QMJBABNQGXMIRU-UHFFFAOYSA-N n-[(2-fluoro-5-hydroxy-4-methoxyphenyl)methyl]-n-[2-(4-hydroxyphenyl)ethyl]formamide Chemical compound C1=C(O)C(OC)=CC(F)=C1CN(C=O)CCC1=CC=C(O)C=C1 QMJBABNQGXMIRU-UHFFFAOYSA-N 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 230000002093 peripheral effect Effects 0.000 description 7
- 239000002244 precipitate Substances 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- VIBBSEDFRPBTLD-UHFFFAOYSA-N 4-fluoro-5-[[2-(4-hydroxyphenyl)ethylamino]methyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC(F)=C1CNCCC1=CC=C(O)C=C1 VIBBSEDFRPBTLD-UHFFFAOYSA-N 0.000 description 6
- WVNSFKGDKALLKW-UHFFFAOYSA-N 7'-bromo-9'-methoxyspiro[1,3-dioxolane-2,14'-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6,8,10(17),15-tetraene]-4'-carbaldehyde Chemical compound C1C2OC(=C34)C(OC)=CC(Br)=C3CN(C=O)CCC24C=CC21OCCO2 WVNSFKGDKALLKW-UHFFFAOYSA-N 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 6
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- 238000010171 animal model Methods 0.000 description 6
- 229910052786 argon Inorganic materials 0.000 description 6
- 238000001212 derivatisation Methods 0.000 description 6
- 238000000605 extraction Methods 0.000 description 6
- 230000002496 gastric effect Effects 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- CCIDTXJAPRZHSL-BXIXQQKLSA-N methyl (2s,3s,4s,5r,6r)-3,4,5-tris(2-methylpropanoyloxy)-6-(2,2,2-trichloroethanimidoyl)oxyoxane-2-carboxylate Chemical compound COC(=O)[C@H]1O[C@H](OC(=N)C(Cl)(Cl)Cl)[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C CCIDTXJAPRZHSL-BXIXQQKLSA-N 0.000 description 6
- 230000000324 neuroprotective effect Effects 0.000 description 6
- 238000003908 quality control method Methods 0.000 description 6
- 239000000758 substrate Substances 0.000 description 6
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 5
- HOQSTFVMSMWXFJ-DHSIGJKJSA-N (3r,4as,9bs)-9-[(dimethylamino)methyl]-9b-ethenyl-6-methoxy-4,4a-dihydro-3h-dibenzofuran-3-ol Chemical compound C([C@@H]1O2)[C@@H](O)C=C[C@@]1(C=C)C1=C2C(OC)=CC=C1CN(C)C HOQSTFVMSMWXFJ-DHSIGJKJSA-N 0.000 description 5
- 102100033639 Acetylcholinesterase Human genes 0.000 description 5
- 206010008531 Chills Diseases 0.000 description 5
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 5
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 5
- 206010047700 Vomiting Diseases 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- 230000004913 activation Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000021615 conjugation Effects 0.000 description 5
- 238000007876 drug discovery Methods 0.000 description 5
- 238000001704 evaporation Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- QORVDGQLPPAFRS-XPSHAMGMSA-N galantamine hydrobromide Chemical compound Br.O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 QORVDGQLPPAFRS-XPSHAMGMSA-N 0.000 description 5
- 238000003384 imaging method Methods 0.000 description 5
- 229960002715 nicotine Drugs 0.000 description 5
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 5
- 238000005192 partition Methods 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 210000002381 plasma Anatomy 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 5
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 5
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 4
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 4
- 108010022752 Acetylcholinesterase Proteins 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 4
- 208000031091 Amnestic disease Diseases 0.000 description 4
- 108090000371 Esterases Proteins 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 238000009825 accumulation Methods 0.000 description 4
- 229940022698 acetylcholinesterase Drugs 0.000 description 4
- 230000006986 amnesia Effects 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 239000000812 cholinergic antagonist Substances 0.000 description 4
- 229940048961 cholinesterase Drugs 0.000 description 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid group Chemical group C(CC(O)(C(=O)O)CC(=O)O)(=O)O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- ADEBPBSSDYVVLD-UHFFFAOYSA-N donepezil Chemical compound O=C1C=2C=C(OC)C(OC)=CC=2CC1CC(CC1)CCN1CC1=CC=CC=C1 ADEBPBSSDYVVLD-UHFFFAOYSA-N 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 206010027175 memory impairment Diseases 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 238000010992 reflux Methods 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 235000011152 sodium sulphate Nutrition 0.000 description 4
- 238000001665 trituration Methods 0.000 description 4
- 230000008673 vomiting Effects 0.000 description 4
- XQEOZRYPRISEMY-DHSIGJKJSA-N (3r,4as,9bs)-9-[(dimethylamino)methyl]-9b-ethyl-6-methoxy-4,4a-dihydro-3h-dibenzofuran-3-ol Chemical compound CN(C)CC1=CC=C(OC)C2=C1[C@]1(CC)C=C[C@H](O)C[C@@H]1O2 XQEOZRYPRISEMY-DHSIGJKJSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 3
- GFFIJCYHQYHUHB-UHFFFAOYSA-N 2-acetylsulfanylethyl(trimethyl)azanium Chemical compound CC(=O)SCC[N+](C)(C)C GFFIJCYHQYHUHB-UHFFFAOYSA-N 0.000 description 3
- QDGAVODICPCDMU-UHFFFAOYSA-N 2-amino-3-[3-[bis(2-chloroethyl)amino]phenyl]propanoic acid Chemical compound OC(=O)C(N)CC1=CC=CC(N(CCCl)CCCl)=C1 QDGAVODICPCDMU-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- 239000007995 HEPES buffer Substances 0.000 description 3
- 208000026139 Memory disease Diseases 0.000 description 3
- 208000005374 Poisoning Diseases 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- 206010039424 Salivary hypersecretion Diseases 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000003542 behavioural effect Effects 0.000 description 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 3
- 238000004364 calculation method Methods 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 229910052681 coesite Inorganic materials 0.000 description 3
- 229910052906 cristobalite Inorganic materials 0.000 description 3
- 238000010511 deprotection reaction Methods 0.000 description 3
- 229960004132 diethyl ether Drugs 0.000 description 3
- 239000002895 emetic Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 229940097043 glucuronic acid Drugs 0.000 description 3
- 229930182480 glucuronide Natural products 0.000 description 3
- 150000008134 glucuronides Chemical class 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229910001629 magnesium chloride Inorganic materials 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 3
- AUBWOCDKQXZRRC-BXIXQQKLSA-N methyl (2s,3s,4s,5r,6r)-6-hydroxy-3,4,5-tris(2-methylpropanoyloxy)oxane-2-carboxylate Chemical compound COC(=O)[C@H]1O[C@@H](O)[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C AUBWOCDKQXZRRC-BXIXQQKLSA-N 0.000 description 3
- IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 description 3
- 229960002237 metoprolol Drugs 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000021317 phosphate Nutrition 0.000 description 3
- 229960004063 propylene glycol Drugs 0.000 description 3
- 235000013772 propylene glycol Nutrition 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 208000026451 salivation Diseases 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 229910052682 stishovite Inorganic materials 0.000 description 3
- 229960004793 sucrose Drugs 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 description 3
- 229910052905 tridymite Inorganic materials 0.000 description 3
- 229940086542 triethylamine Drugs 0.000 description 3
- 239000003039 volatile agent Substances 0.000 description 3
- ZYJPUMXJBDHSIF-NSHDSACASA-N (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZYJPUMXJBDHSIF-NSHDSACASA-N 0.000 description 2
- DZVCTRGYUYGVLO-RVSPLBMKSA-N (3r,4as,9bs)-9b-ethenyl-6-methoxy-9-(methylaminomethyl)-4,4a-dihydro-3h-dibenzofuran-3-ol Chemical compound C([C@@H]1O2)[C@@H](O)C=C[C@@]1(C=C)C1=C2C(OC)=CC=C1CNC DZVCTRGYUYGVLO-RVSPLBMKSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 2
- HHEMQQWULBJWLK-UHFFFAOYSA-N 1h-1-benzazepin-6-ol Chemical compound N1C=CC=CC2=C1C=CC=C2O HHEMQQWULBJWLK-UHFFFAOYSA-N 0.000 description 2
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 2
- VPHHJAOJUJHJKD-UHFFFAOYSA-M 3,4-dichlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C(Cl)=C1 VPHHJAOJUJHJKD-UHFFFAOYSA-M 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- IXHPIPUIOSSAIS-LLVKDONJSA-N CC(C)(C)OC(=O)N[C@H](CC1=CN(C(=O)OC(C)(C)C)C=N1)C(=O)O Chemical compound CC(C)(C)OC(=O)N[C@H](CC1=CN(C(=O)OC(C)(C)C)C=N1)C(=O)O IXHPIPUIOSSAIS-LLVKDONJSA-N 0.000 description 2
- GCVXOCHKVIUBHL-UHFFFAOYSA-N COC1=CC=C2CN(C)CCC34C=CC(OC(=O)CNC(=O)OC(C)(C)C)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CCC34C=CC(OC(=O)CNC(=O)OC(C)(C)C)CC3OC1=C24 GCVXOCHKVIUBHL-UHFFFAOYSA-N 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- XJUZRXYOEPSWMB-UHFFFAOYSA-N Chloromethyl methyl ether Chemical compound COCCl XJUZRXYOEPSWMB-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000234271 Galanthus Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000234479 Narcissus Species 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 229910003849 O-Si Inorganic materials 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 229910003872 O—Si Inorganic materials 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102000007562 Serum Albumin Human genes 0.000 description 2
- 108010071390 Serum Albumin Proteins 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 2
- 201000004810 Vascular dementia Diseases 0.000 description 2
- SPHFAGSLUFUPQA-RLUMKZHBSA-N [(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-yl] (2S)-2-amino-3-(1H-imidazol-5-yl)propanoate hydrochloride Chemical compound Cl.C([C@H](N)C(=O)O[C@H]1C=C[C@]23CCN(C)CC4=CC=C(C(O[C@H]2C1)=C43)OC)C1=CNC=N1 SPHFAGSLUFUPQA-RLUMKZHBSA-N 0.000 description 2
- NXQBXMFNMFILEY-SNLAVWLJSA-N [(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.01,12.06,17]heptadeca-6(17),7,9,15-tetraen-14-yl] (2S)-2-amino-3-(4-hydroxyphenyl)propanoate Chemical compound C([C@H](N)C(=O)O[C@H]1C=C[C@]23CCN(C)CC4=CC=C(C(O[C@H]2C1)=C43)OC)C1=CC=C(O)C=C1 NXQBXMFNMFILEY-SNLAVWLJSA-N 0.000 description 2
- RKDUGVAEUREEIO-RVSPLBMKSA-N [H][C@]12C[C@@H](O)C=C[C@@]1(CC)C1=C(O2)C(OC)=CC=C1CNC Chemical compound [H][C@]12C[C@@H](O)C=C[C@@]1(CC)C1=C(O2)C(OC)=CC=C1CNC RKDUGVAEUREEIO-RVSPLBMKSA-N 0.000 description 2
- JKCHRKZPPIADIY-LTMIRXACSA-N [H][C@]12C[C@@H](OC(=O)C3=CN=CC=C3)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(=O)C3=CN=CC=C3)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 JKCHRKZPPIADIY-LTMIRXACSA-N 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 125000001246 bromo group Chemical group Br* 0.000 description 2
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 2
- 239000001110 calcium chloride Substances 0.000 description 2
- 229910001628 calcium chloride Inorganic materials 0.000 description 2
- 235000011089 carbon dioxide Nutrition 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940112822 chewing gum Drugs 0.000 description 2
- 235000015218 chewing gum Nutrition 0.000 description 2
- 125000001309 chloro group Chemical group Cl* 0.000 description 2
- 229940061627 chloromethyl methyl ether Drugs 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000019771 cognition Effects 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000000205 computational method Methods 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000008025 crystallization Effects 0.000 description 2
- 125000006165 cyclic alkyl group Chemical group 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Chemical class OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 2
- 229960003530 donepezil Drugs 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 229960001484 edetic acid Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000000193 eyeblink Effects 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 125000001153 fluoro group Chemical group F* 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229960002024 galantamine hydrobromide Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 239000012362 glacial acetic acid Substances 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940097042 glucuronate Drugs 0.000 description 2
- 229930195712 glutamate Natural products 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 125000004970 halomethyl group Chemical group 0.000 description 2
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 229960002591 hydroxyproline Drugs 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000006662 intracellular pathway Effects 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 125000002346 iodo group Chemical group I* 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007334 memory performance Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- AUBWOCDKQXZRRC-PQZNDWDZSA-N methyl (2s,3s,4s,5r)-6-hydroxy-3,4,5-tris(2-methylpropanoyloxy)oxane-2-carboxylate Chemical compound COC(=O)[C@H]1OC(O)[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C AUBWOCDKQXZRRC-PQZNDWDZSA-N 0.000 description 2
- RFMOIPHVGPMCMF-UHFFFAOYSA-N methyl 3,4,5,6-tetrakis(2-methylpropanoyloxy)oxane-2-carboxylate Chemical compound COC(=O)C1OC(OC(=O)C(C)C)C(OC(=O)C(C)C)C(OC(=O)C(C)C)C1OC(=O)C(C)C RFMOIPHVGPMCMF-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000003551 muscarinic effect Effects 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 208000018360 neuromuscular disease Diseases 0.000 description 2
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 238000004237 preparative chromatography Methods 0.000 description 2
- VVWRJUBEIPHGQF-UHFFFAOYSA-N propan-2-yl n-propan-2-yloxycarbonyliminocarbamate Chemical compound CC(C)OC(=O)N=NC(=O)OC(C)C VVWRJUBEIPHGQF-UHFFFAOYSA-N 0.000 description 2
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 2
- 230000036632 reaction speed Effects 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Chemical class ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 125000004953 trihalomethyl group Chemical group 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 238000010626 work up procedure Methods 0.000 description 2
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 description 1
- QCGMEWVZBGQOFN-UHFFFAOYSA-N 1,3-oxazole-5-carboxylic acid Chemical compound OC(=O)C1=CN=CO1 QCGMEWVZBGQOFN-UHFFFAOYSA-N 0.000 description 1
- IJVLVRYLIMQVDD-UHFFFAOYSA-M 1,3-thiazole-2-carboxylate Chemical compound [O-]C(=O)C1=NC=CS1 IJVLVRYLIMQVDD-UHFFFAOYSA-M 0.000 description 1
- YZVFSQQHQPPKNX-UHFFFAOYSA-N 1,3-thiazole-5-carboxylic acid Chemical compound OC(=O)C1=CN=CS1 YZVFSQQHQPPKNX-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- QXQAPNSHUJORMC-UHFFFAOYSA-N 1-chloro-4-propylbenzene Chemical compound CCCC1=CC=C(Cl)C=C1 QXQAPNSHUJORMC-UHFFFAOYSA-N 0.000 description 1
- BCFPLUJRJLEPGV-UHFFFAOYSA-N 1-methyl-1,4-dihydropyridin-1-ium-3-carboxylate Chemical compound CN1C=CCC(C(O)=O)=C1 BCFPLUJRJLEPGV-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- NKWCGTOZTHZDHB-UHFFFAOYSA-M 1h-imidazole-5-carboxylate Chemical compound [O-]C(=O)C1=CN=CN1 NKWCGTOZTHZDHB-UHFFFAOYSA-M 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- QLDPCHZQQIASHX-UHFFFAOYSA-N 2,3-dihydroxybutanedioic acid;3-(1-methylpyrrolidin-2-yl)pyridine Chemical compound OC(=O)C(O)C(O)C(O)=O.CN1CCCC1C1=CC=CN=C1 QLDPCHZQQIASHX-UHFFFAOYSA-N 0.000 description 1
- ATCRIUVQKHMXSH-UHFFFAOYSA-M 2,4-dichlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1Cl ATCRIUVQKHMXSH-UHFFFAOYSA-M 0.000 description 1
- NJYBIFYEWYWYAN-UHFFFAOYSA-M 2,4-difluorobenzoate Chemical compound [O-]C(=O)C1=CC=C(F)C=C1F NJYBIFYEWYWYAN-UHFFFAOYSA-M 0.000 description 1
- QVTQYSFCFOGITD-UHFFFAOYSA-M 2,5-dichlorobenzoate Chemical compound [O-]C(=O)C1=CC(Cl)=CC=C1Cl QVTQYSFCFOGITD-UHFFFAOYSA-M 0.000 description 1
- OGLCQHRZUSEXNB-UHFFFAOYSA-N 2-Pinene-9, 10-diol Natural products OC1C(=O)OC2C(O)C(O)OC21 OGLCQHRZUSEXNB-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- IKCLCGXPQILATA-UHFFFAOYSA-M 2-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=CC=C1Cl IKCLCGXPQILATA-UHFFFAOYSA-M 0.000 description 1
- IBBYQNVXKFMSSI-UHFFFAOYSA-N 2-fluoro-4,5-dimethoxybenzaldehyde Chemical compound COC1=CC(F)=C(C=O)C=C1OC IBBYQNVXKFMSSI-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- CXKCZFDUOYMOOP-UHFFFAOYSA-M 3,5-dichlorobenzoate Chemical compound [O-]C(=O)C1=CC(Cl)=CC(Cl)=C1 CXKCZFDUOYMOOP-UHFFFAOYSA-M 0.000 description 1
- NEGFNJRAUMCZMY-UHFFFAOYSA-N 3-(dimethylamino)benzoic acid Chemical compound CN(C)C1=CC=CC(C(O)=O)=C1 NEGFNJRAUMCZMY-UHFFFAOYSA-N 0.000 description 1
- FQXQBFUUVCDIRK-UHFFFAOYSA-M 3-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC=CC(C(F)(F)F)=C1 FQXQBFUUVCDIRK-UHFFFAOYSA-M 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-M 3-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-M 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- AFPHTEQTJZKQAQ-UHFFFAOYSA-M 3-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=CC([N+]([O-])=O)=C1 AFPHTEQTJZKQAQ-UHFFFAOYSA-M 0.000 description 1
- IQXJWOLTFBRYOK-UHFFFAOYSA-N 4-(dimethylamino)-3-methylbenzoic acid Chemical compound CN(C)C1=CC=C(C(O)=O)C=C1C IQXJWOLTFBRYOK-UHFFFAOYSA-N 0.000 description 1
- YDIYEOMDOWUDTJ-UHFFFAOYSA-M 4-(dimethylamino)benzoate Chemical compound CN(C)C1=CC=C(C([O-])=O)C=C1 YDIYEOMDOWUDTJ-UHFFFAOYSA-M 0.000 description 1
- SWKPKONEIZGROQ-UHFFFAOYSA-M 4-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC=C(C(F)(F)F)C=C1 SWKPKONEIZGROQ-UHFFFAOYSA-M 0.000 description 1
- QBHDSQZASIBAAI-UHFFFAOYSA-N 4-acetylbenzoic acid Chemical compound CC(=O)C1=CC=C(C(O)=O)C=C1 QBHDSQZASIBAAI-UHFFFAOYSA-N 0.000 description 1
- 229940086681 4-aminobenzoate Drugs 0.000 description 1
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 1
- PPHHAZOVVZBSCM-UHFFFAOYSA-M 4-chloro-3-(trifluoromethyl)benzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C(C(F)(F)F)=C1 PPHHAZOVVZBSCM-UHFFFAOYSA-M 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-M 4-chlorobenzoate Chemical compound [O-]C(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-M 0.000 description 1
- BBYDXOIZLAWGSL-UHFFFAOYSA-M 4-fluorobenzoate Chemical compound [O-]C(=O)C1=CC=C(F)C=C1 BBYDXOIZLAWGSL-UHFFFAOYSA-M 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ZEYHEAKUIGZSGI-UHFFFAOYSA-N 4-methoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1 ZEYHEAKUIGZSGI-UHFFFAOYSA-N 0.000 description 1
- LVQFHDAKZHGEAJ-UHFFFAOYSA-M 4-methylbenzenesulfonate Chemical compound [CH2]C1=CC=C(S([O-])(=O)=O)C=C1 LVQFHDAKZHGEAJ-UHFFFAOYSA-M 0.000 description 1
- JIQCKYQIVYCTEZ-UHFFFAOYSA-N 4-nitro-3-(trifluoromethyl)benzoic acid Chemical compound OC(=O)C1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 JIQCKYQIVYCTEZ-UHFFFAOYSA-N 0.000 description 1
- SMMIDVLUFMPWFN-UHFFFAOYSA-N 4-nitro-n-[(4-phenyldiazenylphenyl)diazenyl]aniline Chemical compound C1=CC([N+](=O)[O-])=CC=C1NN=NC1=CC=C(N=NC=2C=CC=CC=2)C=C1 SMMIDVLUFMPWFN-UHFFFAOYSA-N 0.000 description 1
- OTLNPYWUJOZPPA-UHFFFAOYSA-M 4-nitrobenzoate Chemical compound [O-]C(=O)C1=CC=C([N+]([O-])=O)C=C1 OTLNPYWUJOZPPA-UHFFFAOYSA-M 0.000 description 1
- KDVYCTOWXSLNNI-UHFFFAOYSA-N 4-t-Butylbenzoic acid Chemical compound CC(C)(C)C1=CC=C(C(O)=O)C=C1 KDVYCTOWXSLNNI-UHFFFAOYSA-N 0.000 description 1
- QZLSBOVWPHXCLT-UHFFFAOYSA-N 5-chlorothiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=C(Cl)S1 QZLSBOVWPHXCLT-UHFFFAOYSA-N 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 229940124596 AChE inhibitor Drugs 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920002126 Acrylic acid copolymer Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 108010053652 Butyrylcholinesterase Proteins 0.000 description 1
- LTZXEBUOHOVHER-PFHJYVPVSA-N C=O.CC(C)C(=O)Cl.CCOCC.CO.COC(=O)[C@H]1OC(O)[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C.COC(=O)[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.COC(=O)[C@H]1O[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C.COC(=O)[C@H]1O[C@H](OC(=N)C(Cl)(Cl)Cl)[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C.CO[Na].FB(F)F.N#CC(Cl)(Cl)Cl.O=C1O[C@@H]2[C@@H](O)C(O)O[C@@H]2[C@H]1O.S.S.S.S.S.S.[H][C@]12C[C@@H](O)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2.[H][C@]12C[C@@H](O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C=C[C@]13CCN(C)C/C1=C/C=C(/OC)C(=C13)O2.[H][C@]12C[C@@H](O[C@@H]3O[C@H](C(=O)OC)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@H]3OC(=O)C(C)C)C=C[C@]13CCN(C)C/C1=C/C=C(/OC)C(=C13)O2.[Na][Na] Chemical compound C=O.CC(C)C(=O)Cl.CCOCC.CO.COC(=O)[C@H]1OC(O)[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C.COC(=O)[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O.COC(=O)[C@H]1O[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C.COC(=O)[C@H]1O[C@H](OC(=N)C(Cl)(Cl)Cl)[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C.CO[Na].FB(F)F.N#CC(Cl)(Cl)Cl.O=C1O[C@@H]2[C@@H](O)C(O)O[C@@H]2[C@H]1O.S.S.S.S.S.S.[H][C@]12C[C@@H](O)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2.[H][C@]12C[C@@H](O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C=C[C@]13CCN(C)C/C1=C/C=C(/OC)C(=C13)O2.[H][C@]12C[C@@H](O[C@@H]3O[C@H](C(=O)OC)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@H]3OC(=O)C(C)C)C=C[C@]13CCN(C)C/C1=C/C=C(/OC)C(=C13)O2.[Na][Na] LTZXEBUOHOVHER-PFHJYVPVSA-N 0.000 description 1
- MLMQPDHYNJCQAO-UHFFFAOYSA-N CC(C)(C)CC(=O)O Chemical compound CC(C)(C)CC(=O)O MLMQPDHYNJCQAO-UHFFFAOYSA-N 0.000 description 1
- UYWMYJQSTUVRHR-GOSISDBHSA-N CC(C)(C)OC(=O)N[C@H](CC1=CC=C(OC(=O)OCC2=CC=CC=C2Br)C=C1)C(=O)O Chemical compound CC(C)(C)OC(=O)N[C@H](CC1=CC=C(OC(=O)OCC2=CC=CC=C2Br)C=C1)C(=O)O UYWMYJQSTUVRHR-GOSISDBHSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N CCC(=O)O Chemical compound CCC(=O)O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- KSALCBJJFIBUQC-ZFBITDKKSA-N CCC(C)C(=O)O[C@H]1C=C[C@@]23CCN(C)CC4=CC=C(OC)C(=C42)OC3C1 Chemical compound CCC(C)C(=O)O[C@H]1C=C[C@@]23CCN(C)CC4=CC=C(OC)C(=C42)OC3C1 KSALCBJJFIBUQC-ZFBITDKKSA-N 0.000 description 1
- JLQWPFUEUWDIHS-GENZYMQKSA-N CCCCC(=O)OC1=CC=C2CN(C)CCC34C=C[C@H](OC)CC3OC1=C24 Chemical compound CCCCC(=O)OC1=CC=C2CN(C)CCC34C=C[C@H](OC)CC3OC1=C24 JLQWPFUEUWDIHS-GENZYMQKSA-N 0.000 description 1
- AAOAIHCANDKICS-JKJNIZQMSA-N CCOCC.COC(=O)[C@H]1O[C@H](OC(=N)C(Cl)(Cl)Cl)[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C.FB(F)F.S.S.S.S.[H][C@]12C[C@@H](O)C=C[C@]13CCN(C)CC1=CC=C(O)C(=C13)O2.[H][C@]12C[C@@H](O[C@@H]3O[C@H](C(=O)OC)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@H]3OC(=O)C(C)C)C=C[C@]13CCN(C)C/C1=C/C=C(/O[C@@H]4O[C@H](C(=O)OC)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@H]4OC(=O)C(C)C)C(=C13)O2 Chemical compound CCOCC.COC(=O)[C@H]1O[C@H](OC(=N)C(Cl)(Cl)Cl)[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C.FB(F)F.S.S.S.S.[H][C@]12C[C@@H](O)C=C[C@]13CCN(C)CC1=CC=C(O)C(=C13)O2.[H][C@]12C[C@@H](O[C@@H]3O[C@H](C(=O)OC)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@H]3OC(=O)C(C)C)C=C[C@]13CCN(C)C/C1=C/C=C(/O[C@@H]4O[C@H](C(=O)OC)[C@@H](OC(=O)C(C)C)[C@H](OC(=O)C(C)C)[C@H]4OC(=O)C(C)C)C(=C13)O2 AAOAIHCANDKICS-JKJNIZQMSA-N 0.000 description 1
- KSALCBJJFIBUQC-AJOQXRKWSA-N CC[C@@H](C)C(=O)O[C@H]1C=C[C@@]23CCN(C)CC4=CC=C(OC)C(=C42)OC3C1 Chemical compound CC[C@@H](C)C(=O)O[C@H]1C=C[C@@]23CCN(C)CC4=CC=C(OC)C(=C42)OC3C1 KSALCBJJFIBUQC-AJOQXRKWSA-N 0.000 description 1
- NLUXTLOWWWNCSY-SHXWDBNESA-N COC1=C(O)C=C(C=O)C(F)=C1.COC1=C(O)C=C(CN(C=O)CCC2=CC=C(O)C=C2)C(F)=C1.COC1=C(O)C=C(CNCCC2=CC=C(O)C=C2)C(F)=C1.COC1=C(OC)C=C(C=O)C(F)=C1.COC1=C2OC3CC(=O)C=CC34CCN(C)CC(=C24)C(F)=C1.COC1=C2OC3CC(=O)C=CC34CCN(C=O)CC(=C24)C(F)=C1.COC1=C2OC3CC4(C=CC35CCN(C=O)CC(=C25)C(F)=C1)OCC(C)O4.COC1=C2OC3C[C@@H](O)C=CC34CCN(C)CC(=C24)C(F)=C1 Chemical compound COC1=C(O)C=C(C=O)C(F)=C1.COC1=C(O)C=C(CN(C=O)CCC2=CC=C(O)C=C2)C(F)=C1.COC1=C(O)C=C(CNCCC2=CC=C(O)C=C2)C(F)=C1.COC1=C(OC)C=C(C=O)C(F)=C1.COC1=C2OC3CC(=O)C=CC34CCN(C)CC(=C24)C(F)=C1.COC1=C2OC3CC(=O)C=CC34CCN(C=O)CC(=C24)C(F)=C1.COC1=C2OC3CC4(C=CC35CCN(C=O)CC(=C25)C(F)=C1)OCC(C)O4.COC1=C2OC3C[C@@H](O)C=CC34CCN(C)CC(=C24)C(F)=C1 NLUXTLOWWWNCSY-SHXWDBNESA-N 0.000 description 1
- LKDIWEKYIRKGFJ-UHFFFAOYSA-N COC1=C2OC3CC(=O)C=CC34CCN(C)CC(=C24)C(Br)=C1 Chemical compound COC1=C2OC3CC(=O)C=CC34CCN(C)CC(=C24)C(Br)=C1 LKDIWEKYIRKGFJ-UHFFFAOYSA-N 0.000 description 1
- CXHBAPSRJIZMRS-UHFFFAOYSA-N COC1=CC(Br)=C2CN(C)CCC34C=CC5(CC3OC1=C24)OCCO5 Chemical compound COC1=CC(Br)=C2CN(C)CCC34C=CC5(CC3OC1=C24)OCCO5 CXHBAPSRJIZMRS-UHFFFAOYSA-N 0.000 description 1
- LVKIZPBPJHTZKX-FRYNGCKNSA-N COC1=CC=C(C(=O)O[C@H]2C=C[C@@]34CCN(C)CC5=CC=C(OC)C(=C53)OC4C2)C=C1 Chemical compound COC1=CC=C(C(=O)O[C@H]2C=C[C@@]34CCN(C)CC5=CC=C(OC)C(=C53)OC4C2)C=C1 LVKIZPBPJHTZKX-FRYNGCKNSA-N 0.000 description 1
- ZADOZOULRZGFEU-UQHVZDHRSA-N COC1=CC=C2CN(C(C)=O)CCC34C=C[C@H](O)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C(C)=O)CCC34C=C[C@H](O)CC3OC1=C24 ZADOZOULRZGFEU-UQHVZDHRSA-N 0.000 description 1
- JCVPJLWNIDZKSV-IJUUXEDSSA-N COC1=CC=C2CN(C)CC[C@@]34/C=C\[C@H](OC(=O)C5CC5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34/C=C\[C@H](OC(=O)C5CC5)CC3OC1=C24 JCVPJLWNIDZKSV-IJUUXEDSSA-N 0.000 description 1
- HDMCEARQOQYUFY-UWPITKESSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=C(Cl)C=C(Cl)C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=C(Cl)C=C(Cl)C=C5)CC3OC1=C24 HDMCEARQOQYUFY-UWPITKESSA-N 0.000 description 1
- CYNYHZYCWNQZQD-UWPITKESSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=C(Cl)C=CC(Cl)=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=C(Cl)C=CC(Cl)=C5)CC3OC1=C24 CYNYHZYCWNQZQD-UWPITKESSA-N 0.000 description 1
- YQBIJQINMWPEET-UWPITKESSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=C(Cl)C=CC=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=C(Cl)C=CC=C5)CC3OC1=C24 YQBIJQINMWPEET-UWPITKESSA-N 0.000 description 1
- CIBBTTIHKLDLNU-UWPITKESSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=C(F)C=C(F)C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=C(F)C=C(F)C=C5)CC3OC1=C24 CIBBTTIHKLDLNU-UWPITKESSA-N 0.000 description 1
- UOYVVXGVMFOPRA-XXWJWZNHSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=C(OC(C)=O)C=CC=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=C(OC(C)=O)C=CC=C5)CC3OC1=C24 UOYVVXGVMFOPRA-XXWJWZNHSA-N 0.000 description 1
- BLDNEDCLEGPXAS-UWPITKESSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(C(F)(F)F)=C(Cl)C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(C(F)(F)F)=C(Cl)C=C5)CC3OC1=C24 BLDNEDCLEGPXAS-UWPITKESSA-N 0.000 description 1
- JXZINMGPJJJRKW-LUMFDWGNSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(C(F)(F)F)=CC=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(C(F)(F)F)=CC=C5)CC3OC1=C24 JXZINMGPJJJRKW-LUMFDWGNSA-N 0.000 description 1
- WGIIPFMYGJAEKT-SBJNEVENSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(C)=C(N(C)C)C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(C)=C(N(C)C)C=C5)CC3OC1=C24 WGIIPFMYGJAEKT-SBJNEVENSA-N 0.000 description 1
- IGWMWEANQFJZQN-FRYNGCKNSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(C)=CC=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(C)=CC=C5)CC3OC1=C24 IGWMWEANQFJZQN-FRYNGCKNSA-N 0.000 description 1
- JWEZIKRIOFBOIH-UWPITKESSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(Cl)=C(Cl)C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(Cl)=C(Cl)C=C5)CC3OC1=C24 JWEZIKRIOFBOIH-UWPITKESSA-N 0.000 description 1
- FSQPWEMJXHAFIC-LUMFDWGNSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(Cl)=CC(Cl)=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(Cl)=CC(Cl)=C5)CC3OC1=C24 FSQPWEMJXHAFIC-LUMFDWGNSA-N 0.000 description 1
- NMNWQNCUKVWKNQ-LUMFDWGNSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(Cl)=CC=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(Cl)=CC=C5)CC3OC1=C24 NMNWQNCUKVWKNQ-LUMFDWGNSA-N 0.000 description 1
- QYICXBXBSXGTEY-GCNITNNDSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(N(C)C)=CC=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC(N(C)C)=CC=C5)CC3OC1=C24 QYICXBXBSXGTEY-GCNITNNDSA-N 0.000 description 1
- QZWDKHAUXCCZKK-LUMFDWGNSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC([N+](=O)[O-])=CC=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC([N+](=O)[O-])=CC=C5)CC3OC1=C24 QZWDKHAUXCCZKK-LUMFDWGNSA-N 0.000 description 1
- XLQIRAQTMCTFMU-URWUTGEKSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC6=C(C=C5)OCO6)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC6=C(C=C5)OCO6)CC3OC1=C24 XLQIRAQTMCTFMU-URWUTGEKSA-N 0.000 description 1
- PTQNWCKKRIUHNV-ZYXWGPAWSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(C(C)(C)C)C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(C(C)(C)C)C=C5)CC3OC1=C24 PTQNWCKKRIUHNV-ZYXWGPAWSA-N 0.000 description 1
- GPVXFFHVVZVADA-GCNITNNDSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(C(C)=O)C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(C(C)=O)C=C5)CC3OC1=C24 GPVXFFHVVZVADA-GCNITNNDSA-N 0.000 description 1
- CYWDHUTZLHSRLX-LUMFDWGNSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(C(F)(F)F)C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(C(F)(F)F)C=C5)CC3OC1=C24 CYWDHUTZLHSRLX-LUMFDWGNSA-N 0.000 description 1
- KEKDPCXDWQMEPQ-FRYNGCKNSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(C)C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(C)C=C5)CC3OC1=C24 KEKDPCXDWQMEPQ-FRYNGCKNSA-N 0.000 description 1
- CUWVIQZMPFIUOA-LUMFDWGNSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(Cl)C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(Cl)C=C5)CC3OC1=C24 CUWVIQZMPFIUOA-LUMFDWGNSA-N 0.000 description 1
- ONYRQKHBNAXEOG-YGZITFEBSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(Cl)S5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(Cl)S5)CC3OC1=C24 ONYRQKHBNAXEOG-YGZITFEBSA-N 0.000 description 1
- UAUOCWZODXHCKO-LUMFDWGNSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(F)C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(F)C=C5)CC3OC1=C24 UAUOCWZODXHCKO-LUMFDWGNSA-N 0.000 description 1
- ZNBDDKOFGICCBU-GCNITNNDSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(N(C)C)C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(N(C)C)C=C5)CC3OC1=C24 ZNBDDKOFGICCBU-GCNITNNDSA-N 0.000 description 1
- COSFPGNZYPGKGH-LUMFDWGNSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(N)C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C(N)C=C5)CC3OC1=C24 COSFPGNZYPGKGH-LUMFDWGNSA-N 0.000 description 1
- ZDKXQSTXDHPPDN-LUMFDWGNSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C([N+](=O)[O-])C=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=C([N+](=O)[O-])C=C5)CC3OC1=C24 ZDKXQSTXDHPPDN-LUMFDWGNSA-N 0.000 description 1
- JKVNJTYHRABHIY-LUMFDWGNSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=CC=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=CC=C5)CC3OC1=C24 JKVNJTYHRABHIY-LUMFDWGNSA-N 0.000 description 1
- QMNADUDTKCQCPT-YXHQUHRKSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=CS5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CC=CS5)CC3OC1=C24 QMNADUDTKCQCPT-YXHQUHRKSA-N 0.000 description 1
- HPHZJRGEEUVCHV-TZNRYSIBSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CN=CN5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CN=CN5)CC3OC1=C24 HPHZJRGEEUVCHV-TZNRYSIBSA-N 0.000 description 1
- IJEVLTIQCHZIFC-TZNRYSIBSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CN=CO5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CN=CO5)CC3OC1=C24 IJEVLTIQCHZIFC-TZNRYSIBSA-N 0.000 description 1
- PINILYDTCBUHPU-TZNRYSIBSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CN=CS5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CN=CS5)CC3OC1=C24 PINILYDTCBUHPU-TZNRYSIBSA-N 0.000 description 1
- KKBWBVGDPWAGKB-QCQPBBGPSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CSC=C5)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)C5=CSC=C5)CC3OC1=C24 KKBWBVGDPWAGKB-QCQPBBGPSA-N 0.000 description 1
- PXNFCHKDVRTDEL-RAEDPMGTSA-N COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)CC(C)(C)C)CC3OC1=C24 Chemical compound COC1=CC=C2CN(C)CC[C@@]34C=C[C@H](OC(=O)CC(C)(C)C)CC3OC1=C24 PXNFCHKDVRTDEL-RAEDPMGTSA-N 0.000 description 1
- ZGPQTZYCVYBDEH-VAXWUYBZSA-N COC1=CC=C2CN(C)CC[C@]34C=C[C@H](O)C[C@@H]3OC1=C24.COC1=CC=C2CN(C)CC[C@]34C=C[C@H](OS(=O)(=O)O)C[C@@H]3OC1=C24.O=S(=O)(O)Cl Chemical compound COC1=CC=C2CN(C)CC[C@]34C=C[C@H](O)C[C@@H]3OC1=C24.COC1=CC=C2CN(C)CC[C@]34C=C[C@H](OS(=O)(=O)O)C[C@@H]3OC1=C24.O=S(=O)(O)Cl ZGPQTZYCVYBDEH-VAXWUYBZSA-N 0.000 description 1
- AIXQQSTVOSFSMO-XOMBGVMMSA-N COC1=CC=C2CNCCC34C=C[C@H](O)CC3OC1=C24 Chemical compound COC1=CC=C2CNCCC34C=C[C@H](O)CC3OC1=C24 AIXQQSTVOSFSMO-XOMBGVMMSA-N 0.000 description 1
- NRSBTIRXFZYUMK-QFLNXZQOSA-N C[C@@H](CC([C@@]1(CCN(C)C2)C=C)Oc3c1c2ccc3OC)OC(c(cc1)ccc1F)=O Chemical compound C[C@@H](CC([C@@]1(CCN(C)C2)C=C)Oc3c1c2ccc3OC)OC(c(cc1)ccc1F)=O NRSBTIRXFZYUMK-QFLNXZQOSA-N 0.000 description 1
- LZIGFXNCDBMIDJ-YFBXQHAESA-N C[C@@H](C[C@@H]([C@@](CCN(C)C1)(C=C)c2c1cc1)Oc2c1OC)OC(c1cnccc1)=O Chemical compound C[C@@H](C[C@@H]([C@@](CCN(C)C1)(C=C)c2c1cc1)Oc2c1OC)OC(c1cnccc1)=O LZIGFXNCDBMIDJ-YFBXQHAESA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical group NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- 108091006146 Channels Proteins 0.000 description 1
- 235000015256 Chionanthus virginicus Nutrition 0.000 description 1
- 102100032404 Cholinesterase Human genes 0.000 description 1
- 206010048650 Cholinesterase inhibition Diseases 0.000 description 1
- 229910020323 ClF3 Inorganic materials 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- UYUXSRADSPPKRZ-SKNVOMKLSA-N D-glucurono-6,3-lactone Chemical compound O=C[C@H](O)[C@H]1OC(=O)[C@@H](O)[C@H]1O UYUXSRADSPPKRZ-SKNVOMKLSA-N 0.000 description 1
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000001828 Gelatine Substances 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- PFRVZQKEOAYKSC-UHFFFAOYSA-N L-eucotamine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC(=O)CC(O)C)C=C2 PFRVZQKEOAYKSC-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- VDDUJINYXKGZLV-UHFFFAOYSA-N LSM-1888 Chemical compound COC1=CC=C2C3OC4=CC=C5NC(C)=C(C(=O)OCC)C5=C4CN3CCC2=C1 VDDUJINYXKGZLV-UHFFFAOYSA-N 0.000 description 1
- 241000319062 Lycoris radiata Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- 229940126655 NDI-034858 Drugs 0.000 description 1
- ZADOZOULRZGFEU-UHFFFAOYSA-N Narcisine Natural products O1C(=C23)C(OC)=CC=C2CN(C(C)=O)CCC23C1CC(O)C=C2 ZADOZOULRZGFEU-UHFFFAOYSA-N 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 241000290929 Nimbus Species 0.000 description 1
- AGBQKNBQESQNJD-UHFFFAOYSA-N O=C(O)CCCCC1CCSS1 Chemical compound O=C(O)CCCCC1CCSS1 AGBQKNBQESQNJD-UHFFFAOYSA-N 0.000 description 1
- 208000007964 Organophosphate Poisoning Diseases 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical class C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- FZJCBOKHFUZSET-HUJQDMNGSA-N S.S.[H][C@]12C[C@@H](O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C=C[C@]13CCN(C)C/C1=C/C=C(/O[C@@H]4O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]4O)C(=C13)O2 Chemical compound S.S.[H][C@]12C[C@@H](O[C@@H]3O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]3O)C=C[C@]13CCN(C)C/C1=C/C=C(/O[C@@H]4O[C@H](C(=O)O)[C@@H](O)[C@H](O)[C@H]4O)C(=C13)O2 FZJCBOKHFUZSET-HUJQDMNGSA-N 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical class [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- DRUIESSIVFYOMK-UHFFFAOYSA-N Trichloroacetonitrile Chemical compound ClC(Cl)(Cl)C#N DRUIESSIVFYOMK-UHFFFAOYSA-N 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-N Tyramine Natural products NCCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- MXRRYJULORAXHI-UHFFFAOYSA-N [4-(4-hexoxybenzoyl)oxyphenyl] 4-aminobenzoate Chemical compound C1=CC(OCCCCCC)=CC=C1C(=O)OC(C=C1)=CC=C1OC(=O)C1=CC=C(N)C=C1 MXRRYJULORAXHI-UHFFFAOYSA-N 0.000 description 1
- JEBVYDIKPLFFQG-WXHHGMJOSA-N [Cl-].[H][C@]12C[C@@H](O)C=C[C@]13CC[N+](C)(COC)CC1=CC=C(OC)C(=C13)O2 Chemical compound [Cl-].[H][C@]12C[C@@H](O)C=C[C@]13CC[N+](C)(COC)CC1=CC=C(OC)C(=C13)O2 JEBVYDIKPLFFQG-WXHHGMJOSA-N 0.000 description 1
- CWBPWEDEZGRSDD-NCHVAJSOSA-N [H][C@]12C[C@@H](O)C=C[C@]13CCN(C)CC1=C(Br)C=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](O)C=C[C@]13CCN(C)CC1=C(Br)C=C(OC)C(=C13)O2 CWBPWEDEZGRSDD-NCHVAJSOSA-N 0.000 description 1
- SJEAPLQXISQGGY-DBIKOVAWSA-N [H][C@]12C[C@@H](O)C=C[C@]13CCN(COC(=O)C(CC1=CC=CC=C1)NC(=O)OC(C)(C)C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](O)C=C[C@]13CCN(COC(=O)C(CC1=CC=CC=C1)NC(=O)OC(C)(C)C)CC1=CC=C(OC)C(=C13)O2 SJEAPLQXISQGGY-DBIKOVAWSA-N 0.000 description 1
- JSYGNMFOUHMFIW-KEWLPNKHSA-N [H][C@]12C[C@@H](O)C=C[C@]13CCN(COC(=O)CNC(=O)OC(C)(C)C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](O)C=C[C@]13CCN(COC(=O)CNC(=O)OC(C)(C)C)CC1=CC=C(OC)C(=C13)O2 JSYGNMFOUHMFIW-KEWLPNKHSA-N 0.000 description 1
- AFUUXYKUROZLEN-LUFJJVMOSA-N [H][C@]12C[C@@H](O)C=C[C@]13CCNCC1=C(Br)C=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](O)C=C[C@]13CCNCC1=C(Br)C=C(OC)C(=C13)O2 AFUUXYKUROZLEN-LUFJJVMOSA-N 0.000 description 1
- ZMIGOOBPSVLJRK-YHEJKZAPSA-N [H][C@]12C[C@@H](OC(=O)C(C)(C)C)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(=O)C(C)(C)C)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 ZMIGOOBPSVLJRK-YHEJKZAPSA-N 0.000 description 1
- SYLQDIWQGQNPIH-WJPUGNRLSA-N [H][C@]12C[C@@H](OC(=O)C(C)C)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(=O)C(C)C)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 SYLQDIWQGQNPIH-WJPUGNRLSA-N 0.000 description 1
- OIVCRGJKALWGEW-RFCOHBRXSA-N [H][C@]12C[C@@H](OC(=O)C(C)CCC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(=O)C(C)CCC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 OIVCRGJKALWGEW-RFCOHBRXSA-N 0.000 description 1
- DNCJPXGMUPGNOD-CPXWISSCSA-N [H][C@]12C[C@@H](OC(=O)C3CCCO3)/C=C\[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(=O)C3CCCO3)/C=C\[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 DNCJPXGMUPGNOD-CPXWISSCSA-N 0.000 description 1
- PLOMKDSCCYHQFD-UVFQYZLESA-N [H][C@]12C[C@@H](OC(=O)CC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(=O)CC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 PLOMKDSCCYHQFD-UVFQYZLESA-N 0.000 description 1
- AUUHIOGZPOLHJT-ZJBJCVSYSA-N [H][C@]12C[C@@H](OC(=O)CC3CC3)/C=C\[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(=O)CC3CC3)/C=C\[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 AUUHIOGZPOLHJT-ZJBJCVSYSA-N 0.000 description 1
- URKXTXRCXZESPQ-WJPUGNRLSA-N [H][C@]12C[C@@H](OC(=O)CCC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(=O)CCC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 URKXTXRCXZESPQ-WJPUGNRLSA-N 0.000 description 1
- OXARJAFJUBIMKN-ZJBJCVSYSA-N [H][C@]12C[C@@H](OC(=O)CCCC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(=O)CCCC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 OXARJAFJUBIMKN-ZJBJCVSYSA-N 0.000 description 1
- JNVLNVAROXVOCX-LTMIRXACSA-N [H][C@]12C[C@@H](OC(=O)CCCCC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(=O)CCCCC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 JNVLNVAROXVOCX-LTMIRXACSA-N 0.000 description 1
- GUOVHHQQMQJDSB-WJPUGNRLSA-N [H][C@]12C[C@@H](OC(=O)CCOC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(=O)CCOC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 GUOVHHQQMQJDSB-WJPUGNRLSA-N 0.000 description 1
- DRWXZUCNVCNXIN-ZJBJCVSYSA-N [H][C@]12C[C@@H](OC(=O)N(CC)CC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(=O)N(CC)CC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 DRWXZUCNVCNXIN-ZJBJCVSYSA-N 0.000 description 1
- NNDZUQPKOVVEPM-ZJBJCVSYSA-N [H][C@]12C[C@@H](OC(=O)NCCCC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(=O)NCCCC)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 NNDZUQPKOVVEPM-ZJBJCVSYSA-N 0.000 description 1
- LBXRKDGNBSYDML-YEWWUXTCSA-N [H][C@]12C[C@@H](OC(C)=O)C=C[C@]13CCN(C)CC1=CC=C(O)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(C)=O)C=C[C@]13CCN(C)CC1=CC=C(O)C(=C13)O2 LBXRKDGNBSYDML-YEWWUXTCSA-N 0.000 description 1
- LPJGQVJRNQZZNV-KNBMTAEXSA-N [H][C@]12C[C@@H](OC(C)=O)C=C[C@]13CCN(C)CC1=CC=C(OC(C)=O)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(C)=O)C=C[C@]13CCN(C)CC1=CC=C(OC(C)=O)C(=C13)O2 LPJGQVJRNQZZNV-KNBMTAEXSA-N 0.000 description 1
- ZTWNMOVEDXUICV-QOKNQOGYSA-N [H][C@]12C[C@@H](OC(C)=O)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@H](OC(C)=O)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 ZTWNMOVEDXUICV-QOKNQOGYSA-N 0.000 description 1
- XNOVCBPGCRJMDO-WMPJOZTASA-N [H][C@]12C[C@@]([H])(OC(=O)C3=CC=C(C)C=C3)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2.[H][C@]12C[C@@]([H])(OC(=O)C3=CC=C(Cl)C=C3)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 Chemical compound [H][C@]12C[C@@]([H])(OC(=O)C3=CC=C(C)C=C3)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2.[H][C@]12C[C@@]([H])(OC(=O)C3=CC=C(Cl)C=C3)C=C[C@]13CCN(C)CC1=CC=C(OC)C(=C13)O2 XNOVCBPGCRJMDO-WMPJOZTASA-N 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 150000008065 acid anhydrides Chemical class 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 239000012790 adhesive layer Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N alpha-ethylcaproic acid Natural products CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- HAMNKKUPIHEESI-UHFFFAOYSA-N aminoguanidine Chemical compound NNC(N)=N HAMNKKUPIHEESI-UHFFFAOYSA-N 0.000 description 1
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940005524 anti-dementia drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- 150000008038 benzoazepines Chemical class 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000011953 bioanalysis Methods 0.000 description 1
- 230000008238 biochemical pathway Effects 0.000 description 1
- 239000012455 biphasic mixture Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 150000005829 chemical entities Chemical class 0.000 description 1
- 230000007073 chemical hydrolysis Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- ZDVSSXVVRYYLKC-LBPRGKRZSA-N chloromethyl (2s)-2-[(2-methylpropan-2-yl)oxycarbonylamino]-3-phenylpropanoate Chemical compound CC(C)(C)OC(=O)N[C@H](C(=O)OCCl)CC1=CC=CC=C1 ZDVSSXVVRYYLKC-LBPRGKRZSA-N 0.000 description 1
- DUFKNCLUXASETI-UHFFFAOYSA-N chloromethyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetate Chemical compound CC(C)(C)OC(=O)NCC(=O)OCCl DUFKNCLUXASETI-UHFFFAOYSA-N 0.000 description 1
- 125000004218 chloromethyl group Chemical group [H]C([H])(Cl)* 0.000 description 1
- 150000001860 citric acid derivatives Chemical class 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000007278 cognition impairment Effects 0.000 description 1
- 230000037411 cognitive enhancing Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- LBJNMUFDOHXDFG-UHFFFAOYSA-N copper;hydrate Chemical compound O.[Cu].[Cu] LBJNMUFDOHXDFG-UHFFFAOYSA-N 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-M cyclopropanecarboxylate Chemical compound [O-]C(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-M 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000013681 dietary sucrose Nutrition 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- OWMBTIRJFMGPAC-UHFFFAOYSA-N dimethylamino 2-methylprop-2-enoate Chemical compound CN(C)OC(=O)C(C)=C OWMBTIRJFMGPAC-UHFFFAOYSA-N 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 125000003438 dodecyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000003372 electrophysiological method Methods 0.000 description 1
- 230000007831 electrophysiology Effects 0.000 description 1
- 238000002001 electrophysiology Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000002329 esterase inhibitor Substances 0.000 description 1
- MDKXBBPLEGPIRI-UHFFFAOYSA-N ethoxyethane;methanol Chemical compound OC.CCOCC MDKXBBPLEGPIRI-UHFFFAOYSA-N 0.000 description 1
- CEIPQQODRKXDSB-UHFFFAOYSA-N ethyl 3-(6-hydroxynaphthalen-2-yl)-1H-indazole-5-carboximidate dihydrochloride Chemical compound Cl.Cl.C1=C(O)C=CC2=CC(C3=NNC4=CC=C(C=C43)C(=N)OCC)=CC=C21 CEIPQQODRKXDSB-UHFFFAOYSA-N 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 229940012017 ethylenediamine Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000000763 evoking effect Effects 0.000 description 1
- 230000009540 excitatory neurotransmission Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 150000002238 fumaric acids Chemical class 0.000 description 1
- 150000002243 furanoses Chemical class 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- BGQUXEGIISTLGG-PFYMQUAWSA-M galanthamine methiodide Chemical compound [I-].O1C(=C23)C(OC)=CC=C2C[N+](C)(C)CCC23[C@@H]1C[C@@H](O)C=C2 BGQUXEGIISTLGG-PFYMQUAWSA-M 0.000 description 1
- LROQBKNDGTWXET-FVWDGWMTSA-N galanthamine n-oxide Chemical compound O1C(=C23)C(OC)=CC=C2C[N+](C)([O-])CC[C@]23[C@@H]1C[C@@H](O)C=C2 LROQBKNDGTWXET-FVWDGWMTSA-N 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000000848 glutamatergic effect Effects 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 235000004554 glutamine Nutrition 0.000 description 1
- MNQZXJOMYWMBOU-UHFFFAOYSA-N glyceraldehyde Chemical compound OCC(O)C=O MNQZXJOMYWMBOU-UHFFFAOYSA-N 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 125000003147 glycosyl group Chemical group 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 150000002386 heptoses Chemical class 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 150000002402 hexoses Chemical class 0.000 description 1
- LNMQRPPRQDGUDR-UHFFFAOYSA-N hexyl prop-2-enoate Chemical compound CCCCCCOC(=O)C=C LNMQRPPRQDGUDR-UHFFFAOYSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- SURQXAFEQWPFPV-UHFFFAOYSA-L iron(2+) sulfate heptahydrate Chemical compound O.O.O.O.O.O.O.[Fe+2].[O-]S([O-])(=O)=O SURQXAFEQWPFPV-UHFFFAOYSA-L 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000013016 learning Effects 0.000 description 1
- 230000007786 learning performance Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- GPSDUZXPYCFOSQ-UHFFFAOYSA-M m-toluate Chemical compound CC1=CC=CC(C([O-])=O)=C1 GPSDUZXPYCFOSQ-UHFFFAOYSA-M 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 238000003760 magnetic stirring Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 150000002689 maleic acids Chemical class 0.000 description 1
- 238000010907 mechanical stirring Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 229960004640 memantine Drugs 0.000 description 1
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 description 1
- 230000015654 memory Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- LULAYUGMBFYYEX-UHFFFAOYSA-N metachloroperbenzoic acid Natural products OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- VHWYCFISAQVCCP-UHFFFAOYSA-N methoxymethanol Chemical compound COCO VHWYCFISAQVCCP-UHFFFAOYSA-N 0.000 description 1
- WLEXLQMWVJVVIX-UHFFFAOYSA-N methoxymethyl trifluoromethanesulfonate Chemical compound COCOS(=O)(=O)C(F)(F)F WLEXLQMWVJVVIX-UHFFFAOYSA-N 0.000 description 1
- UVVZYXYYDVUAQO-CWLGOENISA-N methyl (2s,3s,4s,5r,6s)-3,4,5,6-tetrakis(2,2-dimethylpropanoyloxy)oxane-2-carboxylate Chemical compound COC(=O)[C@H]1O[C@@H](OC(=O)C(C)(C)C)[C@H](OC(=O)C(C)(C)C)[C@@H](OC(=O)C(C)(C)C)[C@@H]1OC(=O)C(C)(C)C UVVZYXYYDVUAQO-CWLGOENISA-N 0.000 description 1
- CCIDTXJAPRZHSL-NNSCZBDESA-N methyl (2s,3s,4s,5r,6s)-3,4,5-tris(2-methylpropanoyloxy)-6-(2,2,2-trichloroethanimidoyl)oxyoxane-2-carboxylate Chemical compound COC(=O)[C@H]1O[C@@H](OC(=N)C(Cl)(Cl)Cl)[C@H](OC(=O)C(C)C)[C@@H](OC(=O)C(C)C)[C@@H]1OC(=O)C(C)C CCIDTXJAPRZHSL-NNSCZBDESA-N 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 1
- 239000003149 muscarinic antagonist Substances 0.000 description 1
- 239000002102 nanobead Substances 0.000 description 1
- 150000002790 naphthalenes Chemical class 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000004112 neuroprotection Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000003367 nicotinic antagonist Substances 0.000 description 1
- LQERIDTXQFOHKA-UHFFFAOYSA-N nonadecane Chemical compound CCCCCCCCCCCCCCCCCCC LQERIDTXQFOHKA-UHFFFAOYSA-N 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000000346 nonvolatile oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 150000002913 oxalic acids Chemical class 0.000 description 1
- LPNBBFKOUUSUDB-UHFFFAOYSA-M p-toluate Chemical compound CC1=CC=C(C([O-])=O)C=C1 LPNBBFKOUUSUDB-UHFFFAOYSA-M 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 230000007903 penetration ability Effects 0.000 description 1
- 125000002958 pentadecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- RGSFGYAAUTVSQA-UHFFFAOYSA-N pentamethylene Natural products C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical class OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 235000008729 phenylalanine Nutrition 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 150000003016 phosphoric acids Chemical class 0.000 description 1
- VDVJGIYXDVPQLP-UHFFFAOYSA-N piperonylic acid Chemical compound OC(=O)C1=CC=C2OCOC2=C1 VDVJGIYXDVPQLP-UHFFFAOYSA-N 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940124606 potential therapeutic agent Drugs 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000039 preparative column chromatography Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 150000003214 pyranose derivatives Chemical class 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000006479 redox reaction Methods 0.000 description 1
- 238000000611 regression analysis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 210000003079 salivary gland Anatomy 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 238000013077 scoring method Methods 0.000 description 1
- 150000007659 semicarbazones Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- IPMKAUAKEGAJNA-XSUJLISDSA-N solanapyrone g Chemical compound C1([C@H]2[C@@H]3CCCC[C@@H]3C=C[C@@H]2C)=CC(N)=C(C=O)C(=O)O1 IPMKAUAKEGAJNA-XSUJLISDSA-N 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 150000003444 succinic acids Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- AWDBHOZBRXWRKS-UHFFFAOYSA-N tetrapotassium;iron(6+);hexacyanide Chemical compound [K+].[K+].[K+].[K+].[Fe+6].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-].N#[C-] AWDBHOZBRXWRKS-UHFFFAOYSA-N 0.000 description 1
- SRVJKTDHMYAMHA-WUXMJOGZSA-N thioacetazone Chemical compound CC(=O)NC1=CC=C(\C=N\NC(N)=S)C=C1 SRVJKTDHMYAMHA-WUXMJOGZSA-N 0.000 description 1
- QERYCTSHXKAMIS-UHFFFAOYSA-M thiophene-2-carboxylate Chemical compound [O-]C(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-M 0.000 description 1
- YNVOMSDITJMNET-UHFFFAOYSA-M thiophene-3-carboxylate Chemical compound [O-]C(=O)C=1C=CSC=1 YNVOMSDITJMNET-UHFFFAOYSA-M 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 229940100640 transdermal system Drugs 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- ILWRPSCZWQJDMK-UHFFFAOYSA-N triethylazanium;chloride Chemical compound Cl.CCN(CC)CC ILWRPSCZWQJDMK-UHFFFAOYSA-N 0.000 description 1
- 229960003732 tyramine Drugs 0.000 description 1
- DZGWFCGJZKJUFP-UHFFFAOYSA-O tyraminium Chemical compound [NH3+]CCC1=CC=C(O)C=C1 DZGWFCGJZKJUFP-UHFFFAOYSA-O 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- NIJJYAXOARWZEE-UHFFFAOYSA-M valproate Chemical compound CCCC(C([O-])=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-M 0.000 description 1
- 229960000604 valproic acid Drugs 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 239000008215 water for injection Substances 0.000 description 1
- 230000003936 working memory Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/91—Dibenzofurans; Hydrogenated dibenzofurans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/06—Peri-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Definitions
- the disclosure refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and to their agonists, of neuronal cholinergic receptors, and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds.
- the compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g., Galantamine, Narwedine and Lycoramine, or from metabolites of said compounds.
- the compounds of the present invention can either interact as such with their target molecules, or they can act as “pro-drugs”, in the sense that after reaching their target regions in the body, they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both.
- the compounds of this disclosure may be used as medicaments for the treatment of human brain diseases associated with a cholinergic deficit, including the neurodegenerative diseases Alzheimer's and Parkinson's disease and the neurological/psychiatric diseases vascular dementia, schizophrenia and epilepsy.
- Galantamine derivatives disclosed herein have higher efficacy and lower levels of adverse side effects in comparison to galantamine, in treatment of human brain diseases.
- the diffusion of compounds from the blood plasma into the brain is complicated by the presence of the blood-brain barrier that is a membrane that segregates the brain interstitial fluid from the circulating blood.
- the blood-brain barrier that is a membrane that segregates the brain interstitial fluid from the circulating blood.
- drugs active in the central nervous system and able to cross the blood-brain barrier one can exploit endogenous active mechanisms, utilize proper delivery techniques or modify the chemical structure through the synthesis of pro-drug derivatives.
- Galantamine is an alkaloid that can be isolated from the bulbs of various snowdrop ( Galanthus ) and narcissus species (daffodils, Amaryllidaceae), and recently in particularly high concentrations from Lycoris radiata , and related species.
- Synthetic Galantamine hydrobromide is manufactured by, among other companies, Sanochemia and Janssen Pharmaceutica. The drug has been approved in more than 70 nations for the treatment of mild-to-moderate Alzheimer's disease (AD), a neurodegenerative brain disease.
- AD Alzheimer's disease
- Extensive studies of the pharmacokinetic profile, tissue distribution and accumulation of Galantamine in mice, rats, rabbits and dogs have shown that Galantamine given orally is by no means preferentially distributed to the brain where it is supposed to exert its therapeutic activity in said brain diseases.
- the present disclosure relates to methods by which the lipophilicity and/or BBB penetration and/or brain-to-plasma ratio of a compound is enhanced by formation of a reversible linkage with one or more suitable groups so as to yield “pro-drugs”, i.e., chemical derivatives that, after having passed through the blood-brain barrier, are converted (back) to the original compound itself inside the patients brain.
- pro-drugs i.e., chemical derivatives that, after having passed through the blood-brain barrier, are converted (back) to the original compound itself inside the patients brain.
- Liberation of the parent compound may be by chemical hydrolysis or enzymatic attack, or by redox reactions.
- the present invention refers to compounds that after chemical modification of the base compound have achieved a lop P value more favourable for BBB penetration, with these derivatives acting as such at their target molecules in the patient's brain.
- the plant alkaloid galantamine has been described as a cholinesterase inhibitor (ChE-I) and as a nicotinic acetylcholine receptor (nAChR) sensitizing agent (APL; allosterically potentiating ligand), and galantamine has been proposed for the treatment of several human brain diseases, including Alzheimer's disease (AD).
- AD Alzheimer's disease
- the compliance of Alzheimer patients to treatment with ChE-I and APL is rather low, of the order of 20%, a key reason being the adverse effects nausea, diarrhea, vomiting, anorexia and muscle cramps.
- the manufacturer's recommended daily dose of the drug is limited to 16-24 mg per day, and this dose is slowly reached by stepwise dose increase, beginning at 4 mg/day and over a period of 2-3 months.
- WO2007/039138 reference is made to the low hydrophobicity and related limited partition into the human brain of galantamine, and several procedures for overcoming these drawbacks of a medication that is supposed to act on target molecules located in the brain's central nervous system are proposed.
- numerous derivatives of galantamine that significantly improve transport of the respective compound through the blood-brain barrier (BBB) are described and they are proposed as drugs for the treatment of a variety of diseases associated with cognitive deficits.
- AD Alzheimer's disease
- cholinergic and the glutamatergic systems a group consisting of cholinergic and the glutamatergic systems.
- Three of the four presently available drugs are cholinergic enhancers (Donepezil, Rivastigmin, Galantamine) in that they all inhibit the family of acetylcholine-degrading enzymes denoted as cholinesterases (ChE).
- Inhibition of ChE increases the synaptic concentrations of acetylcholine (ACh), thereby enhancing and prolonging the action of ACh on muscarinic (mAChR) and nicotinic (nAChR) acetylcholine receptors.
- ACh acetylcholine
- Galantamine also acts by allosterically stimulating (sensitizing) cholinergic receptors.
- Allosteric sensitization of nicotinic receptors enhances their activation by ACh or choline (Ch), thereby correcting for a disease-associated deficit in transmitter or receptor concentration (Maelicke A & Albuquerque E X (1996) Drug Discovery Today 1, 53-59; Maelicke A & Albuquerque E X (2000) Eur J Pharmacol 393, 165-170).
- these drugs induce adverse peripheral and central side effects; the muscarinic ones including nausea, vomiting and diarrhea, and the nicotinic ones including tremors and muscle cramps. From meta data (Cochrane reviews, (2004), Issue 4) and direct comparison clinical studies (Wilcock G K et al.
- Galantamine enhances nicotinic cholinergic neurotransmission by acting directly on nicotinic receptors (Schrattenholz A et al. (1996) Mol Pharmacol 49, 1-6; Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036). The drug binds to a distinct allosteric site on these receptors (Schröder B et al.
- the APL action on human nicotinic receptors has been demonstrated by electrophysiological studies using human brain slices (Alkondon, M. et al., (2000) J Neurosci 20, 66-75) and human recombinant cell lines each expressing a single nAChR subtype (Samochocki M et al (2000) Acta Neuro Scand Suppl 176, 68-73, Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036). All human nAChR subtypes analysed so far are sensitive to enhancement by APL.
- Galantamine increases the slope of the dose-response curve for ACh, which has been interpreted as an increase in the cooperativity between nAChR subunits (Maelicke A & Albuquerque E X (1996) Drug Discovery Today 1, 53-59).
- the APL effect of Galantamine is observed at submicromolar concentrations (Samochocki M et al (2000) Acta Neuro Scand Suppl 176, 68-73, Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036), i.e., below the concentration range at which ChE inhibition takes place.
- nicotinic APL The two modes of action of nicotinic APL are independent of each other, as was shown by ion flux studies (Okonjo K et al (1991) Eur J Biochem 200, 671-677; Kuhlmann J et al (1991) FEBS Lett 279, 216-218) and electrophysiological studies of brain slices from both rats and humans (Santos M D et al (2002) Mol Pharmacol 61, 1222-1234). In these studies, when cholinesterase activity was completely blocked by either reversible or irreversible blocking agents, the nicotinic APL, e.g., Galantamine, still was able to produce an APL effect of the same size as in the absence of the other ChE inhibitors. Of the cholinesterase inhibitors presently approved as AD drugs, Galantamine is the only one with nicotinic APL activity (Maelicke A et al (2000) Behav Brain Res 113, 199-206).
- Galantamine and other APL as a drug treatment strategy for cognitive disorders, including AD and PD was proposed in 1996 (Maelicke A & Albuquerque E X (1996) Drug Discovery Today 1, 53-59). Later, the proposal was extended to vascular and mixed dementia (Maelicke A et al (2001) Biol Psychiatry 49, 279-288), schizophrenia, epilepsy and other diseases with a nicotinic cholinergic deficit.
- Galantamine has primarily been used for the treatment of a number of neuromuscular disorders, including Myasthenia gravis and poliomyelitis.
- EP-A 648 771, EP-A 649 846 and EP-A 653 427 all describe Galantamine derivatives, a process for their preparation and their use as medicaments, however none of these applications considers ways and means of enhancing penetration through the blood-brain barrier and brain-to-plasma ratio of base compounds and derivatives.
- U.S. Pat. No. 6,150,354 refers to several Galantamine analogues for the treatment of Alzheimer's disease. However, selective chemical modification for the purpose of increasing penetration through the blood-brain barrier is not considered.
- WO 01/74820, WO 00/32199 and WO 2005030333 refer to derivatives and analogues of Galantamine for the treatment of a variety of human brain and other diseases, and acute functional brain damage. However, selective chemical modifications or other means of improving blood-brain barrier penetration are not considered.
- WO 88/08708, WO 99/21561, WO 01/43697 and US 2003/0162770 refer to derivatives and analogues of Galantamine for the treatment of various cognitive symptoms. However, selective chemical modifications or other means of improving blood-brain barrier penetration are not considered.
- WO 2005/030713 refers to a method for the synthesis of optical isomers of Galantamine from a Narwedine bromoamide derivative. However, it does not deal with other derivatives of Galantamine, or their use as medicaments, or chemical modifications aimed at enhancing blood-barrier penetration of said compounds.
- WO 97/40049 describes several derivatives of benzazepines and related compounds that may be applied for the treatment of Alzheimer's disease. However, no concept is provided in this application for increasing the penetration of compounds through the blood-brain barrier.
- Some embodiments provide compounds usable as pro-drugs or as a medicament having high pharmacodynamic effects in the brain's central nervous system and low peripheral side effects.
- Other embodiments relate to procedures for achieving a favorable distribution ratio of brain to periphery for antidementia drugs of various kinds, including cholinergic receptor sensitizing agents, cholinesterase inhibitors and neuroprotective drugs.
- the therapeutic effect-to-dose ratio can be increased and adverse side-effects can be reduced when the drugs are administered as medicaments for the diseases mentioned in the present application.
- This object is particularly met e.g., by site-specific chemical modification (derivatization) of said compounds.
- FIG. 1 125 chemical structures and log P values of new compounds that (i) act as cholinergic enhancers, and/or (ii) have higher log P-values than Galantamine (Galantamine included in Table 4 for comparison).
- FIG. 2 Brain esterase inhibition by galantamine and several pro-galantamines.
- a 20% mouse brain homogenate was used, supplemented with 200 ⁇ M of acetylthiocholine as substrate, and the initial reaction kinetics were measured according to Riddles P W, Blakeley R L, Zerner B., “Reassessment of Ellman's reagent” Methods Enzymol. 1983, 91:49-60.
- a non-cleavable galantamine derivative leads to negative values.
- Gln 1063 R1 in Formula V is —O—Si(CH 3 ) 2 —C(CH 3 ) 2 —C(CH 3 ) 2 H.
- FIG. 3 Enzymatic cleavage of pro-galantamine to galantamine. Butyrylcholinesterase, 25 units/ml, was used. Reaction temperature was 37° C. Appearance of the fluorescent reaction product galantamine was determined by fluorescence detection.
- FIG. 4 Interaction of galantamine and pro-galantamine with a4 ⁇ 2 neuronal nicotinic acetylcholine receptor ectopically expressed in HEK-293 cells.
- Galantamine achieved a maximal enhancement of response of ⁇ 40% whereas the pro-galantamine achieved a maximal enhancement of only ⁇ 17%.
- FIG. 5 Pharmacokinetics of pro-galantamine Gln-1062 (3 mg/kg) in the mouse.
- 5a shows the measurable concentration of applied pro-galantamine and the resulting concentration of galantamine by cleavage of the pro-galantamine in brain and blood.
- the curve starting with the highest concentration refers to derivative GLN-1062, which is benzoyl-galantamine, in brain.
- FIG. 5 b is an excerpt (“zoom”) of FIG. 5 a , showing the concentration range between 0.00 and 1.00 ⁇ g/g (substance/body weight) more in detail.
- FIG. 5 Pharmacokinetics of pro-galantamine Gln-1062 (3 mg/kg) in the mouse.
- 5a shows the measurable concentration of applied pro-galantamine and the resulting concentration of galantamine by cleavage of the pro-galantamine in brain and blood.
- the curve starting with the highest concentration refers to derivative GLN-1062, which is benzoyl-galantamine, in brain.
- the curve above refers to the concentration of resulting galantamine in brain
- the middle curve shows the concentration of galantamine in blood
- FIG. 6 Behavioral index for gastro-intestinal side effects in ferrets following application of galantamine and several R1-pro-galantamines, respectively.
- FIG. 7 Reversal from scopolamine-induced amnesia in mice, in the presence of galantamine and several R1-pro-galantamines, respectively. Scopolamine induces a memory deficit that can be measured by increased alternation in a T-maze trial.
- the cognition enhancing drugs were i.p. injected at several different doses together with scopolamine 20 min before a T-maze trial. Recovery was measured as a function of dose, and the EC 50 was determined for each drug.
- the present disclosure relates to significant enhancement in the brain-to-plasma ratio of cholinergic receptor sensitizing agents, such as the APL Galantamine (and related compounds), which is achieved by administering not the drug itself but a “pro-drug” that is converted (back) to the drug itself inside the brain of the patient.
- cholinergic receptor sensitizing agents such as the APL Galantamine (and related compounds)
- the compounds themselves have been chemically modified so as to not only having larger efficacy as nicotinic APL and/or as neuroprotective agent, but in addition having enhanced lipophilicity (higher log P) or otherwise improved BBB transport properties.
- the pro-drugs and other compounds addressed in this application should be significantly more potent as medicaments for the treatment of cognitive disorders than is, for example, Galantamine.
- the invention applies to the compounds, selected pro-drugs and pharmaceutically acceptable salts thereof, which might be administrated via the mouth, blood, skin, by nasal application, or any other suitable application route.
- pro-drug refers to a derivative of a base compound wherein the group(s) added or replaced on said base compound are cleaved or returned to the group originally contained in the base compound when the derivative has reached the area or site of action.
- an effective agent is administrated as a derivative (which is said pro-drug), however, the compound mainly or exclusively effective at the target site within the brain is the agent itself, not the derivatized compound or metabolites thereof.
- derivative refers to any change of a base compound defined in the present application.
- derivative is used to describe a compound which either can be a pro-drug, or can be an effective agent itself/in its own right or in the derivatized form.
- sensitizing agent and “allosterically potentiating ligand, APL” refer to effectors that enhance cholinergic neurotransmission by direct interaction via an allosteric site with cholinergic receptors.
- cholinergic enhancer and “cholinergic agent” refer to compounds that enhance/modulate cholinergic neurotransmission by inhibition of cholinesterases, by allosteric sensitization and/or direct activation of cholinergic receptors and/or by activating/modulating relevant intracellular pathways via second messenger cascades.
- a derivative or pro-drug has an “enhanced blood-brain barrier permeability “according to the present invention or an “enhanced blood-brain barrier penetration” if, after administration of a pro-drug or derivative thereof to a living organism, a higher amount of said compound penetrates through the BBB, resulting in a higher level of effective agent in the brain, as compared to administration of the base compound without derivatization.
- the enhanced BBB penetration should result in an increased brain-to-tissue ratio of the effective agent compared to the ratio of the base compound.
- the “base compound” according to the present invention preferably is Galantamine, Norgalantamine, Narwedine, N-Demethylnarwedine, Lycoramine, Lycoraminone, Sanguinine, Norsanguinine, and others (see table 1).
- log P is defined as the decadic logarithm of the partition coefficient P which is the ratio of the concentration of a compound in aqueous phase to the concentration of a compound in immiscible solvent, as the neutral molecule.
- alkyl shall mean a straight, branched or cyclic alkyl group of the stated number of carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, sec-butyl, t-butyl, and straight and branched chain pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, pentadecyl etc. . . . or the according cyclic alkyls.
- halo shall mean chloro, fluoro, bromo and iodo.
- aryl shall mean phenyl having 0, 1, 2 or 3 substituents independently selected from the group of alkyl, alkoxy, alkylcarbonyl, halo- or trihalomethyl.
- cycloalkyl shall mean a cycloalkyl group of from 3 to 12 carbon atoms and including multiple ring alkyls such as for example, adamantyl, camphoryl, and 3-noradamantyl.
- C 1 -C 8 means C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 or C 8 ; or “between 0.1 and 1” means 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.
- a “natural amino acid” is any amino acid naturally occurring in biochemical pathways or in peptides/proteins. These are particularly alanine, asparagine, cysteine, glutamine, phenylalanine, glycine, histidine, isoleucine, methionine, proline, glutamate, arginine, serine, threonine, valine, thryptophane, tyrosine, their methylated forms or the according salts.
- sugar any suitable sugar, either an aldose or ketose, a pyranose or furanose, heptose or hexose, mono- or polysaccharide, like e.g., glucuronic acid, glucose, fructose, galactose, mannose, saccharose, lactose, maltose etc., however, glucuronic acid is preferred.
- the main focus of the present invention is to improve blood-brain barrier permeability, by increasing the lipophilicity or the transport properties, or the ability of passing the blood-brain barrier, of compounds that are known to act as effective agents in correcting a cholinergic deficit, e.g., APL of nicotinic receptors or inhibitors of cholinesterases.
- the present invention refers to a method for increasing blood-brain barrier penetration of a cholinergic enhancer by preparing derivatives (either formally by their chemical structure or directly by chemical synthesis) of a molecule with a base structure of the general formula (I):
- the compounds listed in Table 1, and other compounds to be used as a base compound for derivatization according to the present invention, can be obtained either by isolation from natural sources or by total chemical synthesis, or by chemical modification of natural or synthetic compounds.
- the compounds to be used according to the present invention can be derivatives of the above listed molecules that can be demonstrated to act as cholinergic enhancers.
- This property of said derivatives may be manifested by one or more of the following properties; by their ability to sensitize cholinergic receptors, and/or inhibit brain cholinesterases, and/or modulate intracellular messenger levels, and/or act neuroprotective.
- the ability to act as sensitizing agent on nicotinic receptors can be determined by electrophysiological and Ca-imaging methods, as described in Schrattenholz A et al. (1996) Mol Pharmacol 49, 1-6 and Samochocki M et al (2000) Acta Neuro Scand Suppl 176, 68-73; Samochocki M et al.
- the ability to inhibit cholinesterases can be determined by the photometric method of Ellman et al., Biochem. Pharmacol. 7,88 (1961).
- the ability to modulate intracellular messenger levels can be determined by Ca-imaging methods (Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036) and other means of recording changes in intracellular messenger levels or effects resulting thereof (Kihara T et al (2004) Biochem Biophys Res Commun 325, 976-982).
- the ability to act neuroprotective can be determined by a variety of in vitro and in vivo test systems, including in cell culture (Arias E et al (2003) Neuropharmacol 46, 103-1S 14; Kihara T et al (2004) Biochem Biophys Res Commun 325, 976-982) and in animal models of neurodegenerative diseases (Capsoni et al (2002) Proc Natl Acad Sci USA 99, 12432-12437).
- Table 2 exemplifies compounds that are derivatives of a base structure of the following general formula (III)
- bonds ⁇ 1> and ⁇ 2> denotes a single- or double bond, with the proviso that the structure is not any of those listed in Table 1 and the bonds ⁇ 1> to ⁇ 2> and ⁇ 11> to ⁇ 12> can be either a single or a double bond, and the bond between ⁇ 10> and ⁇ 11> is either a single bond or no bond and the residues R1-R5 are defined as follows:
- the nitrogen bears an additional positive charge as well as a counterion, selected from chloride, bromide, iodide, sulphate, nitrate, hydrogensulfate, phosphate, methanesulphonate, tosylate or other pharmaceutically acceptable anion.
- a counterion selected from chloride, bromide, iodide, sulphate, nitrate, hydrogensulfate, phosphate, methanesulphonate, tosylate or other pharmaceutically acceptable anion.
- Preferred derivatives of the main concept of the invention are quaternary ammonium salts with a labile nitrogen-carbon bond at R5; mono- or diacylderivatives (esters) of the hydroxyl groups of said base compounds (R1, R2); sugar derivatives, preferably glucuronides (R1, R2); derivatives coupled with nicotinic acid (R1, R2); and selected halogenides (R3).
- Another preferred derivative of the main concept is a lipophilic dihydropyridinium carrier.
- This Redox Chemical Delivery System (RCDS; Misra A et al (2003) J Pharm Pharmaceut Sci 6, 252-273) is known to significantly enhance drug delivery through the BBB into the brain parenchyma.
- the dihydropyridinium moiety is enzymatically oxidized to the corresponding ionic pyridinium salt. Subsequent cleavage of the original compound from the carrier leads to liberation of the original compound and to sustained levels of it in the brain tissue.
- amino acids that are known to be transported into the brain by active amino acid carriers, e.g., tyrosine. Once inside the brain parenchyma, these derivatives can either directly act on their target molecules or are first enzymatically liberated before acting as the original aren't compound.
- the derivatives obtained by chemical modification do not need to work as such as medicaments but rather may initially be pro-drugs that, after penetration though the blood-brain barrier, are converted (e.g., by brain enzymes) to the parent compound or a metabolite thereof and work as such as a medicament.
- Said pro-drug or derivative is used to prepare a medicament or pharmaceutical composition that preferably can be used for the treatment of brain diseases associated with a cholinergic deficit.
- FIG. 1 Examples of new compounds that (i) act as cholinergic enhancers, and/or (ii) have higher log P-values than Galantamine (the latter for comparison only) are shown in FIG. 1 .
- the derivatives shown in Table 3 and FIG. 1 may be used to prepare a medicament or other pharmaceutical composition.
- Such medicament or pharmaceutical composition can be used for the treatment of a disease state associated with a cholinergic deficit.
- the usefulness of the derivatives, before and/or after conversion to the parent compound, to act as effective pharmaceutical agents is manifested by their ability to sensitize cholinergic receptors, and/or inhibit brain cholinesterases, and/or modulate intracellular messenger levels, and/or act neuroprotective.
- the ability to act as sensitizing agent on nicotinic receptors can be determined by electrophysiological and Ca-imaging methods, as described in Schrattenholz A et al. (1996) Mol Pharmacol 49, 1-6 and Samochocki M et al (2000) Acta Neuro Scand Suppl 176, 68-73; Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036.
- the ability to inhibit cholinesterases can be determined by the photometric method of Ellman et al., Biochem. Pharmacol. 7,88 (1961).
- the ability to modulate intracellular messenger levels can be determined by Ca-imaging methods (Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036) and other means of recording changes in intracellular messenger levels or effects resulting thereof (Kihara T et al (2004) Biochem Biophys Res Commun 325, 976-982).
- the ability to act neuroprotective can be determined by a variety of in vitro and in vivo test systems, including in cell culture (Arias E et al (2003) Neuropharmacol 46, 103-1S 14; Kihara T et al (2004) Biochem Biophys Res Commun 325, 976-982) and in animal models of neurodegenerative diseases (Capsoni et al (2002) Proc Natl Acad Sci USA 99, 12432-12437).
- This usefulness can also be ascertained by determining the ability of these compounds (I) to reduce neuronal cell death and amyloid plaque formation as well as cognitive impairment in animal models of Alzheimer's disease (Capsoni et al (2002) Proc Natl Acad Sci USA 99, 12432-12437) and (2) to enhance learning performance in various animal test systems.
- the classical eye blink conditioning is used to study the effect of cognition-enhancing drugs on the septohippocampal cholinergic system.
- An active test compound of the present invention will reduce the number of trials required to learn that the air blow applied onto the animal's eye does not require the animal to close the eye (eye blink) as a protective measure.
- DAA Dark Avoidance Assay
- a nicotinic or muscarinic antagonist i.e., an anticholinergic drug that causes memory impairment
- an anticholinergic drug that causes memory impairment
- test results may be expressed as the percent of a group of animals in which the effect of the anticholinergic drug is blocked or reduced, as manifested by an increased time interval between being placed in the test chamber and re-entering the dark compartment.
- the brain disease that can be treated with the pro-drugs and derivatives provided herewith can be any psychiatric, neurological and neurodegenerative disease associated with a cholinergic deficit of any kind, including a neurodegenerative loss of cholinergic neurotransmitters and/or receptors, ACh-synthesizing and metabolizing enzymes, transport proteins and the like.
- Such diseases are exemplified by Alzheimer's and Parkinson's disease, other types of dementia, schizophrenia, epilepsy, stroke, poliomyelitis, neuritis, myopathy, oxygen and nutrient deficiencies in the brain after hypoxia, anoxia, asphyxia, cardiac arrest, chronic fatigue syndrome, various types of poisoning, anesthesia, particularly neuroleptic anesthesia, spinal cord disorders, inflammation, particularly central inflammatory disorders, postoperative delirium and/or subsyndronal postoperative delirium, neuropathic pain, subsequences of the abuse of alcohol and drugs, addictive alcohol and nicotine craving, and subsequences of radiotherapy, and more.
- anesthesia particularly neuroleptic anesthesia
- spinal cord disorders inflammation, particularly central inflammatory disorders, postoperative delirium and/or subsyndronal postoperative delirium, neuropathic pain, subsequences of the abuse of alcohol and drugs, addictive alcohol and nicotine craving, and subsequences of radiotherapy, and more.
- Galantamine or other cholinesterase inhibitors in treatment of such diseases are described e.g., in WO2005/74535, WO2005/72713, WO2005/41979, WO2005/30332, WO2005/27975, US2004/266659 and WO2004/14393.
- the common feature of the derivatives of the present application is that they all penetrate more effectively through the blood-brain barrier than the base compound, which according to the present invention preferably is Galantamine and related compounds. As a result of their improved BBB penetration properties, these compounds should have higher therapeutic efficacy and lower adverse side effects than e.g., Galantamine.
- the compounds of the present invention whether pro-drugs or otherwise effective agents can be administered as such or as a pharmaceutically acceptable salt thereof.
- the derivatives of the common formulae as defined above can be prepared by any known method, however, it is preferred that the derivatives are prepared with proper use by the methods described for derivatization of according compounds in EP-A 649 846 with reference to scheme I and in the examples; EP-A648 771 with reference to scheme I and in the examples; EP-A 653 427 with reference to scheme I and in the examples; U.S. Pat. No. 6,150,354, paragraph “procedures” and examples; or U.S. Pat. No. 6,638,925, paragraph “experimental section”, respectively.
- a further reference is WO 01/74820, wherein combinatory and/or parallel synthesis is disclosed and synthesis of several compounds is described in the examples. Further the method can be used as described in Gomes, P.
- the compounds of the invention preferably are prepared from the appropriate optical isomer of Galantamine or Narwedine via the intermediate 6-demethylgalantamine, a known therapeutically effective compound, or 6-demethylnarwedine, respectively.
- pro-drugs and derivatives of this invention are selected by the following tests, which shall be considered as examples not limiting the invention:
- log P-values are provided in some of the tables. Improved lipophilicity, as characterized by an increased log P-value, can either be determined experimentally including HPLC methods or by predictive computational methods. Although such calculations cannot replace the experiment, the data are strongly suggestive as to whether a certain modification of the base compound will result in an improved lipophilicity.
- Computer programs that allow such calculations include e.g., ToxBoxes from Pharma Algorithms, ACD-Lab, Molecule Evaluator from Cidrux, and others.
- Another means of estimating the readiness of a compound to transverse the BBB is by experimental comparison of the membrane affinity of said compound to its binding affinity to serum albumin, both determined by the NIMBUS Biotechnology assay (Willmann, S. et al. (2005) J Med Chem, in print).
- Effective quantities of the compounds of the invention may be administered to a patient by any of various methods, including orally as in capsules or tablets, via the skin or by nasal application.
- the free base final products while effective by themselves, may be formulated and administered in the form of a pharmaceutically acceptable salt, e.g., for purposes of stability, convenience of crystallization, increased solubility, release retardation, and the like.
- the pro-drugs/compounds of the present invention pass the blood-brain-barrier easier than the base compounds, there are two advantageous aspects: first is the fast uptake of the pro-drug and therefore a fast onset of effect, second is that the dosage of application can be decreased compared to known medicaments resulting in lower peripheral side effects with high efficacy of the compounds at their effect site (brain). Further the pro-drugs after passage through the blood-brain-barrier are converted in the base compound which has a lower permeability through the blood-brain-barrier, thus the effective compound remains in the brain, resulting in a longer time period of effectiveness.
- the active compounds of the present invention may be orally administered, for example, with an inert diluent or with an edible carrier, or they may be enclosed in gelatine capsules, or they may be compressed into tablets.
- the active compounds of the invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gum and the like.
- Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 0.1 and 50 milligrams of active compound.
- the proposed derivatives were designed as pro-drugs, in the sense that they are able to effectively pass the blood brain barrier (BBB) and, after passing the BBB, they are substrates of endogenous enzymes and, upon enzymatic cleavage, produce galantamine.
- BBB blood brain barrier
- R1 being a substituent having particular sterical and hydrophobic properties.
- esters of galantamine display unexpectedly high brain-to-blood concentration ratios (R BB -proGal>6, as compared to R BB -Gal ⁇ 1.3) and in the brain they are relatively slowly enzymatically cleaved to galantamine. Therefore, as is discussed below in more detail, these pro-galantamines are exceptionally well suited for the treatment of human diseases associated with cholinergic deficits, such as Alzheimer's disease, Parkinson's disease, Schizophrenia and a variety of other psychiatric disorders.
- esters of galantamine to which the present invention refers to have the following general structure:
- R1 either is CH(C 2 H 5 )CH 3 , CH 2 —C(CH 3 ) 3 , or cyclopropane or being an optionally substituted aromatic or hetero-aromatic 5- or 6-membered ring.
- aromatic and hetero-aromatic rings include benzene, naphthalene, thiophene, pyrrole, imidazole, pyrazole, oxazole and thiazole, in case that they are used as medicaments or pro-drugs for the treatment of neurodegenerative or psychiatric or neurological disease associated with a cholinergic deficit.
- Such a disease preferably is selected from Alzheimer's and Parkinson's disease, other types of dementia, schizophrenia, epilepsy, neuritis, various types of poisoning, anesthesia, particularly neuroleptic anesthesia, autism, spinal cord disorders, inflammation, particularly central inflammatory disorders, postoperative delirium and/or subsyndromal postoperative delirium, neuropathic pain, subsequences of the abuse of alcohol and drugs, addictive alcohol and nicotine craving, and subsequences of radiotherapy.
- compounds of formula I having aromatic or hetero-aromatic 5- or 6-membered ring selected from substituted benzene with the proviso that it is not 2-fluorobenzene or 3-nitro-4-fluorobenzene, optionally substituted naphthalene, thiophene, pyrrole, imidazole, pyrazole, oxazole, thiazole; or CH(C 2 H 5 )CH 3 , CH 2 —C(CH 3 ) 3 , or cyclopropane are according to the knowledge of the inventor not yet described at all.
- R2-R6 comprising any substituent selected from H, halogen, optionally substituted C 1 -C 3 alkyl or cyclopropyl, OH, O-alkyl, SH, S-alkyl, NH 2 , NH-alkyl, N-dialkyl, optionally substituted aryl or hetero-aryl, whereby neighbouring substitutents can cooperate to form an additional ring.
- the compounds are selected from the group consisting of the compounds as shown in table A, which is attached below.
- pro-drug refers to a derivative of galantamine (base compound) wherein the group(s) added or replaced on said base compound are cleaved or returned to the hydroxyl group originally contained in the base compound, when the derivative has reached the area or site of action.
- an effective agent is administrated as a derivative (which is said pro-drug), however, the compound mainly or exclusively effective at the target site within the brain is the agent itself, not the derivatized compound or metabolites other than the base compound thereof.
- derivative refers to any change of a base compound defined in the present application.
- derivative is used to describe a compound which either can be a pro-drug, or can be an effective agent itself/in its own right or in the derivatized form.
- pro-galantamine is used for any derivative of galantamine described herein which can be cleaved by an enzyme (esterase) resulting in galantamine.
- sensitizing agent and “allosterically potentiating ligand, APL” refer to effectors that enhance cholinergic neurotransmission by interaction with an allosteric site at cholinergic receptors.
- cholinergic enhancer and “cholinergic agent” refer to compounds that enhance/modulate cholinergic neurotransmission by inhibition of cholinesterases, by allosteric sensitization and/or direct activation of cholinergic receptors and/or by activating/modulating relevant intracellular pathways via second messenger cascades.
- a derivative or pro-drug has an “enhanced blood-brain barrier permeability “according to the present invention or an “enhanced blood-brain barrier penetration” if, after administration of a pro-drug or derivative thereof to a living organism, a higher amount of said compound penetrates through the BBB of that organism.
- the “base compound” as well as the “effective agent” according to the present invention is galantamine.
- the effective agent is obtained by (local) enzymatic cleavage of the derivative.
- log P is defined as the decadic logarithm of the partition coefficient P which is the ratio of the concentration of a compound in aqueous phase to the concentration of a compound in immiscible solvent, as the neutral molecule.
- alkyl shall mean a straight, branched or cyclic alkyl group.
- C 1 to C 10 alkyl groups are preferred, C 2 to C 8 groups are more preferred and C 2 to C 6 groups are most preferred.
- C 1 to C 10 means alkyl groups of the stated number of carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, sec-butyl, t-butyl, and straight and branched chain pentyl, hexyl, heptyl, octyl, nonyl and decyl etc. . . . or the according cyclic alkyls.
- halo shall mean chloro, fluoro, bromo and iodo.
- aryl shall mean phenyl having 0, 1, 2, 3, 4 or 5 substituents independently selected from the group of alkyl, alkoxy, alkylcarbonyl, halo- or trihalomethyl.
- cycloalkyl shall mean a cycloalkyl group of from 3 to 10 carbon atoms and including multiple ring alkyls such as for example, adamantyl, camphoryl, and 3-noradamantyl.
- C 1 -C 10 means C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 or C 10 ; or “between 0.1 and 1” means 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.
- Benzoyl esters of galantamine were previously described in WO 9921561 A1 Davis, Bonnie M. for a method of treatment of disorders of attention with galantamine, lycoramine, and related compounds, but no syntheses or analytical or other data were provided for these compounds.
- the galantamine esters of the present invention have little, if any, activity as acetylcholinesterase inhibitors but rather are substrates of said enzyme (see above).
- the pro-galantamines referred to in the present document are substrates of the enzyme, as is exemplarily demonstrated in FIG. 3 .
- FIGS. 2 and 3 demonstrate that pro-galantamines of the present invention do not act as efficient inhibitors of cholinesterase, as was described in the earlier documents discussed above. Instead, they are substrates of these enzymes. Similarly, they also do not interact to the same extend as galantamine with neuronal nicotinic acetylcholine receptors ( FIG. 4 ).
- pro-galantamines of the present invention therefore either do not interact, or only to a very limited extend, with the established target molecules of galantamine, in particular cholinesterases and neuronal nicotinic acetylcholine receptors.
- pro-drugs they therefore have rather limited, if any, efficacy as cognition enhancers, and also produce only limited peripheral and central side effects, as compared to galantamine (see further below).
- R1-benzoyl-galantamine displays an unexpectedly high brain-to-blood concentration ratio (R BB -proGal>19), a large initial concentration in the brain, and it is only slowly cleaved to galantamine, as seen in the delayed appearance of a galantamine peak in brain and blood.
- the R BB -value is significantly larger than what was expected from the log P value which probably is due to the slow cleavage of the pro-drug in the brain and a depot effect thereby produced.
- R1 substitutions are capable of producing the following advantageous properties of pro-galantamines; high initial concentration in the brain, large R BB , and slow enzymatic conversion to galantamine.
- the preferred R1-prodrugs display little, if any side effects, as they are only very slowly converted to galantamine, thereby largely protecting them from acting as galantamine while being transported from the site of administration to the sites of action in the brain.
- R1-pro-galantamines of the present invention display in ferrets much less gastro-intestinal side effects than galantamine. Ferrets were used in these studies as they are known to be particularly sensitive to gastro-intestinal side effects.
- SA salivation
- SH shivering
- RP respiratory problems
- DI diarrhea
- the compounds of this invention are particularly useful as medicaments for the treatment of human brain diseases associated with a cholinergic deficit, including the neurodegenerative diseases Alzheimer's and Parkinson's disease and the neurological/psychiatric diseases vascular dementia, schizophrenia and epilepsy.
- the compounds Based on preclinical studies using various animal models, the compounds have dramatically reduced side effects as compared to galantamine, including much fewer, if any, incidents of emetic responses, diarrhea and vomiting.
- the resulting galantamine displays an advantageous pharmacokinetic profile in the brain and, due to its enhanced concentration level in the brain, displays also enhanced efficacy in interaction with the target molecules located in the brain. Taken together, these properties make the administration of galantamine as a R1-prodrug a preferred medication in the diseases mentioned above.
- Acids useful for preparing the pharmaceutically acceptable acid addition salts according to the invention include inorganic acids and organic acids, such as sulfamic, amidosulfonic, 1,2-ethanedisulfonic, 2-ethylsuccinic, 2-hydroxyethanesulfonic, 3-hydroxynaphthoic, acetic, benzoic, benzenesulfonic acid, carboxylic, ethylenediamine tetraacetic acid, camphorsulfonic, citric, dodecylsulfonic, ethanesulfonic, ethenesulfonic, ethylenediamine tetraacetic, fumaric, glubionic, glucoheptonic, gluconic, glutamic, hexylresorcinic, hydrobromic, hydrochloric, isethionoc, (bi)carbonic, tartaric, hydriodic, lactic, lactobionic, laevulinic, laurylsul
- the active compounds of the present invention may be orally administered, for example, with an inert diluent or with an edible carrier, or they may be enclosed in gelatin capsules, or they may be compressed into tablets.
- the active compounds of the invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gum and the like. These preparations should contain at least 0.5% of active compounds, but may be varied depending upon the particular form and may conveniently be between 5% to about 70% of the weight of the unit. The amount of active compound in such compositions is such that a suitable dosage will be obtained.
- Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 0.1-50 milligrams of active compound.
- the tablets, pills, capsules, troches and the like may also contain the following ingredients: a binder such as micro-crystalline cellulose, gum tragacanth or gelatin: an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, cornstarch and the like; a lubricant such as magnesium stearate or Sterotex; a glidant such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin may be added or a flavouring agent such as peppermint, methyl salicylate, or orange flavouring.
- a binder such as micro-crystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, cornstarch and the like
- a lubricant such as magnesium stearate or Sterotex
- a glidant such as colloidal silicon dioxide
- dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings.
- tablets or pills may be coated with sugar, shellac, or other enteric coating agents.
- a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, colourings and flavours. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.
- the active compounds of the invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of active compound, but may be varied between 0.5 and about 30% of the weight thereof. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present inventions are prepared so that a nasal or parenteral dosage unit contains between 0.1 to 20 milligrams of active compound.
- the compounds of the present invention can be administered via intranasal delivery to the cerebral spinal fluid as disclosed in detail in WO2004/02404.
- the solutions or suspensions may also include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene-diamine tetraacetic acid; buffers such as acetates; citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
- Parenteral multiple dose vials may be of glass or plastic.
- Typical dosage rates in administration of the active ingredients depend on the nature of the compound that is used and in intravenous administration are in the range of 0.01 to 2.0 mg per day and per kilogram of body weight based on the physical condition and other medications of the patient.
- Tablets and capsules that contain 0.5 to 50 mg.
- Solution for parenteral administration that contains 0.1 to 30 mg of active ingredient/ml.
- Liquid formulations for oral administration at a concentration of 0.1 to 15 mg/ml.
- Liquid formulations for nasal or intra-cerebroventricular administration at a concentration of 0.1 to 5 mg of active ingredient/ml.
- the compounds according to the invention can also be administered by a transdermal system, in which 0.1 to 10 mg/day is released.
- a transdermal dosage system may consists of a storage layer that contains 0.1 to 30 mg of the active substance as a free base or salt, in case together with a penetration accelerator, e.g., dimethyl sulfoxide, or a carboxylic acid, e.g., octanoic acid, and a realistic-looking polyacrylate, e.g., hexylacrylate/vinyl acetate/acrylic acid copolymer including softeners, e.g., isopropylmyristate.
- an active ingredient-impermeable outside layer e.g., a metal-coated, siliconised polyethylene patch with a thickness of, for example, 0.35 mm, can be used.
- an adhesive layer e.g., a dimethylamino-methacrylate/methacrylate copolymer in an organic solvent can be used.
- the invention also relates to pharmaceutical compositions that in a pharmaceutically acceptable adjuvant contain a therapeutically effective amount of at least one of the compounds that are proposed according to the invention.
- DCM dichloromethane
- DMAP 4-dimethylaminopyridine
- DCC dicyclohexylcarbodiimide
- DCHU dicyclohexylurea
- N-Methoxymethyl-galanthaminiumchloride is obtained from Galantamine via alkylation using chloromethylmethylether:
- the crude product (4.20 g, 82%) has a purity of 96% (HPLC).
- HPLC HPLC
- the crude product is dissolved in dry ethanol, stirred after the addition of activated charcoal, filtered and added to ethyl acetate (500 mL). The precipitate is filtered and washed using ethyl acetate (3 ⁇ 50 mL) and dry diethylether (1 ⁇ 50 mL). The product is obtained in the form of colourless crystals (3.85 g, 75% d. Th.) melting at 126-127° C.
- This compound was prepared using the procedure of example 2 with N-Boc-phenylalanine chloromethylester.
- N-methylgalanthaminium iodide 5.0 g, 11.6 mmol
- 35% aqueous potassium hydroxide 150 mL
- aqueous potassium hydroxide 150 mL
- the aqueous phase is basified using conc. ammonia to pH 12 and extracted using dichloromethane (4 ⁇ 100 mL).
- 3-Chloroperbenzoic acid (0.38 g, 75% ig, 1.66 mmol) is added to a solution of (3R,4aS,9bS)-9-dimethylaminomethyl-6-methoxy-3,4,4a,9b-tetrahydro-9b-vinyl-dibenzofuran-3-ol (0.50 g, 1.66 mmol) in dichloromethane (35 mL) and then stirred for 30 minutes at room temperature. After adding a solution of iron(II) sulfate-heptahydrate (0.23 g, 0.83 mmol) in methanol (5 mL) it is then stirred for another 20 minutes at room temperature.
- Ammonia gas pre-dried by passing it through a bed of sodium hydroxide was bubbled through CH 2 Cl 2 (200 mL) at ⁇ 4° C. over 1 h at a rate which kept the temperature below 0° C.
- the above methyl 1,2,3,4-tetra-O-isobutyryl- ⁇ -D-glucopyranuronate (3.0 g, 8 mmol) was added and the solution stirred at 0° C. for 3 h and then left at room temperature for 20 h.
- Nitrogen gas was bubbled through the solution for 30 min. and it was extracted with ice-cold 10% aqueous HCl, then water. The organic phase was dried over Na 2 SO 4 filtered and solvent removed in vacuo to leave the crude product.
- Step 3 Methyl 2,3,4-tri-O-isobutyryl-1-O-trichloroacetimidoyl- ⁇ -D-glucopyranuronate (4)
- Step 5 (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-yl- ⁇ -D-glucopyranosiduronic acid (Galantamine-3-glucuronide) (6)
- This product was converted to the dihydrobromide salt by dissolution in a minimum amount of warm 40% hydrobromic acid followed by cooling and obtained as colorless crystals.
- Step 2 4-Fluoro-5- ⁇ [2-(4-hydroxyphenyl)ethylamino]-methyl]-2-methoxy-phenol (2)
- Step 4 4 ⁇ ,5,9,10,11,12-Hexahydro-1-fluoro-3-methoxy-11-formyl-6H-benzofuro[3a,3,2-ef]benzazepine-6-one (4)
- Step 5 1-Bromo-4a,5,9,10-tetrahydro-3-methoxy-spiro[6H-benzofuro[3a,3,2-ef][2]benzazepine-6,2′-[1,3]dioxolane]-11(12H)-carboxaldehyde (5)
- reaction mixture was cooled to room temperature and extracted with acetic acid (2 ⁇ 25 ml, 10% in water), sodium hydrogen carbonate (2 ⁇ 25 ml, 10% in water) and brine (1 ⁇ 25 ml).
- the toluene solution was dried (Na 2 SO 4 ) and evaporated to give a crude product (1.32 g) as an amber oil. This was crystallized using i-propanol and ligroin to give product (0.92 g, 72%), as a colourless crystals.
- the aqueous phase was extracted using ethyl acetate (3 ⁇ 100 ml), the combined organic phases were washed with brine (50 ml), dried (Na 2 SO 4 ) and evaporated to afford the crude product (515 mg) as a clear, slightly yellow oil which was purified by chromatography on silica using MeOH:CH 2 Cl 2 9:1 to afford the product (0.46 g, 92%, HPLC>99%) as a white powder.
- L-Phenylalanine, (4aS,6S,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-yl ester was prepared from the compound obtained in example 20 by Boc-deprotection using trifluoro acetic acid in methylene chloride followed by the usual workup and resulted in the product as a white powder.
- L-histidine-(4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-yl ester hydrochloride was prepared from the compound of example 14 using HCl in ethyl acetate for deprotection and resulted in the isolation of the product as the hydrochloride.
- Chlorsulfonic acid (0.16 g, 1.39 mmol) was added to dry pyridine (1 ml) preheated to 70-80° C. and stirred at the same temperature for 30 min.
- a solution of galantamine (0.20 g, 0.70 mmol) in dry pyridine (1 ml) was added drop wise and the mixture was stirred overnight at room temperature with the formation of a precipitate.
- MeOH/H 2 O 1:1 (5 ml) was added and the resulting clear solution was stirred for further 30 min. Volatiles were rotoevaporated and another portion of MeOH (5 ml) was added. The resulting fine precipitate was filtered to give (0.21 g, yield 82%, HPLC>99%) of product as a white powder.
- IR 1700.59, 1652.92, 1623.93, 1617.01, 1510.15, 1475.31, 1443.53, 1299.82, 1282.40, 1266.98, 1242.70, 1217.83, 1197.48, 1155.3, 1092.40, 1070.97, 1053.15, 1023.70, 1007.21, 984.45.
- the brain is removed from the animal (mouse), shock frozen in liquid nitrogen and stored at minus 80° C. until use. Before preparing the extract, the frozen brain is thawed on ice and the weight is determined. Ice cold buffer (130 mM NaCl, 5 mM KCl, 2.5 mM CaCl 2 , 1 mM MgCl 2 , 5 mM Glucose, 5 mM HEPES, pH 7.4) is added to the thawed mouse brain (1:4, weight to volume, resulting in a 20% brain homogenate). The tissue is then homogenized in a potter homogeniser on ice, moving the piston up and down 11 times at 240 rpm. The freshly prepared mouse brain homogenate is divided into aliquots.
- a modified Ellmann's esterase test is used. Briefly the method relies on the cleavage of the substrate acetylthiocholine to acetate and thiocholine. The latter reacts with DTNB (5,5′-Dithiobis-(2-nitro-benzoicacid) to a yellow compound, which can be quantified spectrometrically.
- the incubation buffer contains 51 mmol/l sodium phosphate buffer and 0.05% Tween 20, at pH 7.2 and is supplemented with 100 mg/l DTNB, and 0.2% mouse brain homogenate (prepared as described in Example 29). The compound to be investigated is added to the desired concentration. The mixture is brought to 37° C.
- a 405 is measured in 1 s intervals in a microplate reader for 40 s.
- the linear parts of the absorption-time-curves represent the starting speed of the enzymatic reaction and are used for the calculation of the reaction speed.
- the slope of the curve corresponds to the reaction speed.
- the inhibition is expressed as percent of the non inhibited reaction according to following equation:
- pro-galantamine derivatives are added and adjusted to a final concentration of 10 ⁇ M of the prodrug.
- 12 ⁇ l 0.1 M NaOH and 100 ⁇ l saturated KCl are added to the 0.1 ml reaction mixture and mixed thoroughly.
- the remaining prodrug and the released galantamine are extracted by 200 ⁇ l toluene.
- the toluene extraction step is repeated twice using 150 ⁇ l toluene and the obtained extracts are pooled, dried, dissolved in 50% Methanol and used for subsequent HPLC analysis.
- Single HEK-293 cells expressing either human ⁇ 4 ⁇ 2, human ⁇ 3 ⁇ 4, or chimeric chicken ⁇ 7 (with mouse 5HT 3 ) nAChR were plated on fibronectin-coated cover slips for 3 days before measurement.
- the selected nAChR containing cells were placed in the recording bath, filled with extracellular buffer (145 mM NaCl, 5 mM KCl, 1 mM MgCl 2 , 2 mM CaCl 2 , 10 mM D-glucose, 10 mM HEPES, pH 7.3, approximately 300 mOsm).
- Patch-clamp system consisted of an inverted microscope (Zeiss, Germany), computer-controlled patch-clamp amplifier with PatchMaster software (HEKA, Germany), tubing perfusion system (ALA, USA) together with a U-tube applicator (IMM, Germany) and dual micromanipulators.
- the patch pipettes were pulled from fire-polished, 100 mm long and 1.5 mm width, single borosilicate glass capillaries (WPI, Germany).
- a programmable puller (Sutter, USA) was used to prepare a twin pair of ready for use pipettes. Each patch pipette (resistance 4-8 M ⁇ ) was used only once.
- Pipettes were filled with an internal buffer (140 mM CsCl, 11 mM EGTA, 10 mM HEPES, 2 mM MgCl 2 , pH 7.3, approximately 300 mOsm) and connected to the working electrode.
- Working and reference electrodes for experiments were made from daily renewed, freshly chlorinated silver wire (40 mm ⁇ 0.4 mm) and were connected to a headstage circuit of the patch-clamp amplifier. Patching was done using rectangular test pulses with an amplitude of ⁇ 1 mV and a duration of 20 ms.
- the holding potential of ⁇ 70 mV was applied to the patch electrode and whole-cell recordings were established by using negative pressure pulses.
- APL allosteric potentiating ligand
- Mass Parameters (API 3200): Mode MRM Polarity Positive Ion source Turbo spray Analyte Gln-1062 (Q1 Mass 392.4; Q3 Mass 213.2) Galantamine (Q1 Mass 288.3; Q3 Mass 213.1) ISTD Metoprolol (Q1 Mass 268.4; Q3 Mass 116.2)
- Source/Gas Parameters Curtain gas (CUR) 10 Collision gas (Collision associated 5 Dissociation) CAD Ion Spray Voltage 5500 V (IS) Temperature (TEM) 575° C. GS1 55 GS2 45 Ihe ON
- V Galantamine Metoprolol Gln-1062 Declustering Potential
- Recovery was determined by quantifying the concentration of the analytes in extracted matrix QC samples with a standard curve prepared in post-extract (blank extracts) sample matrix as described above in section B of the extraction procedure, entitled “Preparation of Calibration Curve Standards for Recovery.”
- Blood samples were collected from the retro-orbital plexus. 0.5 ml of blood was collected into a pre-labeled polypropylene micro centrifuge tube containing sodium citrate as the anticoagulant, and kept on ice.
- Blood was mixed gently with anticoagulant and an aliquot of 50 ⁇ L of blood sample immediately precipitated as described above in section A of the extraction procedure, entitled “Preparation of STD, QC and Study Samples.” Remaining volume of blood sample at each time point frozen on dry ice.
- brain was perfused with phosphate buffer saline (pH 7.4), removed and frozen on dry ice.
- phosphate buffer saline pH 7.4
- Galantos candidate compound GLN979
- the same vehicle (15% 2-Hydroxypropyl- ⁇ -cyclodextrin/96 mM NaCl) was used for both Galantamine and GLN979 preparation.
- a detailed solubilization protocol was sent by mail by Galantos to Syncrosome and received on Nov. 5, 2007.
- the administrations were performed in unanaesthetized animals through the I.P. route at T 0 .
- Gln 1062, Gln 0979 and galantamine were dissolved in 15%-hydroxypropyl- ⁇ -cyclodextrin in 96 mM NaCl (isotonic) supplied by the sponsor.
- Gln 1062 and Gln 0979 were used in concentrations of 0.01, 0.03, 0.1 and 0.2 mg/ml, which when given in a volume of 10 ml/kg result in doses of 0.1, 0.3, 1 and 2 mg/kg i.p., respectively.
- Galantamine was used in concentrations of 0.03, 0.1, 0.2 and 0.5 mg/ml, which when given in a volume of 10 ml/kg result in doses of 0.3, 1, 2 and 5 mg/kg i.p., respectively.
- Control animals received 15%-hydroxypropyl- ⁇ -cyclodextrin in 96 mM NaCl injection as a vehicle.
- Nicotine ( ⁇ )-Nicotine hydrogen tartrate salt, Sigma, France
- scopolamine ⁇ ( ⁇ )scopolamine hydrochloride, Sigma, France
- saline 0.9% NaCl, Aguettant, France
- mice were group-housed (10 mice per cage) and maintained in a room with controlled temperature (21-22° C.) and a reversed light-dark cycle (12 h/12 h; lights on: 17:30-05:30; lights off: 05:30-17:30) with food and water available ad libitum.
- Gln 1062, Gln 0979 and galantamine were evaluated in scopolamine-treated mice in the T-maze alternation model under the same experimental conditions. Both Gln 1062 and Gln 0979 were tested in doses of 0.1, 0.3, 1 and 2 mg/kg i.p. Galantamine was tested in doses 0.1, 0.3, 1, 2 and 5 mg/kg i.p. Nicotine was tested in a dose of 0.4 mg/kg i.p. All these compounds were administrated immediately after the injection of 1 mg/kg i.p. scopolamine (20 min prior to the T-maze trial) used to induce memory deficit.
- Memory performance was assessed by the percentage of spontaneous alternation in the T-maze. The number of alternation in saline-injected mice was used as the base level of unaltered memory performance.
- mice were housed 10 per cage. Each mouse in a cage was randomly assigned by a unique number (1 to 10) written on the tail with permanent ink.
- Gln 1062, Gln 0979 and galantamine were tested separately in three set of experiments with different animals. Each set of experiments was divided in series of daily experiments that always comprises at least one representative of each of Saline/vehicle, Scopolamine/vehicle and Scopolamine/Nicotine (0.4 mg/kg) groups.
- the T-maze apparatus was made of gray Plexiglas with a main stem (55 cm long ⁇ 10 cm wide ⁇ 20 cm high) and two arms (30 cm long ⁇ 10 cm wide ⁇ 20 cm high) positioned at 90 degree angle relative to the left and right of the main stem.
- a start box (15 cm long ⁇ 10 cm wide) was separated from the main stem by a guillotine door. Horizontal doors were present to close off specific arms during the force choice alternation task.
- the experimental protocol consists of one single session, which starts with 1 “forced-choice” trial, followed by 14 “free-choice” trials.
- the animal In the first “forced-choice” trial, the animal is confined 5 s in the start arm and then released while either the left or right goal arm is blocked by a horizontal door. After the mouse is released, it will negotiate the maze and eventually enter the open goal arm, and return to the start position. Immediately after the return of the animal to the start position, the closed goal door is opened and the animal is now free to choose between the left and right goal arm (“free choice trials”). The animal is considered as entered when it places its four paws in the arm. A session is terminated and the animal is removed from the maze as soon as 14 free-choice trials have been performed or 10 min have elapsed, whatever event occurs first. The average duration of a trial is 6 min.
- the apparatus is cleaned between each animal using alcohol (70°). Urine and feces are removed from the maze.
- the percentage of alternation over the 14 free-choice trials was determined for each mouse and was used as an index of working memory performance. This percentage was defined as entry in a different arm of the T-maze over successive trials (i.e., left-right-left-right, etc).
- ED50 was read from the curve fitting table and represents the effective dose associated with 50% of response.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and their exogenous agonists, of neuronal cholinergic receptors and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g., galantamine, narwedine and lycoramine, or from metabolites of said compounds. The compounds of the present invention can either interact as such with their target molecules, or they can act as “pro-drugs”, in the sense that after reaching their target regions in the body they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both. The compounds of this invention may be used as medicaments.
Description
- This application is a continuation-in-part of application Ser. No. 12/067,799, filed Jul. 2, 2008, which is U.S. National phase of International Application No. PCT/EP2006/009220, filed Sep. 22, 2006, which claims priority to European Patent Application No. EP05020721.6, filed Sep. 22, 2005 and U.S. Provisional Application No. 60/780,243, filed Mar. 7, 2006. This application also claims the benefit of U.S. application Ser. No. 11/683,148, filed Mar. 7, 2007, which claims priority to U.S. Provisional Application No. 60/780,243, filed Mar. 7, 2006. This application also claims the benefit of U.S. provisional application No. 61/046,683, filed Apr. 21, 2008. The entire contents of all these applications are hereby incorporated by reference herein in their entireties, as if fully disclosed herein.
- 1. Field of the Invention
- The disclosure refers to compounds that, in addition to enhancing the sensitivity to acetylcholine and choline, and to their agonists, of neuronal cholinergic receptors, and/or acting as cholinesterase inhibitors and/or neuroprotective agents, have enhanced blood-brain barrier permeability in comparison to their parent compounds. The compounds are derived (either formally by their chemical structure or directly by chemical synthesis) from natural compounds belonging to the class of amaryllidaceae alkaloids e.g., Galantamine, Narwedine and Lycoramine, or from metabolites of said compounds. The compounds of the present invention can either interact as such with their target molecules, or they can act as “pro-drugs”, in the sense that after reaching their target regions in the body, they are converted by hydrolysis or enzymatic attack to the original parent compound and react as such with their target molecules, or both. The compounds of this disclosure may be used as medicaments for the treatment of human brain diseases associated with a cholinergic deficit, including the neurodegenerative diseases Alzheimer's and Parkinson's disease and the neurological/psychiatric diseases vascular dementia, schizophrenia and epilepsy. Galantamine derivatives disclosed herein have higher efficacy and lower levels of adverse side effects in comparison to galantamine, in treatment of human brain diseases.
- 2. Description of the Related Art
- The diffusion of compounds from the blood plasma into the brain is complicated by the presence of the blood-brain barrier that is a membrane that segregates the brain interstitial fluid from the circulating blood. In designing drugs active in the central nervous system and able to cross the blood-brain barrier, one can exploit endogenous active mechanisms, utilize proper delivery techniques or modify the chemical structure through the synthesis of pro-drug derivatives.
- Galantamine is an alkaloid that can be isolated from the bulbs of various snowdrop (Galanthus) and narcissus species (daffodils, Amaryllidaceae), and recently in particularly high concentrations from Lycoris radiata, and related species. Synthetic Galantamine hydrobromide is manufactured by, among other companies, Sanochemia and Janssen Pharmaceutica. The drug has been approved in more than 70 nations for the treatment of mild-to-moderate Alzheimer's disease (AD), a neurodegenerative brain disease. Extensive studies of the pharmacokinetic profile, tissue distribution and accumulation of Galantamine in mice, rats, rabbits and dogs have shown that Galantamine given orally is by no means preferentially distributed to the brain where it is supposed to exert its therapeutic activity in said brain diseases. In contrast, it is accumulated at much higher concentrations in other body tissues. In male and female rat tissues the highest concentrations are observed in kidney (tissue to plasma ratio; T/P˜10-15), salivary and adrenal gland (T/P˜7-14), female rat spleen (T/P˜20), lung, liver, heart, skeletal muscle and testes (T/P˜2-4). In contrast, the brain to plasma ratio is only T/P˜1.5. Similarly, the brain/plasma partition coefficient Kbrain is significantly lower than most other Korgan of Galantamine.
- Limited penetration ability of Galantamine through the blood-brain barrier (BBB) into the central nervous system (CNS) is indicated also by the compound's log P value of 1.3, log P being defined as the decadic logarithm of the partition coefficient P which is the ratio of the concentration of compound in aqueous phase to the concentration of compound in immiscible solvent, as the neutral molecule. The log P value is obtained by predictive computational methods and provides a general guideline as to whether a drug gains rapid access to the CNS, or not. Thus, it has been established over the past more than 30 years that, assuming passive absorption, drugs with optimum CNS penetration generally have log P values around or somewhat above 2. Significantly lower log P values are often associated with low brain-to-plasma and high non-brain tissue-to-plasma ratios (see above: log P and T/P ratios for Galantamine). However, much higher log P values are also of disadvantage, as high lipophilicity is often associated with toxicity, non-specific binding, insufficient oral absorption and limited bioavailability. It follows from this account that BBB penetration and T/P ratios are essential parameters to be considered in the case of drugs that are supposed to act mainly or exclusively in the central nervous system.
- Other important parameters controlling BBB penetration of a compound are the total polar surface area, the existence of ionizable groups on the molecule and the affinity of binding to biological membranes as compared to the affinity of binding to serum albumin. The latter data set is often used to scrutinize calculated log P values. In those cases in which special transport systems do not play a major role for the transport of a compound through the BBB, the predictions of lipophilicity and BBB penetration properties are quite suitable for the design of derivatives that transfer the BBB more efficiently than the parent compound.
- The present disclosure relates to methods by which the lipophilicity and/or BBB penetration and/or brain-to-plasma ratio of a compound is enhanced by formation of a reversible linkage with one or more suitable groups so as to yield “pro-drugs”, i.e., chemical derivatives that, after having passed through the blood-brain barrier, are converted (back) to the original compound itself inside the patients brain. Liberation of the parent compound may be by chemical hydrolysis or enzymatic attack, or by redox reactions. In another embodiment, the present invention refers to compounds that after chemical modification of the base compound have achieved a lop P value more favourable for BBB penetration, with these derivatives acting as such at their target molecules in the patient's brain.
- The plant alkaloid galantamine has been described as a cholinesterase inhibitor (ChE-I) and as a nicotinic acetylcholine receptor (nAChR) sensitizing agent (APL; allosterically potentiating ligand), and galantamine has been proposed for the treatment of several human brain diseases, including Alzheimer's disease (AD). Presently, the compliance of Alzheimer patients to treatment with ChE-I and APL is rather low, of the order of 20%, a key reason being the adverse effects nausea, diarrhea, vomiting, anorexia and muscle cramps. In the case of galantamine, the majority of these adverse effects is due to actions of the drug while passing through the gastro-intestinal tract, and to its rather limited permeation through the blood-brain barrier (BBB) into the brain. To help patients coping with the adverse effects of galantamine, the manufacturer's recommended daily dose of the drug is limited to 16-24 mg per day, and this dose is slowly reached by stepwise dose increase, beginning at 4 mg/day and over a period of 2-3 months.
- The rather low levels of accumulation of galantamine in the brain, when administered as the unmodified drug, are a serious disadvantage with respect to the drug's therapeutic use, i.e., for the treatment of cognitive disorders, such as AD. As indicated by the brain-to-plasma ratio of ˜1.3, only a small part of the administered drug reaches the brain, and the high levels of the drug in other (peripheral) tissues cause most, if not all, of the observed adverse effects. The mostly peripheral action of galantamine is also indicated in its previous use for the treatment of a number of neuromuscular disorders, including Myasthenia gravis and poliomyelitis.
- In WO2007/039138 reference is made to the low hydrophobicity and related limited partition into the human brain of galantamine, and several procedures for overcoming these drawbacks of a medication that is supposed to act on target molecules located in the brain's central nervous system are proposed. In the same document numerous derivatives of galantamine that significantly improve transport of the respective compound through the blood-brain barrier (BBB) are described and they are proposed as drugs for the treatment of a variety of diseases associated with cognitive deficits.
- Presently approved drugs for the treatment of Alzheimer's disease (AD) have in common that they all target excitatory neurotransmission in the brain, namely the cholinergic and the glutamatergic systems. Three of the four presently available drugs (Donepezil, Rivastigmin, Galantamine, Memantine) are cholinergic enhancers (Donepezil, Rivastigmin, Galantamine) in that they all inhibit the family of acetylcholine-degrading enzymes denoted as cholinesterases (ChE). Inhibition of ChE increases the synaptic concentrations of acetylcholine (ACh), thereby enhancing and prolonging the action of ACh on muscarinic (mAChR) and nicotinic (nAChR) acetylcholine receptors. In addition to acting as ChE inhibitor, Galantamine also acts by allosterically stimulating (sensitizing) cholinergic receptors. Allosteric sensitization of nicotinic receptors enhances their activation by ACh or choline (Ch), thereby correcting for a disease-associated deficit in transmitter or receptor concentration (Maelicke A & Albuquerque E X (1996) Drug Discovery Today 1, 53-59; Maelicke A & Albuquerque E X (2000) Eur J Pharmacol 393, 165-170). In addition to their therapeutic benefits, these drugs induce adverse peripheral and central side effects; the muscarinic ones including nausea, vomiting and diarrhea, and the nicotinic ones including tremors and muscle cramps. From meta data (Cochrane reviews, (2004), Issue 4) and direct comparison clinical studies (Wilcock G K et al. (2000) Brit Med Journ 321:1-7), the relatively weakest of the three presently used ChE inhibitors, Galantamine, has the highest clinical efficacy, with the therapeutic benefit achieved at concentrations that are well below those required for effective inhibition of ACHE (Raskind M A et al. (2000)
Neurology 54, 2261-2268; Maelicke A & Albuquerque E X (2000) Eur J Pharmacol 393, 165-170). It has been suggested that the higher therapeutic efficacy of Galantamine, as compared to the other two available ChE inhibitors, is due to an additional or alternative mode of action, i.e., allosteric sensitization of nAChR (Maelicke A & Albuquerque E X (1996) Drug Discovery Today 1, 53-59). - Galantamine enhances nicotinic cholinergic neurotransmission by acting directly on nicotinic receptors (Schrattenholz A et al. (1996) Mol Pharmacol 49, 1-6; Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036). The drug binds to a distinct allosteric site on these receptors (Schröder B et al. (1993) J Biol Chem 269, 10407-10416), from which it acts synergistically with acetylcholine (or choline) to facilitate nAChR activation (Maelicke A & Albuquerque E X (1996) Drug Discovery Today 1, 53-59; Maelicke A & Albuquerque E X (2000) Eur J Pharmacol 393, 165-170). Compounds acting like Galantamine in this way are referred to as “allostericaly potentiating ligands (APL)” (Schrattenholz A et al. (1996) Mol Pharmacol 49, 1-6, Maelicke A & Albuquerque E X (2000) Eur J Pharmacol 393, 165-170).
- The APL action on human nicotinic receptors has been demonstrated by electrophysiological studies using human brain slices (Alkondon, M. et al., (2000) J Neurosci 20, 66-75) and human recombinant cell lines each expressing a single nAChR subtype (Samochocki M et al (2000) Acta Neuro Scand Suppl 176, 68-73, Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036). All human nAChR subtypes analysed so far are sensitive to enhancement by APL. In the presence of Galantamine, the binding affinity and channel opening probability of nAChR are increased, leading to a decrease in EC50 for ACh between 30% and 65% (Samochocki M et al (2000) Acta Neuro Scand Suppl 176, 68-73, Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036). Furthermore, Galantamine increases the slope of the dose-response curve for ACh, which has been interpreted as an increase in the cooperativity between nAChR subunits (Maelicke A & Albuquerque E X (1996) Drug Discovery Today 1, 53-59).
- The APL effect of Galantamine is observed at submicromolar concentrations (Samochocki M et al (2000) Acta Neuro Scand Suppl 176, 68-73, Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036), i.e., below the concentration range at which ChE inhibition takes place. The two modes of action of nicotinic APL are independent of each other, as was shown by ion flux studies (Okonjo K et al (1991) Eur J Biochem 200, 671-677; Kuhlmann J et al (1991) FEBS Lett 279, 216-218) and electrophysiological studies of brain slices from both rats and humans (Santos M D et al (2002)
Mol Pharmacol 61, 1222-1234). In these studies, when cholinesterase activity was completely blocked by either reversible or irreversible blocking agents, the nicotinic APL, e.g., Galantamine, still was able to produce an APL effect of the same size as in the absence of the other ChE inhibitors. Of the cholinesterase inhibitors presently approved as AD drugs, Galantamine is the only one with nicotinic APL activity (Maelicke A et al (2000)Behav Brain Res 113, 199-206). - The use of Galantamine and other APL as a drug treatment strategy for cognitive disorders, including AD and PD was proposed in 1996 (Maelicke A & Albuquerque E X (1996)
Drug Discovery Today 1, 53-59). Later, the proposal was extended to vascular and mixed dementia (Maelicke A et al (2001)Biol Psychiatry 49, 279-288), schizophrenia, epilepsy and other diseases with a nicotinic cholinergic deficit. - The comparatively low levels of accumulation of Galantamine in the brain are a serious disadvantage with respect to the drug's therapeutic use, i.e., for the treatment of cognitive disorders, such as AD. As indicated by the T/P ratios, only a small part of the administered drug reaches the brain, and the high levels of the drug in other (peripheral) tissues may be responsible for some of the observed adverse side effects. As a point in case, long before having been approved for the treatment of AD, Galantamine has primarily been used for the treatment of a number of neuromuscular disorders, including Myasthenia gravis and poliomyelitis.
- EP-A 648 771, EP-A 649 846 and EP-A 653 427 all describe Galantamine derivatives, a process for their preparation and their use as medicaments, however none of these applications considers ways and means of enhancing penetration through the blood-brain barrier and brain-to-plasma ratio of base compounds and derivatives.
- U.S. Pat. No. 6,150,354 refers to several Galantamine analogues for the treatment of Alzheimer's disease. However, selective chemical modification for the purpose of increasing penetration through the blood-brain barrier is not considered.
- WO 01/74820, WO 00/32199 and WO 2005030333 refer to derivatives and analogues of Galantamine for the treatment of a variety of human brain and other diseases, and acute functional brain damage. However, selective chemical modifications or other means of improving blood-brain barrier penetration are not considered.
- WO 88/08708, WO 99/21561, WO 01/43697 and US 2003/0162770 refer to derivatives and analogues of Galantamine for the treatment of various cognitive symptoms. However, selective chemical modifications or other means of improving blood-brain barrier penetration are not considered.
- WO 2005/030713 refers to a method for the synthesis of optical isomers of Galantamine from a Narwedine bromoamide derivative. However, it does not deal with other derivatives of Galantamine, or their use as medicaments, or chemical modifications aimed at enhancing blood-barrier penetration of said compounds.
- WO 97/40049 describes several derivatives of benzazepines and related compounds that may be applied for the treatment of Alzheimer's disease. However, no concept is provided in this application for increasing the penetration of compounds through the blood-brain barrier.
- Some embodiments provide compounds usable as pro-drugs or as a medicament having high pharmacodynamic effects in the brain's central nervous system and low peripheral side effects.
- Compounds disclosed herein include those described by formula (III):
-
- wherein the bond <1> to >2> is a single or a double bond and the bond between <3> and R1 is a single or a double bond and bond <10> to <11> is a single or no bond and residues are
- R1: OH, OCO-(3-pyridyl)(=nicotinic acid residue), OCO-(3-methyl-3-pyridyl), OCO—(C1-C6 alkyl), OCO—(C1-C21 alkenyl), OCO—NH—(C1-C6 alkyl), OCO—(CH2)x—NH—COO—(C1-C6 alkyl), O—CH2—O—(C1-C6 alkyl), O—(CH2)x—OCO—(C1-C6 alkyl), O—(CH2)x—OCO—(CH2)x—N—COO—(C1-C6 alkyl), O—(CH2)x—OCO—(CH2)y-aryl, OCOO—(C1-C6 aminalkyl), OCOO—(CH2)X-tetrahydrofuranyl, or a sugar, preferably glucuronic acid residue, wherein x=1, 2, 3 or 4 and y=0, 1, 2, 3 or 4;
- wherein if bond <3> to R1 is a double bond, then R1=O, NH, NOH, NOR6, N—CO—NH2, N—CS—NH2, N—C(═NH)—NH2, N—NH-phenyl, N—NHR6, N—N(R6)2, N—N═(CH2)n, with R6=C1-C5 unbranched or branched, saturated or unsaturated (ar)alkyl, phenyl or benzyl and n=2−8; and
- wherein if bond <3> to R1 is a single bond, then R1=OH, SH, NH2, NHR6, N(R6)2, OR7, O—CR8R9-O—CO—CHR10-NR11R12, or O—CO—R14,
- with R7=C1-C22 unbranched or branched, (poly-)unsaturated or saturated alkyl, optionally containing an additional (ar)alkoxy or di(ar)alkylamino group, a sugar or sugar derivative residue, preferably glucuronic acid residue, a phosphoryl, alkylphosphoryl or arylphosphoryl group, a sulfatyl or alkylsufatyl group, or COR13,
- where R13=R6 or R7 or pyridyl or dihydropyridyl or OR6, preferably methyl, 3-pyridyl, 4-pyridyl, 3-dihydropyridyl, 4-dihydropyridyl
- R8 and R9 are the same or different and any of H, Me, Ph or they together form a spiro-ring —(CH2)n- with n=4-6
- R10=H or the side chain of a natural amino acid including R10, R11 together are forming a proline or hydroxy-proline derivative
- R11 either is together with R10 forming a proline or hydroxy-proline derivative or is H
- R12 is a carbamate protecting group including t-butoxycarbonyl, benzyloxycarbonyl and other N-protecting groups;
- R14 is an aromatic or heteroaromatic 5- or 6-membered ring, selected from substituted benzene with the proviso that it is not 2-fluorobenzene or 3-nitro-4-fluorobenzene, optionally substituted naphthaline, thiophene, pyrrole, imidazole, pyrazole, oxazole, thiazole; or CH(C2HS)CH3, CH2—C(CH3)3, or cyclopropane;
- R2: R7, or O—CR8R9-O—CO—CHR10-NR11R12 with the same definitions of R7-R12 as above, H, CH3, CO—(C1-C6 alkyl), CH2—OCO—(CH2)X-aryl, or a sugar, preferably glucuronic acid residue;
- R3: H, F, Cl, Br, I, NH2, NO2, CN, CH3;
- R4: H, C1-C6 alkyl, preferably CH3, CO—(C1-C6 alkyl), CO-(3-pyridyl)(=nicotinic acid residue), CO-(3-methyl-3-pyridyl), CO—(CH-mercaptoalkyl)-(CH2)X-aryl, (CH2)x—OCO—(CH2)x—N—COO—(C1-C6 alkyl), (CH2)x—OCO—(CH-arylalkyl)-N—COO—(C1-C6 alkyl), wherein x=1, 2, 3 or 4;
- R5: if R4=H, then R5 is an electron pair;
- if R4=CH3 then R5 is either hydrogen or a C1-C5 (ar)alkyl group, CH2—O—CH3, CH2—O—CO—R6, CH2—O—CR8R9-O—CO—CHR10-NR11R12 with the same definitions of R6 and R8-R12 as above, whereby in all the latter cases the nitrogen has an additional positive charge as well as a counterion, selected from chloride, bromide, iodide, sulphate, nitrate, hydrogensulfate, phosphate, methanesulphonate, tosylate or any other pharmaceutically acceptable anion, with the proviso that the resulting compound is not Galantamine, Norgalantamine, Sanguinine, Norsanguinine, Lycoramine, Norlycoramine, Lycoraminone, Narwedine, Nomarwedine,3-Amino-3-deoxy-galantamine or 3-amino-3-deoxy-1,2-dihydro-galantamine;
- or R5=(CH2)x—O—(C1-C6 alkyl), (CH2)x—OCO—(C1-C6 alkyl), (CH2)x—OCO—(CH2)x-aryl, (CH2)x—OCO—(CH2)x—N—COO—(C1-C6 alkyl), wherein x=1, 2, 3 or 4; in case that bond <10> to <11> is a single bond the nitrogen has a positive charge and the counterion is chloride, with the proviso that the compound is not Galantamine, Norgalantamine, Sanguinine, Norsanguinine, Lycoramine, Norlycoramine, Lycoraminone, Narwedine, Nomarwedine,3-Amino-3-deoxy-galantamine or 3-amino-3-deoxy-1,2-dihydro-galantamine as a pro-drug or medicament with improved blood-brain barrier permeability compared to Galantamine.
- if R4=CH3 then R5 is either hydrogen or a C1-C5 (ar)alkyl group, CH2—O—CH3, CH2—O—CO—R6, CH2—O—CR8R9-O—CO—CHR10-NR11R12 with the same definitions of R6 and R8-R12 as above, whereby in all the latter cases the nitrogen has an additional positive charge as well as a counterion, selected from chloride, bromide, iodide, sulphate, nitrate, hydrogensulfate, phosphate, methanesulphonate, tosylate or any other pharmaceutically acceptable anion, with the proviso that the resulting compound is not Galantamine, Norgalantamine, Sanguinine, Norsanguinine, Lycoramine, Norlycoramine, Lycoraminone, Narwedine, Nomarwedine,3-Amino-3-deoxy-galantamine or 3-amino-3-deoxy-1,2-dihydro-galantamine;
- R1: OH, OCO-(3-pyridyl)(=nicotinic acid residue), OCO-(3-methyl-3-pyridyl), OCO—(C1-C6 alkyl), OCO—(C1-C21 alkenyl), OCO—NH—(C1-C6 alkyl), OCO—(CH2)x—NH—COO—(C1-C6 alkyl), O—CH2—O—(C1-C6 alkyl), O—(CH2)x—OCO—(C1-C6 alkyl), O—(CH2)x—OCO—(CH2)x—N—COO—(C1-C6 alkyl), O—(CH2)x—OCO—(CH2)y-aryl, OCOO—(C1-C6 aminalkyl), OCOO—(CH2)X-tetrahydrofuranyl, or a sugar, preferably glucuronic acid residue, wherein x=1, 2, 3 or 4 and y=0, 1, 2, 3 or 4;
- wherein the bond <1> to >2> is a single or a double bond and the bond between <3> and R1 is a single or a double bond and bond <10> to <11> is a single or no bond and residues are
- Other embodiments relate to procedures for achieving a favorable distribution ratio of brain to periphery for antidementia drugs of various kinds, including cholinergic receptor sensitizing agents, cholinesterase inhibitors and neuroprotective drugs.
- In this way the therapeutic effect-to-dose ratio can be increased and adverse side-effects can be reduced when the drugs are administered as medicaments for the diseases mentioned in the present application. This object is particularly met e.g., by site-specific chemical modification (derivatization) of said compounds.
-
FIG. 1 : 125 chemical structures and log P values of new compounds that (i) act as cholinergic enhancers, and/or (ii) have higher log P-values than Galantamine (Galantamine included in Table 4 for comparison). -
FIG. 2 : Brain esterase inhibition by galantamine and several pro-galantamines. A 20% mouse brain homogenate was used, supplemented with 200 μM of acetylthiocholine as substrate, and the initial reaction kinetics were measured according to Riddles P W, Blakeley R L, Zerner B., “Reassessment of Ellman's reagent” Methods Enzymol. 1983, 91:49-60. As shown in the figure, even 50 μM of the respective pro-galantamines were unable to achieve a level of inhibition of brain cholinesterase that is comparable in size to that of 1 μM galantamine. A non-cleavable galantamine derivative (Gln 1063) leads to negative values. In derivative Gln 1063 R1 in Formula V is —O—Si(CH3)2—C(CH3)2—C(CH3)2H. -
FIG. 3 : Enzymatic cleavage of pro-galantamine to galantamine. Butyrylcholinesterase, 25 units/ml, was used. Reaction temperature was 37° C. Appearance of the fluorescent reaction product galantamine was determined by fluorescence detection. -
FIG. 4 : Interaction of galantamine and pro-galantamine with a4β2 neuronal nicotinic acetylcholine receptor ectopically expressed in HEK-293 cells. The increase in response to acetylcholine in the presence of galantamine and Gln-1062, respectively, was determined by whole-cell patch clamp recording. Galantamine achieved a maximal enhancement of response of ˜40% whereas the pro-galantamine achieved a maximal enhancement of only ˜17%. -
FIG. 5 : Pharmacokinetics of pro-galantamine Gln-1062 (3 mg/kg) in the mouse. 5a shows the measurable concentration of applied pro-galantamine and the resulting concentration of galantamine by cleavage of the pro-galantamine in brain and blood. The curve starting with the highest concentration refers to derivative GLN-1062, which is benzoyl-galantamine, in brain.FIG. 5 b is an excerpt (“zoom”) ofFIG. 5 a, showing the concentration range between 0.00 and 1.00 μg/g (substance/body weight) more in detail. InFIG. 5 b the curve above refers to the concentration of resulting galantamine in brain, the middle curve shows the concentration of galantamine in blood and the curve starting with a concentration of about 0.3 μg/g and decreasing refers to the concentration of GLN-1062 in blood. -
FIG. 6 : Behavioral index for gastro-intestinal side effects in ferrets following application of galantamine and several R1-pro-galantamines, respectively. -
FIG. 7 : Reversal from scopolamine-induced amnesia in mice, in the presence of galantamine and several R1-pro-galantamines, respectively. Scopolamine induces a memory deficit that can be measured by increased alternation in a T-maze trial. The cognition enhancing drugs were i.p. injected at several different doses together withscopolamine 20 min before a T-maze trial. Recovery was measured as a function of dose, and the EC50 was determined for each drug. - The present disclosure relates to significant enhancement in the brain-to-plasma ratio of cholinergic receptor sensitizing agents, such as the APL Galantamine (and related compounds), which is achieved by administering not the drug itself but a “pro-drug” that is converted (back) to the drug itself inside the brain of the patient. As another means for improving penetration through the blood-brain barrier (BBB) and thereby the therapeutic efficacy of the drug, the compounds themselves have been chemically modified so as to not only having larger efficacy as nicotinic APL and/or as neuroprotective agent, but in addition having enhanced lipophilicity (higher log P) or otherwise improved BBB transport properties. Due to these improvements, the pro-drugs and other compounds addressed in this application should be significantly more potent as medicaments for the treatment of cognitive disorders than is, for example, Galantamine. The invention applies to the compounds, selected pro-drugs and pharmaceutically acceptable salts thereof, which might be administrated via the mouth, blood, skin, by nasal application, or any other suitable application route.
- Herein the term “pro-drug” refers to a derivative of a base compound wherein the group(s) added or replaced on said base compound are cleaved or returned to the group originally contained in the base compound when the derivative has reached the area or site of action. Thus, in case of a “pro-drug”, an effective agent is administrated as a derivative (which is said pro-drug), however, the compound mainly or exclusively effective at the target site within the brain is the agent itself, not the derivatized compound or metabolites thereof.
- The term “derivative” refers to any change of a base compound defined in the present application. The term “derivative” is used to describe a compound which either can be a pro-drug, or can be an effective agent itself/in its own right or in the derivatized form.
- The terms “sensitizing agent” and “allosterically potentiating ligand, APL” refer to effectors that enhance cholinergic neurotransmission by direct interaction via an allosteric site with cholinergic receptors.
- The terms “cholinergic enhancer” and “cholinergic agent” refer to compounds that enhance/modulate cholinergic neurotransmission by inhibition of cholinesterases, by allosteric sensitization and/or direct activation of cholinergic receptors and/or by activating/modulating relevant intracellular pathways via second messenger cascades.
- A derivative or pro-drug has an “enhanced blood-brain barrier permeability “according to the present invention or an “enhanced blood-brain barrier penetration” if, after administration of a pro-drug or derivative thereof to a living organism, a higher amount of said compound penetrates through the BBB, resulting in a higher level of effective agent in the brain, as compared to administration of the base compound without derivatization. The enhanced BBB penetration should result in an increased brain-to-tissue ratio of the effective agent compared to the ratio of the base compound. Methods for determination of an enhanced BBB permeability are disclosed in this application (see supra).
- The “base compound” according to the present invention preferably is Galantamine, Norgalantamine, Narwedine, N-Demethylnarwedine, Lycoramine, Lycoraminone, Sanguinine, Norsanguinine, and others (see table 1).
- “log P” is defined as the decadic logarithm of the partition coefficient P which is the ratio of the concentration of a compound in aqueous phase to the concentration of a compound in immiscible solvent, as the neutral molecule.
- The term “alkyl” shall mean a straight, branched or cyclic alkyl group of the stated number of carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, sec-butyl, t-butyl, and straight and branched chain pentyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl, pentadecyl etc. . . . or the according cyclic alkyls.
- The term “halo” shall mean chloro, fluoro, bromo and iodo.
- The term “aryl” shall mean phenyl having 0, 1, 2 or 3 substituents independently selected from the group of alkyl, alkoxy, alkylcarbonyl, halo- or trihalomethyl.
- The term “cycloalkyl” shall mean a cycloalkyl group of from 3 to 12 carbon atoms and including multiple ring alkyls such as for example, adamantyl, camphoryl, and 3-noradamantyl.
- In any case when a range between two limits is described it is meant that any value or integer in this range is disclosed. For example “C1-C8” means C1, C2, C3, C4, C5, C6, C7 or C8; or “between 0.1 and 1” means 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.
- A “natural amino acid” is any amino acid naturally occurring in biochemical pathways or in peptides/proteins. These are particularly alanine, asparagine, cysteine, glutamine, phenylalanine, glycine, histidine, isoleucine, methionine, proline, glutamate, arginine, serine, threonine, valine, thryptophane, tyrosine, their methylated forms or the according salts.
- With “sugar” is meant any suitable sugar, either an aldose or ketose, a pyranose or furanose, heptose or hexose, mono- or polysaccharide, like e.g., glucuronic acid, glucose, fructose, galactose, mannose, saccharose, lactose, maltose etc., however, glucuronic acid is preferred.
- The main focus of the present invention is to improve blood-brain barrier permeability, by increasing the lipophilicity or the transport properties, or the ability of passing the blood-brain barrier, of compounds that are known to act as effective agents in correcting a cholinergic deficit, e.g., APL of nicotinic receptors or inhibitors of cholinesterases.
- In one preferred embodiment the present invention refers to a method for increasing blood-brain barrier penetration of a cholinergic enhancer by preparing derivatives (either formally by their chemical structure or directly by chemical synthesis) of a molecule with a base structure of the general formula (I):
- wherein the bond between positions <1> and <2> as well as <11> and <12> denotes a single- or double bond, and the bond between <10> and <11> is either a single bond or no bond.
-
- R1=═O, ═NOH, ═NH—NHCH3, —OH, —OCOCH3, —NH2, or a (substituted) derivative of the ketone, like semicarbazone, thiosemicarbazone, aminoguanidine etc.
- R2=H, CH3, acetyl
- R3=H, CH3, F, Cl, Br, I
- R4=H, CH3.
- In Table 1, compounds are exemplified with a base structure of the general formula (II)
- that belong to the structures summarized in formula (I):
-
TABLE 1 Bond Bond logP R1 R2 R3 R4 <1>-<2> <3>-R1 Name calcd. (1) OH CH3 H CH3 Double Single Galantamine 1.30 OH CH3 H H Double Single Norgalantamine 1.38 OH H H CH3 Double Single Sanguinine 0.83 OH H H H Double Single Norsanguinine 0.91 MeCH(OH)CH2—CO H H CH3 Double Single Leucotamine 1.23 OH CH3 H CH3 Single Single Lycoramine 1.28 OH CH3 H H Single Single Norlycoramine 1.36 O CH3 H CH3 Single Double Lycoraminone 0.85 O CH3 H CH3 Double Double Narwedine 0.74 O CH3 H H Double Double Nornarwedine 0.82 NH2 CH3 H CH3 Double Single 3-Amino-3-deoxy- 1.05 galantamine NH2 CH3 H CH3 Single Single 3-amino-3-deoxy-1,2- 0.89 dihydro-galantamine (1) Calculated using Advanced Pharma Algorithms Software ToxBoxes V1.0.2 - The compounds listed in Table 1, and other compounds to be used as a base compound for derivatization according to the present invention, can be obtained either by isolation from natural sources or by total chemical synthesis, or by chemical modification of natural or synthetic compounds.
- The compounds to be used according to the present invention can be derivatives of the above listed molecules that can be demonstrated to act as cholinergic enhancers. This property of said derivatives may be manifested by one or more of the following properties; by their ability to sensitize cholinergic receptors, and/or inhibit brain cholinesterases, and/or modulate intracellular messenger levels, and/or act neuroprotective. The ability to act as sensitizing agent on nicotinic receptors can be determined by electrophysiological and Ca-imaging methods, as described in Schrattenholz A et al. (1996)
Mol Pharmacol 49, 1-6 and Samochocki M et al (2000) Acta Neuro Scand Suppl 176, 68-73; Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036. The ability to inhibit cholinesterases can be determined by the photometric method of Ellman et al., Biochem. Pharmacol. 7,88 (1961). The ability to modulate intracellular messenger levels can be determined by Ca-imaging methods (Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036) and other means of recording changes in intracellular messenger levels or effects resulting thereof (Kihara T et al (2004) Biochem Biophys Res Commun 325, 976-982). The ability to act neuroprotective can be determined by a variety of in vitro and in vivo test systems, including in cell culture (Arias E et al (2003)Neuropharmacol 46, 103-1S 14; Kihara T et al (2004) Biochem Biophys Res Commun 325, 976-982) and in animal models of neurodegenerative diseases (Capsoni et al (2002) Proc NatlAcad Sci USA 99, 12432-12437). - As specific examples, Table 2 exemplifies compounds that are derivatives of a base structure of the following general formula (III)
- and act in any way as cholinergic enhancers:
-
TABLE 2 Bond Bond Bond logP R1 R2 R3 R4 R5 Bond 1-2 3-R1 10-11 11-12 Name calcd (1) OH CH3 H CH3 CH3 D S n S 10,11-Seco- 2.67 10-methyl- galantamine OH CH3 H CH3 H D S n D 10,11-Seco- 2.09 11,12- dehydro- galantamine NOH CH3 H CH3 e D D S S Narwedinoxim 1.15 NNHCH3 CH3 H CH3 e D D S S Narwedin-N- 0.34 methyl- hydrazone OH CH3 F CH3 e D S S S 8-Fluoro- 1.25 galantamine OH CH3 Br CH3 e D S S S 8-Bromo- 2.27 galantamine OH CH3 I CH3 e D S S S 8-Iodo- 2.26 galantamine OH CH3 Br CH3 O D S S S 8-Bromo- 2.68 galantamine- N-oxide OH H H CH3 E D S S S Sanguinine 0.83 O CH3 H CH3 e D D S S Narwedin 0.74 O CH3 CH3 CH3 e D D S S 8-Methyl- 1.15 narwedine O—CO—(CH2)11—CH3 CH3 H CH3 e D S S S GLN-0962 7.42 O—CO—(CH2)6—CO—gal- CH3 H CH3 e D S S S GLN-0971 7.80 6-yl O—CO—(CH2)11—CH3 CO—(CH2)11—CH3 H CH3 e D S S S GLN-0935 11.7 (1) Calculated using Advanced Pharma Algorithms Software ToxBoxes V1.0.2. Abbreviations: s: single bond; d: double bond; n: no bond; e: electron pair - Most of the compounds listed in Table 2 are not only efficacious agents in one or more of the tests cited above, but most of them also have more favourable log P and/or transport properties than the base compounds from which they are derived.
- To further improve BBB permeability and brain/plasma distribution ratio, modifications of the following kinds can be performed so as to make the compounds exemplified in Tables 1 and 2 more lipophilic or enhance otherwise their transport into the CNS, in comparison to the base compound:
-
- 1. Conjugations to groups or molecules that are known to occur in the course of metabolic conversions, e.g., carbohydrate conjugates such as glycosyls, glucuronides and natural metabolites, or are otherwise known to readily pass the blood-brain barrier, e.g., amino acids, vitamins, various messenger molecules and drugs.
- 2. Conjugations to groups leading to quaternary ammonium salts with a labile nitrogen-carbon bond (see e.g., Example 1).
- 3. Conjugations to groups leading to esters, e.g., acylderivates with enhanced lipophilicity and BBB penetration properties. For example, such compounds may be esters of the oxygen function in
position 3 and/or 6 of the following base structure (IV):
-
-
- a) Esters with saturated or unsaturated fatty acids containing 1-22 carbon atoms optionally containing an additional (ar)alkoxy or di(ar)alkylamino group
- b) Esters with carbonic acid where one acidic function of carbonic acid is esterified with the 3- and/or 6-position of galantamine and the other represents an ester as defined in 3a.
- c) Esters with (substituted) pyridine- or (substituted) dihydropyridine-carboxylic acids (see e.g., Example 2)
- d) Esters with phosphoric and sulfonic acids
- 4. Formation of ketals or animals of substituents in
positions - 5. Formation of basic and/or quaternary carbamates of said compounds that are chemically or metabolically unstable.
- 6. Conjugation to a lipophilic dihydropyridinium carrier, e.g., as 1,4-dihydro-1-methyl-3-pyridinecarboxylate, that in the brain is enzymatically oxidised to the corresponding ionic pyrimidinium salt.
- 7. Conjugation with nicotinic acid, nicotinic acid amide, various cofactors, messenger molecules and other chemical entities that enhance lipophilicity and transport through the BBB.
-
- These modifications lead to compounds of the following general formula (III)
- wherein the bond between positions <1> and <2> denotes a single- or double bond, with the proviso that the structure is not any of those listed in Table 1 and the bonds <1> to <2> and <11> to <12> can be either a single or a double bond, and the bond between <10> and <11> is either a single bond or no bond and the residues R1-R5 are defined as follows:
- a) if bond <3> to R1 is a double bond, then
-
- R1=O, NH, NOH, NOR6, N—CO—NH2, N—CS—NH2, N—C(═NH)—NH2, N—NH-phenyl, N—NHR6, N—N(R6)2, N—N═(CH2)n
- with R6=C1-C5 unbranched or branched, saturated or unsaturated (ar)alkyl, phenyl or benzyl and n=2-8
- b) if bond <3> to R1 is a single bond, then
-
- R1=OH, SH, NH2, NHR6, N(R6)2, OR7, O—CR8R9-O—CO—CHR10-NR11R12
- with R7=C1-C22 unbranched or branched, (poly-)unsaturated or saturated alkyl, optionally containing an additional (ar)alkoxy or di(ar)alkylamino group, a sugar or sugar derivative residue, preferably glucuronic acid, a phosphoryl, alkylphosphoryl or arylphosphoryl group, a sulfatyl or alkylsufatyl group
- or COR13,
- where R13=R6 or R7 or pyridyl or dihydropyridyl or OR6, preferably methyl, 3-pyridyl, 4-pyridyl, 3-dihydropyridyl, 4-dihydropyridyl
- R8 and R9 are the same or different and any of H, Me, Ph or they together form spiro-ring —(CH2)n— with n=4-6
- R10=H or the side chain of a natural amino acid including R10 and R11 together are forming a proline or hydroxy-proline derivative
- R11 either is together with R10 forming a proline or hydroxy-proline derivative or is H
- R12 is a carbamate protecting group including t-butoxycarbonyl, benzyloxycarbonyl and other N-protecting groups
- R1=OH, SH, NH2, NHR6, N(R6)2, OR7, O—CR8R9-O—CO—CHR10-NR11R12
-
-
- H, R7, or O—CR8R9-O—CO—CHR10-NR11R12, with the same definitions of R7-R12 as above
-
-
- H, F, Cl, Br, I, NH2, NO2, CN, CH3
-
-
- H or CH3
-
-
- If R4=H, then R5 is an electron pair
- if R4=CH3 then R5 is either hydrogen or a C1-C5 (ar)alkyl group, CH2—O—CH3,
- CH2—O—CO—R6, CH2—O—CR8R9-O—CO—CHR10-NR11R12 with the same definitions of R6 and R8-R12 as above;
- In all the latter cases, the nitrogen bears an additional positive charge as well as a counterion, selected from chloride, bromide, iodide, sulphate, nitrate, hydrogensulfate, phosphate, methanesulphonate, tosylate or other pharmaceutically acceptable anion.
- Preferred derivatives of the main concept of the invention are quaternary ammonium salts with a labile nitrogen-carbon bond at R5; mono- or diacylderivatives (esters) of the hydroxyl groups of said base compounds (R1, R2); sugar derivatives, preferably glucuronides (R1, R2); derivatives coupled with nicotinic acid (R1, R2); and selected halogenides (R3).
- Another preferred derivative of the main concept is a lipophilic dihydropyridinium carrier. This Redox Chemical Delivery System (RCDS; Misra A et al (2003) J
Pharm Pharmaceut Sci 6, 252-273) is known to significantly enhance drug delivery through the BBB into the brain parenchyma. Once inside the brain, the dihydropyridinium moiety is enzymatically oxidized to the corresponding ionic pyridinium salt. Subsequent cleavage of the original compound from the carrier leads to liberation of the original compound and to sustained levels of it in the brain tissue. - Other preferred derivatives of the main concept are amino acids that are known to be transported into the brain by active amino acid carriers, e.g., tyrosine. Once inside the brain parenchyma, these derivatives can either directly act on their target molecules or are first enzymatically liberated before acting as the original aren't compound.
- As a further aspect of the present invention, the derivatives obtained by chemical modification do not need to work as such as medicaments but rather may initially be pro-drugs that, after penetration though the blood-brain barrier, are converted (e.g., by brain enzymes) to the parent compound or a metabolite thereof and work as such as a medicament. Said pro-drug or derivative is used to prepare a medicament or pharmaceutical composition that preferably can be used for the treatment of brain diseases associated with a cholinergic deficit.
- Of the derivatives contained in the general structure of formula (III) and with the proviso and definitions provided there, the following are of particular interest in regard to the present invention, as they have not yet been described or developed under the premise of having higher lipophilicity and/or better BBB transport properties and/or higher brain-to-plasma ratio than their parent compounds (Table 1) from which they are derived by chemical modification:
-
TABLE 3 Examples of compounds described in previous publications/patents presently shown that they (i) act as cholinergic enhancers, and/or (ii) have higher logP-values than Galantamine STRUCTURE logP Name 1.30 Galantamine 1.38 Norgalantamine 1.68 3-O-Acetyl-6-O- demethyl-galantamine 1.72 8-Bromonarwedine 1.76 Narcisine 1.99 2.15 2.27 2.35 2.69 3.07 3.27 4.09 4.90
Han, So Yeop; Mayer, Scott C.; Schweiger, Edwin J.; Davis, Bonnie M.; Joullie, Madeleine M. Synthesis and biological activity of galantamine derivatives as acetylcholinesterase (AChE) inhibitors. Bioorganic & Medicinal Chemistry Letters (1991), 1(11), 579-80. - The following derivatives covered by the general structure of formula (III) and with the proviso and definitions provided there are particularly preferred derivatives of the main concept of the invention in that they have not yet been mentioned or described in any other publication or patent.
- Examples of new compounds that (i) act as cholinergic enhancers, and/or (ii) have higher log P-values than Galantamine (the latter for comparison only) are shown in
FIG. 1 . - The derivatives shown in Table 3 and
FIG. 1 may be used to prepare a medicament or other pharmaceutical composition. Such medicament or pharmaceutical composition can be used for the treatment of a disease state associated with a cholinergic deficit. - The usefulness of the derivatives, before and/or after conversion to the parent compound, to act as effective pharmaceutical agents is manifested by their ability to sensitize cholinergic receptors, and/or inhibit brain cholinesterases, and/or modulate intracellular messenger levels, and/or act neuroprotective. The ability to act as sensitizing agent on nicotinic receptors can be determined by electrophysiological and Ca-imaging methods, as described in Schrattenholz A et al. (1996)
Mol Pharmacol 49, 1-6 and Samochocki M et al (2000) Acta Neuro Scand Suppl 176, 68-73; Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036. The ability to inhibit cholinesterases can be determined by the photometric method of Ellman et al., Biochem. Pharmacol. 7,88 (1961). The ability to modulate intracellular messenger levels can be determined by Ca-imaging methods (Samochocki M et al. (2003) J Pharmacol Exp Therap 305, 1024-1036) and other means of recording changes in intracellular messenger levels or effects resulting thereof (Kihara T et al (2004) Biochem Biophys Res Commun 325, 976-982). The ability to act neuroprotective can be determined by a variety of in vitro and in vivo test systems, including in cell culture (Arias E et al (2003)Neuropharmacol 46, 103-1S 14; Kihara T et al (2004) Biochem Biophys Res Commun 325, 976-982) and in animal models of neurodegenerative diseases (Capsoni et al (2002) Proc NatlAcad Sci USA 99, 12432-12437). - This usefulness can also be ascertained by determining the ability of these compounds (I) to reduce neuronal cell death and amyloid plaque formation as well as cognitive impairment in animal models of Alzheimer's disease (Capsoni et al (2002) Proc Natl
Acad Sci USA 99, 12432-12437) and (2) to enhance learning performance in various animal test systems. In one particular learning paradigm applied to old and young rabbits (Woodruff-Pak D et al (2001) Proc Natl Acad Sci USA, 98, 2089-2094), the classical eye blink conditioning is used to study the effect of cognition-enhancing drugs on the septohippocampal cholinergic system. An active test compound of the present invention will reduce the number of trials required to learn that the air blow applied onto the animal's eye does not require the animal to close the eye (eye blink) as a protective measure. - This usefulness can also be ascertained by determining the ability of these compounds to restore deficient memory due to a cholinergic deficit in the Dark Avoidance Assay (DAA). In this assay mice are tested for their ability to remember an unpleasant stimulus for a period of e.g., 24 hours. A mouse is placed in a chamber that contains a dark compartment; a strong incandescent light drives it to the dark compartment, where an electric shock is administered through metal plates on the floor. The animal is removed from the testing apparatus and tested again, 24 hours later, for the ability to remember the electric shock administered in the dark compartment.
- If a nicotinic or muscarinic antagonist, i.e., an anticholinergic drug that causes memory impairment, is administered before an animal's initial exposure to the test chamber, the animal tends to re-enter the dark compartment much sooner than in the absence of the anticholinergic drug when being placed in the
test chamber 24 hours later. This effect of an anticholinergic drug is blocked by an active test compound, resulting in a greater interval before re-entry into the dark compartment. - The test results may be expressed as the percent of a group of animals in which the effect of the anticholinergic drug is blocked or reduced, as manifested by an increased time interval between being placed in the test chamber and re-entering the dark compartment.
- According to the present intention and approach, the brain disease that can be treated with the pro-drugs and derivatives provided herewith can be any psychiatric, neurological and neurodegenerative disease associated with a cholinergic deficit of any kind, including a neurodegenerative loss of cholinergic neurotransmitters and/or receptors, ACh-synthesizing and metabolizing enzymes, transport proteins and the like. Such diseases are exemplified by Alzheimer's and Parkinson's disease, other types of dementia, schizophrenia, epilepsy, stroke, poliomyelitis, neuritis, myopathy, oxygen and nutrient deficiencies in the brain after hypoxia, anoxia, asphyxia, cardiac arrest, chronic fatigue syndrome, various types of poisoning, anesthesia, particularly neuroleptic anesthesia, spinal cord disorders, inflammation, particularly central inflammatory disorders, postoperative delirium and/or subsyndronal postoperative delirium, neuropathic pain, subsequences of the abuse of alcohol and drugs, addictive alcohol and nicotine craving, and subsequences of radiotherapy, and more. The effect of Galantamine or other cholinesterase inhibitors in treatment of such diseases are described e.g., in WO2005/74535, WO2005/72713, WO2005/41979, WO2005/30332, WO2005/27975, US2004/266659 and WO2004/14393.
- All the derivatives described in the general (base) structure of formula (III) and Tables 2 and 3 and
FIG. 1 either have an effect as a pro-drug, which means that the derivative, after entering the brain, is “converted back” into an effective agent, e.g., Galantamine, Narwedine, Lycoramine, or the other said base compounds, or they are effective (i.e., as cholinergic enhancers or agents according to the definition) as derivatives themselves, meaning that they are not necessarily converted or metabolised before they act as agents at their target molecules, e.g., cholinergic receptors or cholinesterases. The common feature of the derivatives of the present application is that they all penetrate more effectively through the blood-brain barrier than the base compound, which according to the present invention preferably is Galantamine and related compounds. As a result of their improved BBB penetration properties, these compounds should have higher therapeutic efficacy and lower adverse side effects than e.g., Galantamine. - The compounds of the present invention whether pro-drugs or otherwise effective agents can be administered as such or as a pharmaceutically acceptable salt thereof.
- The derivatives of the common formulae as defined above can be prepared by any known method, however, it is preferred that the derivatives are prepared with proper use by the methods described for derivatization of according compounds in EP-A 649 846 with reference to scheme I and in the examples; EP-A648 771 with reference to scheme I and in the examples; EP-A 653 427 with reference to scheme I and in the examples; U.S. Pat. No. 6,150,354, paragraph “procedures” and examples; or U.S. Pat. No. 6,638,925, paragraph “experimental section”, respectively. A further reference is WO 01/74820, wherein combinatory and/or parallel synthesis is disclosed and synthesis of several compounds is described in the examples. Further the method can be used as described in Gomes, P. et al., Rui. Centro de Investigacao em Quimica da Universidade do Porto, Oporto, Port. Synthetic Communications (2003), 33(10), 1683-1693. A skilled person clearly will understand that in any case an appropriate educt/appropriate educts has/have to be used to obtain the desired derivatization of the base structure. The preparation method is not limiting the invention as long as the compounds presently described are obtained.
- The compounds of the invention preferably are prepared from the appropriate optical isomer of Galantamine or Narwedine via the intermediate 6-demethylgalantamine, a known therapeutically effective compound, or 6-demethylnarwedine, respectively.
- The pro-drugs and derivatives of this invention are selected by the following tests, which shall be considered as examples not limiting the invention:
-
- 1. Activity as nicotinic “allosterically potentiating ligand (APL), preferentially determined by electrophysiological methods and, Ca-imaging, using human cell lines that express individual subtypes of human neuronal nicotinic acetylcholine receptors (nAChR).
- In the case of a compound acting as such: The activation of nAChR by ACh or agonist is enhanced in the presence of said compound, with the APL activity being selectively blocked by antibody FK1.
- In the case of a pro-drug: Enhanced activity as a centrally acting APL after the pro-drug has been converted to the base compound by treatment with a rat brain or human brain homogenate extract.
- Kinetics of conversion from pro-drug to drug when incubated with a rat or human brain extract.
- 2. Activity as centrally acting cholinesterase inhibitor, as tested by various in-vitro, cell culture and in-vivo test systems.
- In the case of a pro-drug: Enhanced cholinesterase inhibition—or the same level of inhibition at a significantly reduced dose—is observed when the pro-drug is administered instead of the original base compound.
- Kinetics of conversion from pro-drug to drug when incubated with a rat or human brain extract.
- 3. Neuroprotective activity in acute toxicity protection tests (organophosphate poisoning of animals, in-vitro poisoning by AB and/or glutamate) and in animal models of neurodegeneraton.
- In the case of a pro-drug: Enhanced neuroprotective activity—or the same level of neuroprotection at a significantly reduced dose—is observed when the pro-drug is administered instead of the original base compound.
- 4. Accumulation of the derivatives in the brain of mammals as compared to unmodified Galantamine or other base compound.
- 5. Lipophilicity, as measured by shake-flask (e.g., octanol/buffer), HPLC-retention and nanobeads absorption methods.
- 6. Bioconversion t1/2 in the brain as compared to blood (systemic).
- 7. Theoretical/empirical estimates of distribution and log P values.
- 8. Other miscellaneous tests.
- 1. Activity as nicotinic “allosterically potentiating ligand (APL), preferentially determined by electrophysiological methods and, Ca-imaging, using human cell lines that express individual subtypes of human neuronal nicotinic acetylcholine receptors (nAChR).
- As one way of estimating improved lipophilicity of the derivatized compounds, log P-values are provided in some of the tables. Improved lipophilicity, as characterized by an increased log P-value, can either be determined experimentally including HPLC methods or by predictive computational methods. Although such calculations cannot replace the experiment, the data are strongly suggestive as to whether a certain modification of the base compound will result in an improved lipophilicity. Computer programs that allow such calculations include e.g., ToxBoxes from Pharma Algorithms, ACD-Lab, Molecule Evaluator from Cidrux, and others.
- Another means of estimating the readiness of a compound to transverse the BBB is by experimental comparison of the membrane affinity of said compound to its binding affinity to serum albumin, both determined by the NIMBUS Biotechnology assay (Willmann, S. et al. (2005) J Med Chem, in print).
- Effective quantities of the compounds of the invention may be administered to a patient by any of various methods, including orally as in capsules or tablets, via the skin or by nasal application. The free base final products, while effective by themselves, may be formulated and administered in the form of a pharmaceutically acceptable salt, e.g., for purposes of stability, convenience of crystallization, increased solubility, release retardation, and the like.
- Since the pro-drugs/compounds of the present invention pass the blood-brain-barrier easier than the base compounds, there are two advantageous aspects: first is the fast uptake of the pro-drug and therefore a fast onset of effect, second is that the dosage of application can be decreased compared to known medicaments resulting in lower peripheral side effects with high efficacy of the compounds at their effect site (brain). Further the pro-drugs after passage through the blood-brain-barrier are converted in the base compound which has a lower permeability through the blood-brain-barrier, thus the effective compound remains in the brain, resulting in a longer time period of effectiveness.
- As a representative case, the active compounds of the present invention may be orally administered, for example, with an inert diluent or with an edible carrier, or they may be enclosed in gelatine capsules, or they may be compressed into tablets. Furthermore, the active compounds of the invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gum and the like. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 0.1 and 50 milligrams of active compound.
- Because BBB penetration and brain-to-plasma ratio of the compounds modified according to this invention are significantly enhanced, the dosages of administered drug may be dramatically reduced, as compared to previous applications, clinical studies and estimates.
- The proposed derivatives were designed as pro-drugs, in the sense that they are able to effectively pass the blood brain barrier (BBB) and, after passing the BBB, they are substrates of endogenous enzymes and, upon enzymatic cleavage, produce galantamine. As a result of enzymatic cleavage to galantamine of such pro-galantamines in the brain, a significantly higher local concentration of galantamine is achieved in the brain than by administration of the same dose of original galantamine. The relatively higher drug concentration in the brain achieved by pro-galantamine administration will then result in higher efficacy at a given dose, and the better brain-to-peripheral tissues distribution will result in fewer or less significant side effects of treatment. These effects are significant improvements of present treatment regimens because the efficacy as treatment for brain diseases of unmodified galantamine (and all other ChE-I presently approved for this purpose) is rather limited, albeit statistically significant, possibly due to low dosing. Thus, efficacy is usually reached only after careful (months-long) up-titration of daily dose, so as to maintain sufficient compliance of patients to the largely gastro-intestinal side effects associated with ChE-I treatment.
- According to some embodiments, it was found that careful selection concerning the type of substituent and the position of substitution using galantamine as base structure result in highly efficacious compounds. Such very efficacious compounds having good blood brain barrier passing properties and being efficiently cleaved by an esterase after passage through the BBB are obtained with compounds having the general formula V
- with R1 being a substituent having particular sterical and hydrophobic properties.
- These embodiments focus on esters of galantamine that, as such, have little or no activity as ChE-I and APL compared to galantamine. Therefore, as long as these compounds remain uncleaved, they do not interact with the usual target molecules of galantamine and hence are largely inactive in producing therapeutic and/or side effects. The reduced reactivity of pro-galantamines is demonstrated by the following results:
- 1. Significantly reduced activity as ChE-I, as compared to galantamine.
- 2. Reduced activity as nicotinic APL, as compared to galantamine.
- 3. Reduced gastro-intestinal side effects, as compared to galantamine.
- All these approaches were investigated and are explained in the examples and shown in the figures.
- According to the invention it has been discovered that a particular group of esters of galantamine display unexpectedly high brain-to-blood concentration ratios (RBB-proGal>6, as compared to RBB-Gal˜1.3) and in the brain they are relatively slowly enzymatically cleaved to galantamine. Therefore, as is discussed below in more detail, these pro-galantamines are exceptionally well suited for the treatment of human diseases associated with cholinergic deficits, such as Alzheimer's disease, Parkinson's disease, Schizophrenia and a variety of other psychiatric disorders.
- The esters of galantamine to which the present invention refers to have the following general structure:
- wherein R1 either is CH(C2H5)CH3, CH2—C(CH3)3, or cyclopropane or being an optionally substituted aromatic or hetero-aromatic 5- or 6-membered ring. Specifically, such aromatic and hetero-aromatic rings include benzene, naphthalene, thiophene, pyrrole, imidazole, pyrazole, oxazole and thiazole, in case that they are used as medicaments or pro-drugs for the treatment of neurodegenerative or psychiatric or neurological disease associated with a cholinergic deficit.
- Such a disease preferably is selected from Alzheimer's and Parkinson's disease, other types of dementia, schizophrenia, epilepsy, neuritis, various types of poisoning, anesthesia, particularly neuroleptic anesthesia, autism, spinal cord disorders, inflammation, particularly central inflammatory disorders, postoperative delirium and/or subsyndromal postoperative delirium, neuropathic pain, subsequences of the abuse of alcohol and drugs, addictive alcohol and nicotine craving, and subsequences of radiotherapy.
- The above mentioned compounds were not yet described for the treatment of such diseases. Furthermore, compounds of formula I having aromatic or hetero-aromatic 5- or 6-membered ring, selected from substituted benzene with the proviso that it is not 2-fluorobenzene or 3-nitro-4-fluorobenzene, optionally substituted naphthalene, thiophene, pyrrole, imidazole, pyrazole, oxazole, thiazole; or CH(C2H5)CH3, CH2—C(CH3)3, or cyclopropane are according to the knowledge of the inventor not yet described at all.
- In one preferred embodiment the compounds of the present invention are selected from
- wherein R2-R6 comprising any substituent selected from H, halogen, optionally substituted C1-C3 alkyl or cyclopropyl, OH, O-alkyl, SH, S-alkyl, NH2, NH-alkyl, N-dialkyl, optionally substituted aryl or hetero-aryl, whereby neighbouring substitutents can cooperate to form an additional ring.
- In another preferred embodiment of the present invention the compounds are selected from the group consisting of the compounds as shown in table A, which is attached below.
- Herein the term “pro-drug” refers to a derivative of galantamine (base compound) wherein the group(s) added or replaced on said base compound are cleaved or returned to the hydroxyl group originally contained in the base compound, when the derivative has reached the area or site of action. Thus, in case of a “pro-drug”, an effective agent is administrated as a derivative (which is said pro-drug), however, the compound mainly or exclusively effective at the target site within the brain is the agent itself, not the derivatized compound or metabolites other than the base compound thereof.
- The term “derivative” refers to any change of a base compound defined in the present application. The term “derivative” is used to describe a compound which either can be a pro-drug, or can be an effective agent itself/in its own right or in the derivatized form.
- The term “pro-galantamine” is used for any derivative of galantamine described herein which can be cleaved by an enzyme (esterase) resulting in galantamine.
- The terms “sensitizing agent” and “allosterically potentiating ligand, APL” refer to effectors that enhance cholinergic neurotransmission by interaction with an allosteric site at cholinergic receptors.
- The terms “cholinergic enhancer” and “cholinergic agent” refer to compounds that enhance/modulate cholinergic neurotransmission by inhibition of cholinesterases, by allosteric sensitization and/or direct activation of cholinergic receptors and/or by activating/modulating relevant intracellular pathways via second messenger cascades.
- A derivative or pro-drug has an “enhanced blood-brain barrier permeability “according to the present invention or an “enhanced blood-brain barrier penetration” if, after administration of a pro-drug or derivative thereof to a living organism, a higher amount of said compound penetrates through the BBB of that organism.
- A compound of the present invention provides an increased “brain-to-blood concentration ratio” or “brain-to-tissue concentration ratio” resulting in a higher level of effective agent in the brain, as compared to administration of the base compound without derivatization. Methods for determination of an enhanced BBB permeability are disclosed in WO 2007/039138.
- The “base compound” as well as the “effective agent” according to the present invention is galantamine. The effective agent is obtained by (local) enzymatic cleavage of the derivative.
- “log P” is defined as the decadic logarithm of the partition coefficient P which is the ratio of the concentration of a compound in aqueous phase to the concentration of a compound in immiscible solvent, as the neutral molecule.
- The term “alkyl” shall mean a straight, branched or cyclic alkyl group. As “alkyl” C1 to C10 alkyl groups are preferred, C2 to C8 groups are more preferred and C2 to C6 groups are most preferred. C1 to C10 means alkyl groups of the stated number of carbon atoms. Examples include, but are not limited to methyl, ethyl, n-propyl, iso-propyl, n-butyl, isobutyl, sec-butyl, t-butyl, and straight and branched chain pentyl, hexyl, heptyl, octyl, nonyl and decyl etc. . . . or the according cyclic alkyls.
- The term “halo” shall mean chloro, fluoro, bromo and iodo.
- The term “aryl” shall mean phenyl having 0, 1, 2, 3, 4 or 5 substituents independently selected from the group of alkyl, alkoxy, alkylcarbonyl, halo- or trihalomethyl.
- The term “cycloalkyl” shall mean a cycloalkyl group of from 3 to 10 carbon atoms and including multiple ring alkyls such as for example, adamantyl, camphoryl, and 3-noradamantyl.
- In any case when a range between two limits is described it is meant that any value or integer in this range is disclosed. For example “C1-C10” means C1, C2, C3, C4, C5, C6, C7, C8, C9 or C10; or “between 0.1 and 1” means 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9 or 1.
- The stereo chemistry of the described derivatives are the same as that of galantamine.
- Benzoyl esters of galantamine were previously described in WO 9921561 A1 Davis, Bonnie M. for a method of treatment of disorders of attention with galantamine, lycoramine, and related compounds, but no syntheses or analytical or other data were provided for these compounds.
- Substituted benzoyl esters were previously described in “Synthesis and biological activity of galantamine derivatives as acetylcholinesterase (AChE) inhibitors” by Han, So Yeop; Mayer, Scott C.; Schweiger, Edwin J.; Davis, Bonnie M.; Joullie, Madeleine M. Dep. Chem., Univ. Pennsylvania, Philadelphia, Pa., USA. Bioorganic & Medicinal Chemistry Letters (1991), 1(11), 579-80. CODEN: BMCLE8 ISSN: 0960-894X. Journal written in English. CAN 116:83569 AN 1992:83569 CAPLUS. In this document the synthesis of several ester and carbamate derivatives of galantamine are described as well as it was suggested that these compounds are potential therapeutic agents in the treatment of Alzheimer's disease, based on their properties as ACHE inhibitors.
- In contrast to the teaching of these documents, the galantamine esters of the present invention have little, if any, activity as acetylcholinesterase inhibitors but rather are substrates of said enzyme (see above).
- As representatively demonstrated for the benzoyl derivative in
FIG. 2 , these esters have little, if any cholinesterase inhibitory activity but rather are hydrolysed by cholinesterases to form galantamine and accordingly act as pro-drugs of galantamine. As soon as galantamine is generated from these compounds, it acts as ChE-I and APL, as has previously been described. The structures of the tested derivatives can be seen in Table 4. As a comparative derivative a non-cleavable galantamine ether is also tested. Such derivative results in negative values of inhibition. In derivative Gln 1063 R1 in formula V is —O—Si(CH3)2—C(CH3)2—C(CH3)2H. -
TABLE 4 Mol Reg. No. Molecular structure Abbreviation GLN-1062 Bz-Gal GLN-1081 4-Cl-Bz-Gal GLN-1082 4-MeO-Bz-Gal GLN-1083 4-Me-Bz-Gal GLN-1084 3,4-Cl2-Bz-Gal GLN-1085 4-tBu-Bz-Gal GLN-1086 3-CF3-4-Cl-Bz-Gal GLN-1088 4-CF3-Bz-Gal GLN-1089 2,4-Cl2-Bz-Gal GLN-1090 4-NO2-Bz-Gal GLN-1091 3-Cl-Bz-Gal GLN-1092 3-CF3-Bz-Gal GLN-1093 3-NO2-Bz-Gal GLN-1094 3,5-Cl2-Bz-Gal GLN-1095 3-Me2N-Bz-Gal GLN-1096 3-Me-Bz-Gal GLN-1097 2-Cl-Bz-Gal GLN-1098 2,4-F2-Bz-Gal GLN-1099 2,5-Cl2-Bz-Gal GLN-1100 4-F-Bz-Gal GLN-1101 4-NMe2-Bz-Gal GLN-1102 4-NH2-Bz-Gal GLN-1103 3-Me-4-NMe2-Bz-Gal GLN-1104 3,4-OCH2O-Bz-Gal GLN-1105 4-Ac-Bz-Gal GLN-1113 2-AcO-Bz-Gal GLN-0978 n-prop-Gal GLN-0979 i-but-Gal GLN-0992 GLN-0993 n-Hex-Gal GLN-1011 neo-pent-Gal GLN-1060 GLN-1061 GLN-1067 R/S-i-pent-Gal GLN-1069 GLN-1070 GLN-1071 GLN-1076 CyBu-Gal GLN-1077 GLN-1080 R/S-i-pent-Gal GLN-1106 3-Th-Bz-Gal GLN-1107 2-Th-Bz-Gal GLN-1108 5-Cl-2-Th-Bz-Gal GLN-1109 5-Im-Bz-Gal GLN-1110 5-OA-Bz-Gal GLN-1111 5-Th-Bz-Gal GLN-0926 Nic-Gal GLN-1066 - Rather than inhibiting cholinesterases, the pro-galantamines referred to in the present document are substrates of the enzyme, as is exemplarily demonstrated in
FIG. 3 . - The data of
FIGS. 2 and 3 demonstrate that pro-galantamines of the present invention do not act as efficient inhibitors of cholinesterase, as was described in the earlier documents discussed above. Instead, they are substrates of these enzymes. Similarly, they also do not interact to the same extend as galantamine with neuronal nicotinic acetylcholine receptors (FIG. 4 ). - The pro-galantamines of the present invention therefore either do not interact, or only to a very limited extend, with the established target molecules of galantamine, in particular cholinesterases and neuronal nicotinic acetylcholine receptors. As pro-drugs they therefore have rather limited, if any, efficacy as cognition enhancers, and also produce only limited peripheral and central side effects, as compared to galantamine (see further below).
- As is exemplified and demonstrated by pharmacokinetics in mice (
FIGS. 5 a and 5 b, Table 5), R1-benzoyl-galantamine displays an unexpectedly high brain-to-blood concentration ratio (RBB-proGal>19), a large initial concentration in the brain, and it is only slowly cleaved to galantamine, as seen in the delayed appearance of a galantamine peak in brain and blood. The RBB-value is significantly larger than what was expected from the log P value which probably is due to the slow cleavage of the pro-drug in the brain and a depot effect thereby produced. - In Table 5, the key pharmacokinetic data of benzoyl-galantamine, of several other R1-pro-galantamines and of galantamine (for comparison) are listed.
-
TABLE 5 Pharmacokinetic data of several R1-pro-galantamines in the mouse Gln number (for reference see table 4) logP Co (Brain) R-Pro R- Gal 1062 3.0 4812 19.3 2.2 1067 2.8 4665 7.5 1.7 0979 2.5 3166 6.2 2.4 0993 3.7 2150 6.4 0.6 0978 2.2 1985 6.9 2.3 1076 2.4 1245 1.1 1.0 Gal 1.7 1741 1.2
Co is the highest pro-galantamine concentration (ng/ml) achieved in mouse brain after i.v. injection of 3 mg/kg of pro-galantamine. R-Pro is the brain-to-blood concentration ratio of pro-galantamine, R-Gal that of galantamine under these experimental conditions. For comparison, Co and R-Gal are also provided for i.v. injection of the same amount of galantamine. - These data establish that only a particular selection of R1 substitutions is capable of producing the following advantageous properties of pro-galantamines; high initial concentration in the brain, large RBB, and slow enzymatic conversion to galantamine. In addition (not shown in the table), the preferred R1-prodrugs display little, if any side effects, as they are only very slowly converted to galantamine, thereby largely protecting them from acting as galantamine while being transported from the site of administration to the sites of action in the brain.
- These properties may have significant impact for the use of these compounds as drugs in Alzheimer's disease and other brain diseases. As is representatively shown in
FIG. 5 , R1-pro-galantamines of the present invention display in ferrets much less gastro-intestinal side effects than galantamine. Ferrets were used in these studies as they are known to be particularly sensitive to gastro-intestinal side effects. In addition to the classical emetic responses to galantamine and other ChE inhibitors, we recorded salivation (SA), shivering (SH), respiratory problems (RP) and diarrhea (DI) at the levels “none; 0”, “moderate; 0.5” (behaviour observed at low frequency and/or at low intensity) and “intense; 1.0” (behaviour observed frequently and/or continuously and/or at high intensity), and summated the scores for the four animals each used per drug dose in these studies. - The data depicted in
FIG. 6 for the two pro-galantamines demonstrate that their side effects profile in ferrets is much less severe (5-6 times less) than that of the same dose of galantamine. The advantageous side effects profile is probably due to the reduced affinity of interaction of these R1-pro-galantamines with cholinesterases and neuronal nicotinic acetylcholine receptors (FIGS. 2 , 4). - The advantages of enhanced transport of selected R1-produgs through the blood-brain barrier into the brain, enzymatic conversion to galantamine close to target sites in the central nervous system, and interaction with such sites is producing enhanced reversal of drug-induced amnesia in mice, as is shown in
FIG. 7 for three pro-glantamines (and for galantamine in comparison). - The data of
FIG. 7 suggest that Gln-1062 is approximately 4-times more potent than galantamine in reversing scopolamine-induced amnesia in mice. It may be expected that a similar or larger increase in drug efficacy can be achieved in man when the particular R1-pro-galantamine is administered instead of galantamine. The advantageous drug properties of R1-pro-galantamines (higher efficacy, lesser or less intense side effects) were also shown in other animal models. - In summary, the compounds of this invention are particularly useful as medicaments for the treatment of human brain diseases associated with a cholinergic deficit, including the neurodegenerative diseases Alzheimer's and Parkinson's disease and the neurological/psychiatric diseases vascular dementia, schizophrenia and epilepsy. Based on preclinical studies using various animal models, the compounds have dramatically reduced side effects as compared to galantamine, including much fewer, if any, incidents of emetic responses, diarrhea and vomiting. Moreover, when enzymatically cleaved, the resulting galantamine displays an advantageous pharmacokinetic profile in the brain and, due to its enhanced concentration level in the brain, displays also enhanced efficacy in interaction with the target molecules located in the brain. Taken together, these properties make the administration of galantamine as a R1-prodrug a preferred medication in the diseases mentioned above.
- Acids useful for preparing the pharmaceutically acceptable acid addition salts according to the invention include inorganic acids and organic acids, such as sulfamic, amidosulfonic, 1,2-ethanedisulfonic, 2-ethylsuccinic, 2-hydroxyethanesulfonic, 3-hydroxynaphthoic, acetic, benzoic, benzenesulfonic acid, carboxylic, ethylenediamine tetraacetic acid, camphorsulfonic, citric, dodecylsulfonic, ethanesulfonic, ethenesulfonic, ethylenediamine tetraacetic, fumaric, glubionic, glucoheptonic, gluconic, glutamic, hexylresorcinic, hydrobromic, hydrochloric, isethionoc, (bi)carbonic, tartaric, hydriodic, lactic, lactobionic, laevulinic, laurylsulfuric, lipoic, malic, maleic, malonic, mandelic, methanesulfonic, mucic, naphthalenesulfonic, nitric, oxalic, pamoic, pantothenic, perchloric, phosphoric, polygalacturonic, pectic, propionic, salicylic, succinic or sulfuric acid, p-tuluenesulfonic, wherein hydrochloric, hydrobromic, sulfuric, nitric, phosphoric and perchloric acids, as well as tartaric, citric, acetic, succinic, maleic, fumaric and oxalic acids are preferred.
- The active compounds of the present invention may be orally administered, for example, with an inert diluent or with an edible carrier, or they may be enclosed in gelatin capsules, or they may be compressed into tablets. For the purpose of oral therapeutic administration, the active compounds of the invention may be incorporated with excipients and used in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, chewing gum and the like. These preparations should contain at least 0.5% of active compounds, but may be varied depending upon the particular form and may conveniently be between 5% to about 70% of the weight of the unit. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present invention are prepared so that an oral dosage unit form contains between 0.1-50 milligrams of active compound.
- The tablets, pills, capsules, troches and the like may also contain the following ingredients: a binder such as micro-crystalline cellulose, gum tragacanth or gelatin: an excipient such as starch or lactose, a disintegrating agent such as alginic acid, Primogel, cornstarch and the like; a lubricant such as magnesium stearate or Sterotex; a glidant such as colloidal silicon dioxide; and a sweetening agent such as sucrose or saccharin may be added or a flavouring agent such as peppermint, methyl salicylate, or orange flavouring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above-type, a liquid carrier such as an oil. Other dosage unit forms may contain other various materials which modify the physical form of the dosage unit, for example, as coatings. Thus, tablets or pills may be coated with sugar, shellac, or other enteric coating agents. A syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, colourings and flavours. Materials used in preparing these various compositions should be pharmaceutically pure and non-toxic in the amounts used.
- For the purpose of nasal or parenteral therapeutic administration, the active compounds of the invention may be incorporated into a solution or suspension. These preparations should contain at least 0.1% of active compound, but may be varied between 0.5 and about 30% of the weight thereof. The amount of active compound in such compositions is such that a suitable dosage will be obtained. Preferred compositions and preparations according to the present inventions are prepared so that a nasal or parenteral dosage unit contains between 0.1 to 20 milligrams of active compound.
- Further the compounds of the present invention can be administered via intranasal delivery to the cerebral spinal fluid as disclosed in detail in WO2004/02404.
- The solutions or suspensions may also include the following components: a sterile diluent such as water for injection, saline solution, fixed oils, polyethylene glycols, glycerine, propylene glycol or other synthetic solvents; antibacterial agents, such as benzyl alcohol or methyl parabens; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylene-diamine tetraacetic acid; buffers such as acetates; citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. Parenteral multiple dose vials may be of glass or plastic.
- Typical dosage rates in administration of the active ingredients depend on the nature of the compound that is used and in intravenous administration are in the range of 0.01 to 2.0 mg per day and per kilogram of body weight based on the physical condition and other medications of the patient.
- The following specific formulations exemplify suitable applications: Tablets and capsules that contain 0.5 to 50 mg. Solution for parenteral administration that contains 0.1 to 30 mg of active ingredient/ml. Liquid formulations for oral administration at a concentration of 0.1 to 15 mg/ml. Liquid formulations for nasal or intra-cerebroventricular administration at a concentration of 0.1 to 5 mg of active ingredient/ml. The compounds according to the invention can also be administered by a transdermal system, in which 0.1 to 10 mg/day is released. A transdermal dosage system may consists of a storage layer that contains 0.1 to 30 mg of the active substance as a free base or salt, in case together with a penetration accelerator, e.g., dimethyl sulfoxide, or a carboxylic acid, e.g., octanoic acid, and a realistic-looking polyacrylate, e.g., hexylacrylate/vinyl acetate/acrylic acid copolymer including softeners, e.g., isopropylmyristate. As a covering, an active ingredient-impermeable outside layer, e.g., a metal-coated, siliconised polyethylene patch with a thickness of, for example, 0.35 mm, can be used. To produce an adhesive layer, e.g., a dimethylamino-methacrylate/methacrylate copolymer in an organic solvent can be used.
- The invention also relates to pharmaceutical compositions that in a pharmaceutically acceptable adjuvant contain a therapeutically effective amount of at least one of the compounds that are proposed according to the invention.
- Examples of chemical synthesis and properties of derivatives are given in the following examples. Abbreviations: DCM: dichloromethane; DMAP: 4-dimethylaminopyridine; DCC: dicyclohexylcarbodiimide; DCHU: dicyclohexylurea.
- N-Methoxymethyl-galanthaminiumchloride is obtained from Galantamine via alkylation using chloromethylmethylether:
- To a solution of (−)-Galantamine (5.00 g, 17.4 mmol) in dry dimethylformamide (12 mL) chloromethylmethylether (1.12 g, 13.9 mmol) is added at −5
bis 0° C. in the course of 15 min and stirred for 4 hrs. at room temperature. The reaction mixture is poured on ethyl acetatet (500 mL) and the precipitate obtained is filtered and washed using ethyl acetate (3×50 mL). - The crude product (4.20 g, 82%) has a purity of 96% (HPLC). For further purification the crude product is dissolved in dry ethanol, stirred after the addition of activated charcoal, filtered and added to ethyl acetate (500 mL). The precipitate is filtered and washed using ethyl acetate (3×50 mL) and dry diethylether (1×50 mL). The product is obtained in the form of colourless crystals (3.85 g, 75% d. Th.) melting at 126-127° C.
- Opt. Rotation:_[α]D 20=−113.9° (c=0.18 g/water) calcd. For C19H26ClNO4*0.33H2O C, 61.04; H, 7.19; N, 3.75; found: C, 61.10; H, 7.07; N, 3.75
- 1 H NMR (DMSO-d6) δ 6.86 (s, 2H), 6.29 (d, J=10 Hz, 1H), 5.88 (d, J=10 Hz, J=4 Hz, 1H), 5.13 (bs, 3H), 4.66 (s, 2H), 4.48 (d, J=14 Hz, 1H), 4.22-3.90 (m, 2H), 3.81 (s, 3H), 3.70 (s, 3H), 3.70-3.52 (m, 1H), 2.75 (s, 3H), 2.44-1.79 (m, 4H); 13 C NMR (DMSO-d6) δ 146.4 (s), 145.2 (s), 132.8 (s), 130.2 (d), 125.3 (d), 123.7 (d), 117.8 (s), 112.1 (d), 94.8 (t), 86.4 (d), 61.7 (d), 60.3 (t), 59.4 (q), 56.2 (t), 55.6 (q), 46.2 (s), 40.2 (q), 31.1 (2 t);
- The chemical and biological stability of this compound has been determined in various buffers (chemical stability), in rat blood serum, and in rat brain extract, suggesting that the derivative can act as a pro-drug.
- Instead of chloromethyl or methyl ether the following reagents can be used alternatively: Methoxymethanolbenzenesulfonate, trifluoromethanesulfonic acid methoxymethyl ester, or methoxymethanol 4-methylbenzenesulfonate.
-
- To a solution of N-Boc-glycine chloromethylester (1.0 mmol) and norgalantamine (1.0 mmol) in dry DMF (2.0 mL) triethylamine (3 mmol) was added dropwise and the reaction stirred under nitrogen for 3 days. The triethylammonium chloride formed was filtered and washed with dry ether and the filtrate rotoevaporated to dryness. The residue was redissolved in dry acetone (2 ml) upon heating and left to stand overnight at 4° C. for additional precipitation of the triethylammonium salt. After renewed filtration and rotoevaporation the mixture was chromatographed on silica using ethyl acetate/petrol ether. The target product was isolated as an oil.
- 13 H NMR (DMSO-d6) δ 28.5, 33.9, 37.9, 42.0, 48.2, 51.2, 56.2, 56.9, 61.9, 79.5, 79.9, 88.8, 111.8, 121.3, 126.6, 129.8, 130.8, 133.6, 145.8, 148.2, 156.3, 169.6.
-
- This compound was prepared using the procedure of example 2 with N-Boc-phenylalanine chloromethylester.
- 13 H NMR (DMSO-d6) δ 28.5, 33.9, 36.9, 37.9, 48.2, 51.2, 54.6, 56.2, 56.9, 61.9, 79.5, 80.2, 88.8, 111.8, 121.3, 126.0, 126.6, 127.8, 128.7, 129.8, 130.8, 133.6, 139.5, 145.8, 148.2, 4156.0, 171.6.
-
- A solution of N-methylgalanthaminium iodide (5.0 g, 11.6 mmol) in 35% aqueous potassium hydroxide (150 mL) is heated under reflux for 48 hrs, diluted with water (200 mL) and acidified using conc. hydrochloric acid to pH=3-4 and extracted with dichloromethane (2×50 mL) to remove non-basic compounds. The aqueous phase is basified using conc. ammonia to
pH 12 and extracted using dichloromethane (4×100 mL). The combined organic extracts are washed with brine (2×50 mL), dried using sodium sulfate and rotoevaporated to obtain the crude product which is purified by MPLC (200 g SiO2, chloroform:methanol=99:1+1% conc. ammonia). The product is obtained as yellow oil (2.5 g, 71% d. Th.). The fumarate (colourless crystals) and oxalate salt (off-white crystals) where obtained in the usual way: m.p.: 151-153° C. (fumarate), 116-118° C. (oxalate). [α]D 20=−56.5° (0.212 g/100 mL H2O) (fumarate). -
fumarate: oxalate C18H25NO3 * 1.0 C4H4O4 C18H25NO3 * 1.0 C2H2O4 * 0.75 H2O Calcd.: C, 62.99; H, 6.97; N, 3.34 Calcd.: C, 59.32; H, 6.60; N, 3.46 Found: C, 62.89; H, 6.62; N, 3.32 Found.: C, 59.48; H, 6.31; N, 3.38 - 1 H-NMR (CDCl3): δ 6.83 (d, J=8.4 Hz, 1H), 6.72 (d, J=8.4 Hz, 1H), 6.13-5.95 (m, 3H), 5.32 (dd, J=10.3, 1.1 Hz, 1H), 5.25 (dd, J=18.3, 1.1 Hz), 4.63 (b, 1H), 4.15 (b, 1H), 3.85 (s, 3H), 3.58 (d, J=12.8 Hz, 1H), 3.07 (d, J=12.8 Hz, 1H), 2.56 (m, 1H), 2.15 (s, 6H), 1.96 (ddd, J=16.2, 4.9, 2.3 Hz, 1H); 13 C-NMR (CDCl3): δ 146.6 (s), 144.1 (s), 139.0 (t), 132.2 (s), 128.6 (s), 128.1 (d), 127.8 (d), 123.6 (d), 117.3 (t), 111.1 (d), 86.0 (d), 62.0 (t), 59.7 (t), 55.7 (q), 52.9 (s), 44.7 (q), 28.6 (t)
-
- 3-Chloroperbenzoic acid (0.38 g, 75% ig, 1.66 mmol) is added to a solution of (3R,4aS,9bS)-9-dimethylaminomethyl-6-methoxy-3,4,4a,9b-tetrahydro-9b-vinyl-dibenzofuran-3-ol (0.50 g, 1.66 mmol) in dichloromethane (35 mL) and then stirred for 30 minutes at room temperature. After adding a solution of iron(II) sulfate-heptahydrate (0.23 g, 0.83 mmol) in methanol (5 mL) it is then stirred for another 20 minutes at room temperature. Then 2N hydrochloric acid (30 mL) is added, stirred for 5 minutes and most of the dichloromethane is removed by rotoevaporation. The remaining aqueous phase is washed with diethyl ether (4×20 mL), basified to
pH 12 using concentrated ammonia and then extracted with dichloromethane (4×40 mL). The combined organic phases are washed with saturated sodium chloride solution (30 mL), dried using sodium sulphate, filtered and the solvent is again removed by rotoevaporation to obtain the crude product which is then further purified using MPLC (Büchi, 110 g SiO2, chloroform:methanol 97:3+1% concentrated ammonia) and obtained as a yellow oil (0.30 g, 63% d. Th.). The oxalate is prepared in the usual way and obtained as colourless crystals, 0.37 g, 59% d. Th., m.p. 127-129°. The purity is checked by TLC (chloroform:methanol=9:1+1% conc. ammonia, Rf=0.35). [α]D 20=−41.8° (0.220 g/100 mL H2O) (Oxalate) - C17H21NO3*1.0 C2H2O4*0.5H2O
- Calcd.: C, 59.06; H, 6.26; N, 3.62
- Found: C, 59.35; H, 6.00; N, 3.56
- 1 H-NMR (CDCl3): δ 6.88 (d, J=8.4 Hz, 1H), 6.75 (d, J=8.4 Hz, 1H), 6.15-5.82 (m, 3H), 4.67 (b, 1H), 4.09-4.20 (m, 1H), 3.85 (s, 3H), 3.68 (s, 2H), 2.52-2.49 (m, 1H), 2.42 (s, 3H), 1.97 (ddd, J=16.2, 4.9, 2.3 Hz, 1H); 13C-NMR (CDCl3): δ 146.6 (s), 144.0 (s), 139.4 (d), 131.6 (s), 129.5 (s), 128.9 (d), 127.2 (d), 122.7 (d), 117.6 (t), 111.8 (d), 86.0 (d), 62.0 (d), 55.9 (q), 52.8 (t), 51.1 (s), 36.0 (q), 28.8 (t)
-
- Palladium (10%) on active carbon (90 mg) is pre-hydrogenated in methanol (40 mL) and conc. acetic acid (2 mL) in the Parr-apparatus at 10 psi and room temperature for 45 minutes. After adding (3R,4aS,9bS)-9-dimethylaminomethyl-6-methoxy-3,4,4a,9b-tetrahydro-9b-vinyl-dibenzofuran-3-ol (0.90 g, 2.99 mmol) it is then hydrated for 8 hrs. at 15-20 psi and room temperature. The catalyst is then filtered and the solvent is removed by rotoevaporation. The residue is then dissolved in water (100 mL), basified using conc. ammonia and extracted using dichloromethane (5×40 mL). The combined aqueous phases are washed with a saturated sodium chloride solution (2×20 mL), dried using sodium sulphate and the solvent is removed by rotoevaporation. It is then further purified using MPLC (Büchi, 110 g SiO2, chloroform:methanol=98:2+1% conc. ammonia), obtained as a colourless oil (0.80 g, 88%) and converted to the hydrochloride m.p. 248-249°. [α]D 20=−47.3° (0.220 g/100 mL H2O). TLC chloroform:methanol=9:1+1% conc. ammonia, Rf=0.45.
- C18H25NO3*2.0HCl
- Calcd.: C, 57.45; H, 7.23; N, 3.72
- Found: C, 57.95; H, 6.85; N, 3.48
- 1 H-NMR (CDCl3): δ 6.78 (d, J=8.3 Hz, 1H), 6.67 (d, J=8.3 Hz, 1H), 6.12 (d, J=10.2 Hz, 1H), 5.89 (dd, J=10.2, 4.3 Hz, 1H), 4.74 (b, 1H), 4.19-4.09 (m, 1H), 3.84 (s, 3H), 3.54 (d, J=12.9 Hz, 1H), 3.19 (d, J=12.9 Hz, 1H), 2.53-2.32 (m, 1H), 1.94-2.13 (m, 2H), 1.69 (ddd, J=16.2, 4.9, 2.3 Hz, 1H), 0.85 (t, J=7.6 Hz, 3H); 13 C-NMR (CDCl3): δ 146.8 (s), 144.4 (s), 131.6 (d), 128.2 (s), 127.7 (d), 123.6 (d), 110.6 (d), 83.8 (d), 62.7 (d), 61.6 (s), 55.7 (q), 51.1 (s), 45.2 (q), 31.6 (t), 27.5 (t),
-
- Following the procedure of example 6 using (3R,4aS,9bS)-9-Dimethylaminomethyl-9b-ethyl-6-methoxy-3,4,4a,9b-tetrahydro-dibenzofuran-3-ol the pure product is obtained as a yellow oil (0.17 g, 59% d. Th.) and converted to the oxalate and fumarate.
- M.p. (oxalate) 162-164°, [α]D 20=−51.2° (0.146 g/100 mL H2O) (oxalate).
- TLC chloroform:Methanol=9:1+1% conc. ammonia, Rf=0.39
-
fumarate: oxalate C17H23NO3 * 1 C4H4O4 * 0.33 H2O C17H23NO3 * 1 C2H2O4 * 0.25 H2O Calcd.: C, 61.31; H, 6.78; N, 3.40 Calcd.: C, 59.44; H, 6.69; N, 3.65 Found: C, 61.22; H, 6.67; N, 3.22 Found; C, 59.53; H, 6.78; N, 3.65 - 1 H-NMR (CDCl3): δ 6.85 (d, J=8.4 Hz, 1H), 6.73 (d, J=8.4 Hz, 1H), 5.97-5.92 (m, 2H), 4.74 (dd, J=5.8, 3.5 Hz, 1H), 4.22-4.12 (m, 1H), 3.84 (s, 3H), 3.74 (d, J=7.2 Hz, 2H), 2.48 (s, 3H), 2.45-2.28 (m, 2H), 2.20-1.62 (m, 5H), 0.85 (t, J=7.46, 3H); 13 C-NMR (CDCl3): δ 146.6 (s), 144.2 (s), 131.1 (s), 131.0 (d), 128.9 (s), 128.8 (d), 122.3 (d), 111.1 (d), 83.8 (d), 62.8 (d), 55.8 (q), 51.0 (s), 36.3 (q), 32.5 (t), 29.1 (t),
-
- To a solution of NaOMe (26 mg, 0.48 mmol) in MeOH (150 mL) was added glucurono-6,3-lactone (20.6 g, 154 mmol) in portions with stirring until dissolved. The solvent was then removed in vacuo, the residue taken up in pyridine (85 mL, 1.08 mol) and the solution cooled to 0° C. Isobutyryl chloride (110 mL, 1.06 mol) in CH2Cl2 (70 mL) was then added with strong mechanical stirring at a rate that kept the temperature below 10° C., and the reaction mixture was left at room temperature overnight. More CH2Cl2 (100 mL) was then added and the solution washed with water (400 mL), 2 M HCl (3×50 mL), saturated sodium bicarbonate (5×50 mL) and brine (50 mL). After drying, filtering and evaporating in vacuo, a gum was obtained which crystallized on trituration with petroleum ether (40-60° C.). Filtration and drying at 40° C. in a vacuum oven yielded the title product. Recrystallisation from MeOH or petrol ether afforded the
pure β isomer 2 as needles, mp 127° C., (21.6 g, 37%, from mother liquid some more product could be isolated) [α]D=+11.12 (c 1.7 CHCl3); δH (300 MHz, CDCl3): 5.78 (d, J=8 Hz), 5.39 (t, J=9.5 Hz), 5.25 (t, J=9.5 Hz), 5.23 (dd, J=9.5, 8 Hz), 4.19 (d, J=9.5 Hz), 3.75 (s, OMe), 2.65-2.45 (m, 4×CHMe2), 1.17-1.07 (m, 4×CHMe2). - An alternative procedure with pivaloyl chloride was also used to prepare
methyl compound 2 was easier). - Ammonia gas pre-dried by passing it through a bed of sodium hydroxide was bubbled through CH2Cl2 (200 mL) at −4° C. over 1 h at a rate which kept the temperature below 0° C. The above
methyl mp 89° C. δH (300 MHz, CDCl3): 5.65 (t, J=10 Hz), 5.54 (d, J=3.5 Hz), 4.92 (dd, J=10, 3.5 Hz), 4.60 (d, J=10 Hz), 3.75 (s, OMe), 2.61-2.43 (m, 4×CHMe2), 1.20-1.05 (m, 4×CHMe2). - To a stirred solution of
methyl title product 4 as a semi crystalline gum which crystallized from dry isopropanol as white prisms,mp 108° C. (422 mg, 75%). δH (300 MHz, CDCl3): 8.72 (s, NH), 6.66 (d, J=3.5 Hz), 5.70 (t, J=10 Hz), 5.30 70 (t, J=10 Hz), 5.20 (dd, J=10, 3.5 Hz), 4.51 (d, J=10 Hz), 3.75 (s, OMe), 2.60-2.43 (m, 3×CHMe2), 1.17-1.06 (m, 3×CHMe2). - A suspension of dried galantamine hydrobromide (92 mg, 0.25 mmol) and the
above methyl - 2M-NaOH (2.0 mL) was added to a stirred suspension of the glucuronate 5 (30 mg) in MeOH (4 mL), and the mixture left overnight. The solution was then acidified with glacial acetic acid to pH 5.5, the solvent evaporated and purified over silica with CHCl3: MeOH (saturated with dry NH3) 95:5. The product-fraction was freeze-dried to afford 14 mg of 6 as a white powder, m.p. 238° (dec.).
- 1H NMR (MeOD, 200 MHz): 1.63-1.73 (m, 1H), 2.02-2.21 (m, 2H), 2.38 (s, 3H), 2.43-2.53 (m, 1H), 2.99-3.06 (m, 1H), 3.19-3.33 (m, 1H), 3.47-3.49 (m, 1H), 3.65-3.71 (d, 1H, J=14.9 Hz), 3.78 (s, 3H), 4.05-4.13 (d, 1H, J=14.9 Hz), 4.58 (m, 1H), 5.85-5.94 (dd, 1H, J2=4.8 Hz, J2=10.2 Hz), 6.15-6.21 (d, 1H, J2=10.2 Hz), 6.63-6.77 (m, 2H)
- 13C NMR (MeOD, 200 MHz): 23.22, 28.65, 34.57, 42.02, 43.33, 48.09, 54.03, 55.64, 60.43, 88.54, 112.18, 122.30, 127.16, 127.70, 128.64, 133.49, 144.65, 146.39
-
- Following the procedure for the preparation of Galantamine-6-
methyl pure product 7. - 2M-NaOH (2.0 mL) was added to a stirred suspension of the above glucuronate 7 (130 mg) in MeOH (4 mL), and the mixture left overnight. The solution was then acidified with glacial acetic acid to pH 5.5, the solvents removed by freeze drying and the product chromatographed on silica using CHCl3:MeOH (saturated with dry NH3) 95:5. gave 48 mg (63.5%) of the
product 8. - 1H NMR (CDCl3, 200 MHz): 1.60-1.72 (m, 2H), 1.82-2.6 (m, 10H), 2.88-3.30 (m, 3H), 3.50-3.67 (m, 6H), 3.80-4.20 (m, 3H), 4.30-4.70 (m, 1H), 4.94-5.30 (m, 6H), 5.76-6.21 (m, 2H), 6.42-6.56 (m, 1H), 6.74-6.86 (m, 1H)
-
- A solution of galantamine (431 mg, 1.5 mmol) in dry pyridine (25 mL) was treated with nicotinoyl chloride (240 mg, 1.7 mmol) and 4-N,N-dimethylaminepyridine (5 mg) at 0° and the solution stirred to room temp. for 2 hrs. followed by heating to 45° for 1 hr. The reaction mixture was poured on water (150 mL) and the pH adjusted to 8.0 followed by extraction with dichloromethane. The organic extract was washed with water and brine, dried (sodium sulphate) and evaporated to give the crude product (480 mg, 81.5%)
- 13 H NMR (DMSO-d6) δ 27.7, 34.3, 41.7, 47.8, 53.6, 55.9, 60.3, 63.2, 86.2, 111.5, 121.3, 122.1, 122.7, 126.0, 129.2, 130.6, 131.9, 136.4, 143.9, 146.5, 150.4, 151.5, 166.0.
- This product was converted to the dihydrobromide salt by dissolution in a minimum amount of warm 40% hydrobromic acid followed by cooling and obtained as colorless crystals.
- Anal. calcd. for C23H24N2O4. 2 HBr. 0.33H2° C. 49.31; H, 4.80; N, 5.00. Found C, 49.10; H, 5.05; N, 4.85.
-
- Sulphuric acid (50 ml, 95-98%) was heated with stirring to the 90-95° C. under a dry nitrogen and 4,5-dimethoxy-2-fluoro benzaldehyde (10.1 g, 54.8 mmol) added quickly and this mixture was stirred at the same temperature for 3.5 h. Reaction was followed by HPLC and found to be complete after this time. The reaction mixture was poured on crushed ice (150 g) and the white slurry obtained was heated to 65° C. and allowed to cool in the fridge overnight. The white precipitate was filtered and washed with water (2×100 ml). The wet cake was dried in the desiccator under reduced pressure to afford the product (7.6 g, 82%,
HPLC 95%, m.p.: 146-148) as off white crystals. - A solution of 1 (7.6 g, 45 mmol) and tyramine (6.7 g, 49 mmol) in dry toluene (250 ml) and n-butanol (250 ml) was heated and stirred to reflux for 5 h on the Dean-Stark apparatus to remove the water. Reaction development was controlled by TLC (MeOH:CH2Cl2 1:9) and reaction was found to be complete after this time. Solvents were rotoevaporated and residue was dissolved in dry methanol (500 ml). NaBH4 (1.8 g, 45 mmol) was added at the temperature 0-5° C. and this mixture was stirred overnight while the temperature was raised to room temperature and a white solid precipitated from the reaction mixture. The solid was filtered and washed with cold methanol (2×50 ml). The white, wet cake was dried in the desiccator at reduced pressure to give the product (9.6 g, 74%, HPLC>99%) as a white powder. The filtrate was rotaevaporated to give a brown slurry (3.6 g), which was chromatographed on silica (dichloromathane/methanol, gradient 0-10%) to give another (2.5 g, 19%, HPLC>99%) of product as a off white powder (
total yield 93%, m.p.: 160-162° C.). - 1H NMR (MeOD, 200 MHz): 2.69 (s, broad, 4H), 3.66 (s, 2H), 3.80 (s, 3H), 6.66-6.77 (m, 4H), 6.96-7.00 (m, 2H).
- To a suspension of 2 (7.63 g, 26.1 mmol) in dioxane (50 ml) a solution of ethyl formiate (3.1 ml, 37.7 mmol), DMF (1.5 ml) and formic acid (0.25 ml, 6.62 mmol) was added dropwise and the reaction mixture was heated under argon to reflux for 10 h. The reaction development was controlled by HPLC and showed complete conversion after this time. Volatiles were removed under reduced pressure, the residue was dissolved in methanol (32 ml) and poured on crushed ice (160 ml), the white precipitate formed was stirred magnetically for 1 h, filtered, washed with water (3×100 ml) and dried to weight to afford the product (6.8 g, 81.3%, HPLC>99%, m.p.: 153-168° C.) as a white powder.
- 1H NMR (DMSO, 200 MHz): 2.49-2.67 (m, 2H), 3.15-3.29 (m, 2H), 3.75 (s, 3H), 4.28-4.35 (d, 2H, J2=13.89 Hz), 6.64-6.95 (m, 6H), 7.84 (s, 0.5H), 8.20 (s, 0.5H), 8.95-9.00 (d, 1H, 10.17 Hz), 9.18-9.20 (d, 1H, J=2.44 Hz).
- To the vigorously stirred biphasic mixture of potassium carbonate (13.2 g, 95.5 mmol) and potassium hexacyanoferrate (28 g, 85.4 mmol) in toluene (580 ml) and water (120 ml), preheated to 50° C., finely pulverized 3 (6.83 g, 21.4 mmol) was added in one portion and this suspension was heated at 50-60° C. with intense stirring for 1 h. After this time the reaction mixture was filtered trough the pad of celite, the toluene phase separated and the water phase was extracted with toluene (2×100 ml). The combined organic phases were dried (Na2SO4) and roto-evaporated under reduced pressure to afford the product (1.3 g, 19%,
HPLC 98%) as a white powder. - 1H NMR (DMSO, 200 MHz): 1.75-1.93 (m, 1H), 2.15-2.30 (m, 1H), 2.73-2.83 (m, 1H), 3.00-3.12 (m, 1H), 3.40 (s, 4H), 3.98-4.13 (m, 1H), 4.28-4.35 (m, 0.5H), 4.51-4.97 (m, 2H), 5.27-5.34 (d, 0.5H, J=15.45 Hz), 5.94-6.00 (d, 1H, J=10.37 Hz), 6.77-6.86 (m, 1H), 7.15-7.26 (m, 1H), 8.10-8.15 (d, 1H, J=8.99 Hz)
- 13C NMR (DMSO, 200 MHz): 34.02, 37.21, 37.32, 45.45, 49.33, 49.53, 56.05, 87.29, 100.20, 100.34, 100.77, 100.90, 114.55, 114.93, 115.08, 126.66, 130.83, 130.93, 143.12, 143.43, 143.64, 143.76, 144.29, 144.52, 162.39, 162.62, 194.77.
- To the solution of 4 (1.084 g, 3.42 mmol) in toluene (10 ml) a solution of 4-toluene sulphonic acid (0.02 g, 0.116 mmol) in 1,2-propane-diol (1.13 ml) was added and the mixture heated to the reflux for 1 h while the water was removed using a Dean-Stark apparatus. Another portion of 4-toluene sulphonic acid (0.05 g) in 1,2-propanediol (0.65 ml) was added and heating continued for another 5 h. Reaction development was controlled by HPLC and the reaction found to be complete after this time. The reaction mixture was cooled to room temperature and extracted with acetic acid (2×25 ml, 10% in water), sodium hydrogen carbonate (2×25 ml, 10% in water) and brine (1×25 ml). The toluene solution was dried (Na2SO4) and evaporated to give a crude product (1.32 g) as an amber oil. This was crystallized using i-propanol and ligroin to give product (0.92 g, 72%), as a colourless crystals.
- 1H NMR (CDCl3, 200 MHz): 0.74-2.66 (m, 10H), 2.98-4.86 (m, 8H), 5.44-5.74 (m, 1H), 6.34-6.39 (m, 1H), 7.98-8.03 (m, 1H).
- To the solution of 5 (0.91 g, 2.43 mmol) in dry THF (15 ml) lithium aluminium hydride (1.21 ml, 2.3 mol suspension in THF) was added at 0-5° C. under a continuous stream of dry nitrogen and this mixture was stirred for 1 h. Another portion of lithium aluminium hydride (0.605 ml, 2.3 mmol suspension in THF) was added and stirring continued for additional 1 h while the temperature raised slowly to room temperature. Reaction development was controlled by HPLC and no starting material was detected after this time. The reaction mixture was quenched with water/THF 1:1 (20 ml) and volatiles removed under reduced pressure. The residue was dissolved in 2N-hydrochloric acid (25 ml) and stirred at room temperature for 30 min. The clear solution was than treated with ammonia to
pH 12 and extracted with ethyl acetate (3×50 ml). The combined organic phases were dried (Na2SO4), treated with charcoal, filtered and evaporated to dryness to give 720 mg of the crude product as an brown oil. Chromatography on silica using 7 N NH3 in MeOH: CH2Cl2 5:95 as solvents afforded the product (590 mg, yield 80%,HPLC 97%) as an amber oil. - 1H NMR (CDCl3, 200 MHz): 1.77-1.84 (m, 1H), 2.09-2.24 (m, 1H), 2.38 (s, 3H), 2.60-2.71 (m, 1H), 2.98-3.11 (m, 3H), 3.64-3.72 (m, 4H), 4.03-4.11 (d, 1H, J=15.65 Hz), 4.65 (s, 1H), 5.93-5.98 (d, 1H, J=10.56 Hz), 6.40-6.46 (d, 1H, J=11.34 Hz), 6.84-6.89 (m, 1H)
- 13C NMR (CDCl3, 200 MHz): 33.41, 37.22, 43.18, 49.42, 49.46, 51.91, 51.99, 54.13, 56.20, 88.12, 99.99, 100.58, 114.98, 115.34, 127.31, 131.33, 131.43, 142.84, 143.51, 143.71, 144.11, 152.42, 157.18, 194.13.
- To the solution of 6 (500 mg, 1.64 mmol) in dry THF (30 ml) L-Selectride (1.50 ml, 1 M solution in THF) was added dropwise at −5 to 0° C. under dry nitrogen and this mixture was stirred at the same temperature for 30 min. The reaction was monitored by HPLC and no starting material was detected after this time. The reaction was quenched using water/THF 2:1 (50 ml) and solvents were removed under reduced pressure. The residue was dissolved in 2N-hydrochloric acid (100 ml) and kept overnight in the fridge. The aqueous solution was than washed with diethyl ether (2×30 ml) and ammonia was added to
pH 12. The aqueous phase was extracted using ethyl acetate (3×100 ml), the combined organic phases were washed with brine (50 ml), dried (Na2SO4) and evaporated to afford the crude product (515 mg) as a clear, slightly yellow oil which was purified by chromatography on silica using MeOH:CH2Cl2 9:1 to afford the product (0.46 g, 92%, HPLC>99%) as a white powder. - 1H NMR (CDCl3, 400 MHz): 1.25 (s, 1H), 1.55-1.67 (m, 1H), 1.92-2.10 (m, 2H), 2.41 (s, 4H), 2.62-2.70 (m, 1H), 2.98-3.29 (m, 2H), 3.72-3.78 (d, 1H), 3.81 (s, 3H), 4.07-4.20 (m, 2H), 4.60 (s, 1H), 6.03 (s, 2H), 6.47-6.49 (d, 1H),
- 13C NMR (CDCl3, 400 MHz): 30.11 (C-5), 34.31 (C-9), 43.10 (N—CH3), 49.21 (C-8a), 52.15 (C-10), 54.32 (OCH3), 56.55 (C-12), 62.37 (C-6), 89.29 (C-4a), 99.86 (C-2), 100.16 (C-12a), 126.89 (C-12b), 134.25 (C-8), 134.30 (C-7), 142.09 (C-3a), 144.23 (C-3), 154.31 (C-1), 156.69 (C-1).
- The enantiomers of (+−)-8-fluorogalantamine were separated using chiral preparative column chromatography (Chiracel OD, 5 μm, 5□50 cm, 80% n-heptane/20% i-PrOH) to afford two isomers which were converted to the corresponding hydrobromide salts. The progress and the result of this chiral separation was analyzed by chiral HPLC (Chiracel I OD-H, 80% n-heptane+0.1% diethyl amine/20% i-PrOH). The crystal structure of (−) 2-HBr was determined thus confirming the expectation, that (−)-8-fluorogalanthamine has the same absolute configuration as (−)galantamine.
- (−)Galantamine (287 mg, 1 mmol), 2-propyl-pentanoic acid (216 mg, 1.5 mmol), 4-dimethylaminopyridine (244 mg, 2 mmoles) are added to dry CH2Cl2 and stirred for 5 min. A solution of dicyclohexylcarbodiimide (DCC, 2 ml of a 1M solution in CH2Cl2) was added in increments and the mixture stirred for 20 h under argon. After completion of reaction (as determined by TLC, MeOH/CH2Cl2 10:90, visualization with molybdato phosphoric acid) the precipitate was filtered using Hyflo (=diatomaceous earth) and the filtrate was washed with 10% NaHCO3 and water. The organic phase was evaporated and the crude product obtained purified by preparative chromatography using a gradient of 0 to 8% methanol and methylene chloride with UV detection. The pure product was isolated by evaporation of the appropriate fractions as a white solid.
- 1H NMR (CDCl3): 0.84 (6H, m); 1.28 (6H, m); 1.57 (3H, m); 2.20 (6H, m); 2.52 (1H, m); 3.11 (1H, m); 3.42 (1H, m); 3.79 (4H, m); 4.28 (1H, m); 4.56 (1H, m); 5.31 (1H, m); 5.91 (1H, m); 6.32 (1H, m); 6.59 (2H, q).
- Following the same procedure the following examples were prepared:
-
Example No. R 1H NMR (CDCl3) 13 1.38 (9H, s); 1.67 (1H, m); 2.11 (2H, m); 2.48 (3H, s); 2.59 (1H, m); 2.97 (2H, m); 3.29 (2H, m); 3,78 (3H, s); 3.65 (2H, m); 4.10 (1H, m); 4.44 (1H, m); 5.31 (1H, m); 5.81 (1H, m); 6.34 (1H, m); 6.61 (2H, m); 7.19 (5H, m) 14 1.31 (9H, s); 1.54 (1H, m); 1.96 (2H, m); 2.32 (3H, s); 2.56 (1H, m); 3.01 (2H, m); 3.30 (2H, m); 3.78 (3H, s); 3.65 (2H, m); 4.08 (1H, m); 4.42 (1H, m); 5.23 (1H, m); 5.38 (2H, m); 5.79 (1H, m); 6.28 (1H, m); 6.51 (2H, m); 7.13 (8H, m) 15 1.41 (2H, m); 1.61 (4H, m); 1.81 (1H, m); 2.03 (2H, m); 2.38 (6H, m); 2.69 (1H, m); 3.09 (3H, m); 3.30 (1H, m); 3.70 (1H, m); 3.83 (3H, s); 4.08 (1H, m); 4.55 (1H, m); 5.29 (1H, m); 5.90 (1H, q); 6.31 (1H, d); 6.63 (2H, m) 16 1.49 (9H, m); 1.54 (9H, m); 2.13 (2H, m); 2.49 (4H, m); 2.63 (1H, m); 3.17 (4H, m); 3.78 (5H, m); 4.57 (2H, m); 5.33 (1H, m); 6.07 (1H, m); 6.31 (1H, m); 6.63 (2H, q); 7.27 (2H, m) 17 1.03 (3H, t); 1.54 (1H, m); 2.00 (2H, m); 2.25 (2H, m); 2.55 (3H, s); 2.64 (1H, m); 2.94 (1H, m); 3.02 (1H, m); 3.54 (1H, m); 3.76 (3H, s); 4.09 (1H, m); 4.48 (1H, m); 5.26 (1H, m); 5.76 (1H, m); 6.19 (1H, m); 6.56 (2H, q) 18 1.06 (6H, m); 1.41 (1H, m); 1.59 (1H, m); 2.05 (2H, m); 2.32 (3H, m); 2.53 (1H, m); 3.01 (1H, m), 3.23 (1H, m); 3.55 (1H, m); 3.78 (3H, s); 4.09 (1H, m); 4.48 (1H, m); 5.22 (1H, m); 5.83 (1H, m); 6.47 (1H, d); 6.60 (2H, q) 19 1.07 (9H, m); 1.51 (1H, m); 2.00 (2H, m); 2.26 (2H, m); 2.59 (3H, s); 2.54 (1H, m); 2.98 (1H, m); 3.02 (1H, m); 3.54 (1H, m); 3.76 (3H, s); 4.09 (1H, m); 4.48 (1H, m); 5.26 (1H, m); 5.81 (1H, m); 6.21 (1H, m); 6.62 (2H, q) - To solution of (−) galantamine (287 mg, 1.0 mmol) in dry CH2Cl2 (30 mL) N-Boc-phenylalanine (400 mg, 1.5 mmol) and triphenyl phosphine (340 mg, 1.3 mmol) are added with magnetic stirring followed by the drop-wise addition of diisopropyl azodicarboxylate (DIAD) (270 mg, 1.34 mmoles.) to the reaction mixture at −10° C. The reaction was stirred overnight at room temperature under argon. After the completion of the reaction (TLC-MeOH/CH2Cl2 (10:90)) the reaction mixture was filtered and the filtrate was washed with 10% NaHCO3 and water. The organic phase was evaporated and the crude product obtained purified by preparative chromatography using a gradient of 0 to 8% methanol and methylene chloride with UV detection. From the fractions containing the pure products these were isolated by evaporation of the solvents. This procedure results in the inversion of configuration on oxygen in
position 6. - 1H NMR (CDCl3) 1.35 (9H, s); 1.60 (1H, m); 2.05 (2H, m); 2.36 (3H, s); 2.59 (1H, m); 2.90 (2H, m); 3.30 (2H, m); 3.58 (3H, s); 3.65 (2H, m); 4.08 (1H, m); 4.42 (1H, m); 5.23 (1H, m); 5.79 (1H, m); 6.28 (1H, m); 6.54 (2H, m); 7.13 (5H, m)
- L-Phenylalanine, (4aS,6S,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-yl ester was prepared from the compound obtained in example 20 by Boc-deprotection using trifluoro acetic acid in methylene chloride followed by the usual workup and resulted in the product as a white powder.
- 1H NMR (CDCl3) 1.82 (2H, m); 2.05 (2H, m); 2.36 (3H, s); 2.59 (1H, m); 2.90 (2H, m); 3.30 (2H, m); 3.58 (3H, s); 3.65 (2H, m); 4.08 (1H, m); 4.42 (1H, m); 5.23 (1H, m); 5.79 (1H, m); 6.28 (1H, m); 6.54 (2H, m); 7.13 (5H, m)
- L-tyrosine-(4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-yl ester was prepared from the compound of example 13 using the same deprotection method as in example 21.
- 1H NMR (CDCl3) 1.68 (2H, m); 1.96 (2H, m); 2.32 (3H, s); 2.56 (1H, m); 3.01 (2H, m); 3.30 (2H, m); 3.78 (3H, s); 3.65 (2H, m); 4.08 (1H, m); 4.42 (1H, m); 5.23 (1H, m); 5.79 (2H, m); 6.28 (1H, m); 6.51 (2H, m); 7.13 (4H, dd)
- L-histidine-(4aS,6R,8aS)-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-yl ester hydrochloride was prepared from the compound of example 14 using HCl in ethyl acetate for deprotection and resulted in the isolation of the product as the hydrochloride.
- 1H NMR (CDCl3) 2.34 (2H, m); 2.54 (4H, m); 2.78 (1H, m); 3.21 (4H, m); 3.79 (5H, m); 4.58 (2H, m); 5.41 (1H, m); 6.18 (1H, m); 6.48 (1H, m); 6.65 (2H, q); 7.38 (2H, m)
-
- Chlorsulfonic acid (0.16 g, 1.39 mmol) was added to dry pyridine (1 ml) preheated to 70-80° C. and stirred at the same temperature for 30 min. A solution of galantamine (0.20 g, 0.70 mmol) in dry pyridine (1 ml) was added drop wise and the mixture was stirred overnight at room temperature with the formation of a precipitate. MeOH/H2O 1:1 (5 ml) was added and the resulting clear solution was stirred for further 30 min. Volatiles were rotoevaporated and another portion of MeOH (5 ml) was added. The resulting fine precipitate was filtered to give (0.21 g, yield 82%, HPLC>99%) of product as a white powder.
- IR: 1700.59, 1652.92, 1623.93, 1617.01, 1510.15, 1475.31, 1443.53, 1299.82, 1282.40, 1266.98, 1242.70, 1217.83, 1197.48, 1155.3, 1092.40, 1070.97, 1053.15, 1023.70, 1007.21, 984.45.
- To the solution of (−)-galantamine hydrobromide (1.0 mole) and triethyl amine (4.0 mol) in DCM (30 mL), DMAP (0.5 mol) was added followed by respective acid chloride or acid anhydride (1.2 mol). The mixture was stirred overnight at room temperature under argon. The reaction mixture was washed with 10% NaHCO3 and brine, dried (Na2SO4) and concentrated. The crude compound obtained was purified by column chromatography or recrystallization to give the pure product.
- Using this procedure the following compounds were obtained:
- O-Benzoyl-galantamine(=(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, benzoate (ester)); yield: 78%
- O-3,4-Dichlorobenzoyl-galantamine(=(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 3,4-dichlorobenzoate (ester)); off-white solid; mp. 69-70° C.
- 1H NMR (200 MHz, CDCl3) δ (ppm) 8.02 (d, J=1.88 Hz, 1H), 7.81 (dd, J=1.88 Hz, J=8.38 Hz, 1H), 7.38 (d, J=8.32 Hz, 1H), 6.62 (d, J=8.18 Hz, 1H), 6.52 (d, J=8.18 Hz, 1H), 6.32 (d, J=10.34 Hz, 1H), 5.89-5.97 (m, 1H), 5.51 (t, J=4.43 Hz, 1H), 4.58 (s, 1H), 4.07 (d, J=15.16 Hz, 1H), 3.18 (s, 3H), 3.61 (d, J=15.16 Hz, 1H), 3.21-3.45 (m, 1H), 2.96-3.05 (m, 1H), 2.66-2.76 (m, 1H), 2.34 (s, 3H), 2.0-2.19 (m, 2H), 1.51-1.59 (m, 1H).
- O-4-Methoxybenzoyl-galantamine(=(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4-methoxybenzoate (ester)); off-white solid; mp. 183-184° C.
- 1H NMR (200 MHz, CDCl3) δ (ppm) 8.01 (d, J=9.0 Hz, 2H), 8.56 (d, J=8.86 Hz, 2H), 6.69 (d, J=8.18 Hz, 1H), 6.58 (d, J=8.2 Hz, 1H), 6.35 (d, J=10.2 Hz, 1H), 6.0-6.07 (m, 1H), 5.56 (t, J=4.49 Hz, 1H), 4.66 (s, 1H), 4.15 (d, J=15.18 Hz, 1H), 3.89 (s, 3H), 3.84 (s, 3H), 3.68 (d, J=15.18 Hz, 1H), 3.29-3.53 (m, 1H), 3.04-3.12 (m, 1H), 2.73-2.81 (m, 1H), 2.41 (s, 3H), 2.08-2.26 (m, 2H), 1.58-1.66 (m, 1H).
- O-4-Methylbenzoyl-galantamine(=(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4-methylbenzoate (ester)); off-white solid; mp. 71-72° C.
- 1H NMR (200 MHz, CDCl3) δ (ppm) 7.94 (d, J=8.18 Hz, 2H), 7.17 (d, J=8.06 Hz, 2H), 6.69 (d, J=8.18 Hz, 1H), 6.58 (d, J=8.2 Hz, 1H), 6.35 (d, J=9.52 Hz, 1H), 6.0-6.08 (m, 1H), 5.57 (t, J=4.43 Hz, 1H), 4.66 (s, 1H), 4.17 (d, J=15.18 Hz, 1H), 3.89 (s, 3H), 3.70 (d, J=15.18 Hz, 1H), 3.31-3.43 (m, 1H), 3.06-3.13 (m, 1H), 2.74-2.83 (m, 1H), 2.42 (s, 3H), 2.38 (s, 3H), 2.08-2.26 (m, 2H), 1.59-1.67 (m, 1H).
- O-4-Chlorobenzoyl-galantamine(=(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 4-chlorobenzoate (ester)); off-white solid; mp. 72-74° C.
- 1H NMR (200 MHz, CDCl3) δ (ppm) 7.91 (d, J=8.74 Hz, 2H), 7.27 (d, J=8.72 Hz, 2H), 6.62 (d, J=8.2 Hz, 1H), 6.52 (d, J=8.2 Hz, 1H), 6.30 (d, J=10.34 Hz, 1H), 5.92-6.0 (m, 1H), 5.5 (t, J=4.36 Hz, 1H), 4.59 (s, 1H), 4.09 (d, J=15.18 Hz, 1H), 3.82 (s, 3H), 3.63 (d, J=15.18 Hz, 1H), 3.23-3.46 (m, 1H), 2.99-3.06 (m, 1H), 2.66-2.76 (m, 1H), 2.35 (s, 3H), 2.0-2.2 (m, 2H), 1.52-1.6 (m, 1H).
- O-2-Thenoyl-galantamine(=(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, thiophene-2-carboxylate (ester)); off-white solid; mp. 115-116° C.
- 1H NMR (200 MHz, CDCl3) δ (ppm) 7.78 (dd, J=1.2 Hz, J=3.8 Hz, 1H), 7.51 (dd, J=1.34 Hz, J=4.96 Hz, 1H), 7.04 (dd, J=3.76 Hz, J=4.98 Hz, 1H), 6.69 (d, J=8.18 Hz, 1H), 6.59 (d, J=8.04 Hz, 1H), 6.35 (d, J=10.2 Hz, 1H), 6.02 (dd, J=4.7 Hz, J=10.2 Hz, 1H), 5.54 (t, J=4.49 Hz, 1H), 4.63 (s, 1H), 4.18 (d, J=15.02 Hz, 1H), 3.87 (s, 3H), 3.71 (d, J=15.18 Hz, 1H), 3.31-3.5 (m, 1H), 3.07-3.14 (m, 1H), 2.73-2.83 (m, 1H), 2.42 (s, 3H), 2.04-2.26 (m, 2H), 1.6-1.68 (m, 1H).
- O-5-Chloro-2-thenoyl-galantamine(=(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-1-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 5-chlorothiophene-2-carboxylate (ester)); off-white solid; mp. 58-59° C.
- 1H NMR (200 MHz, CDCl3) δ (ppm) 7.5 (d, J=4.04 Hz, 1H), 7.80 (d, J=4.02 Hz, 1H), 6.62 (d, J=8.04 Hz, 1H), 6.52 (d, J=8.06 Hz, 1H), 6.31 (d, J=10.2 Hz, 1H), 5.92 (dd, J=4.57 Hz, J=10.2 Hz, 1H), 5.45 (t, J=4.36 Hz, 1H), 4.56 (s, 1H), 4.08 (d, J=15.16 Hz, 1H), 3.81 (s, 3H), 3.61 (d, J=15.18 Hz, 1H), 3.21-3.34 (m, 1H), 2.97-3.04 (m, 1H), 2.64-2.74 (m, 1H), 2.34 (s, 3H), 1.97-2.19 (m, 2H), 1.5-1.57 (m, 1H).
- To the solution of the corresponding acid (13.87 g, 135.8 mmol) in DCM (250 mL) was added DCC (33.62 g, 162.9 mmol) followed by DMAP (3.32 g, 27.15 mmol), reaction mixture was stirred for additional 30 minutes at room temperature To this (−)-galantamine hydrobromide (10.0 g, 27.15 mmol) and triethyl amine (4.6 mL, 32.59 mmol) was added, the mixture was stirred overnight at room temperature under argon. The precipitated DCHU was removed by filtration and the filtrate was evaporated. The additional DCHU was removed by subsequent trituration with cold ethyl acetate and filtration. The ethyl acetate solution was roto-evaporated and the crude product obtained was purified by column chromatography to give the desired product.
- 2-Methyl-butanoyl-galantamine(=(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 2-methyl-butanoate (ester)) was obtained in 53% yield as a solid using the
general procedure 2. - The same product, identical in every respect (HPLC, m.p., 1H-NMR), was also obtained in 58% yield using the
general procedure 1. - 2-Methyl-propanoyl-galantamine(=(4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol, 2-methyl-propanoate (ester)) was obtained in 63% yield as a solid using the
general procedure 1. - To the solution of 2-methyl-propanoyl-galantamine (150 mg, 0.43 mmol) in ethyl acetate (5 mL), ethyl acetate saturated with HCl (5 mL) was added slowly with stirring at 0° C. The reaction mixture was stirred at room temperature for 1 h. Solvent was evaporated and the residue obtained was washed with dry ether and was dried under high vacuum to give 164 mg (97%) of desired product as an off-white solid.
- Anal. calcd for C21H27NO4 (1.5 HCl): C, 61.2; H, 6.97; N, 3.40. Found: C, 61.62; H, 6.95; N, 3.91.
- To the solution of 2-methyl-propanoyl-galantamine (150 mg, 0.43 mmol) in methanol (5 mL), a solution of citric acid in methanol (5 mL) was added slowly with stirring at room temperature. The reaction mixture was stirred at room temperature for 1 h. Solvent was evaporated and the residue obtained was precipitated from methanol-diethyl ether and was dried under high vacuum to give 187 mg (81%) of desired product as a off-white solid.
- Anal. calcd for C27H35NO11 (1.0H2O): C, 57.14; H, 6.57; N, 2.47. Found: C, 57.43; H, 6.48; N, 2.53.
- To a stirred solution of (−)-galantamine hydrobromide (1.10 mmol) in pyridine (6 mL) at 0° C. under nitrogen, the corresponding acid chloride (2.2 mmol) was added and the mixture was stirred until a TLC showed the reaction to be complete. Then CH2CL2 (10 mL) and water (10 mL) were added and stirring was continued for 30 min. The organic layer was separated, washed with water (2×10 mL), dried over anhydrous MgSO4 and the solvent removed. The residue was purified by flash chromatography giving the product identical in all respects to O-Benzoyl-galantamine.
- In addition to the examples provided above, the following compounds were prepared by the described general procedures:
-
TABLE 6 MF MW Substituent R1 C21H25NO4 355.43 cyclopropanecarboxylate C24H23Cl2NO4 460.3 3,4-dichlorobenzoate C28H33NO4 447.57 4-tert-butylbenzoate C2 5H23ClF3NO4 493.91 4-chloro-3-(trifluoromethyl)benzoate C25H23F3N2O6 504.46 4-nitro-3-(trifluoromethyl)benzoate C25H24F3NO4 459.47 4-(trifluoromethyl)benzoate C24H23Cl2NO4 460.36 2,4-dichlorobenzoate C24H24N2O6 436.47 4-nitrobenzoate C24H24ClNO4 425.92 3-chlorobenzoate C25H24F3NO4 459.47 3-(trifluoromethyl)benzoate C24H24N2O6 436.47 3-nitrobenzoate C24H23Cl2NO4 460.36 3,5-dichlorobenzoate C26H30N2O4 434.54 3-(dimethylamino)benzoate C25H27NO4 405.50 3-methylbenzoate C24H24ClNO4 425.92 2-chlorobenzoate C24H23F2NO4 427.45 2,4-difluorobenzoate C24H23Cl2NO4 460.36 2,5-dichlorobenzoate C24H24FNO4 409.46 4-fluorobenzoate C26H30N2O4 434.54 4-(dimethylamino)benzoate C24H26N2O4 406.49 4-aminobenzoate C27H32N2O4 448.57 4-(dimethylamino)-3-methylbenzoate C25H25NO6 435.48 2H-1,3-benzodioxole-5-carboxylate C26H27NO5 433.51 4-acetylbenzoate C22H23NO4S 397.50 thiophene-3-carboxylate C21H23N3O4 381.44 1H-imidazole-5-carboxylate C21H22N2O5 382.42 1,3-oxazole-5-carboxylate C21H22N2O4S 398.48 1,3-thiazole-5-carboxylate C21H22N2O4S 398.48 1,3-thiazole-2-carboxylate C26H27NO6 449.51 2-(acetyloxy)benzoate - The brain is removed from the animal (mouse), shock frozen in liquid nitrogen and stored at minus 80° C. until use. Before preparing the extract, the frozen brain is thawed on ice and the weight is determined. Ice cold buffer (130 mM NaCl, 5 mM KCl, 2.5 mM CaCl2, 1 mM MgCl2, 5 mM Glucose, 5 mM HEPES, pH 7.4) is added to the thawed mouse brain (1:4, weight to volume, resulting in a 20% brain homogenate). The tissue is then homogenized in a potter homogeniser on ice, moving the piston up and down 11 times at 240 rpm. The freshly prepared mouse brain homogenate is divided into aliquots.
- A modified Ellmann's esterase test is used. Briefly the method relies on the cleavage of the substrate acetylthiocholine to acetate and thiocholine. The latter reacts with DTNB (5,5′-Dithiobis-(2-nitro-benzoicacid) to a yellow compound, which can be quantified spectrometrically. The incubation buffer contains 51 mmol/l sodium phosphate buffer and 0.05
% Tween 20, at pH 7.2 and is supplemented with 100 mg/l DTNB, and 0.2% mouse brain homogenate (prepared as described in Example 29). The compound to be investigated is added to the desired concentration. The mixture is brought to 37° C. and the reaction is started by addition of 200 μM acetylthiocholine. A405 is measured in 1 s intervals in a microplate reader for 40 s. The linear parts of the absorption-time-curves represent the starting speed of the enzymatic reaction and are used for the calculation of the reaction speed. The slope of the curve corresponds to the reaction speed. The inhibition is expressed as percent of the non inhibited reaction according to following equation: -
% Inhibition=100*(1−(Slopeinhibited/Slopenoninhibited)). - To aliquots of mouse brain homogenate as prepared according to Example 13 pro-galantamine derivatives are added and adjusted to a final concentration of 10 μM of the prodrug. At the end of the incubation time, 12 μl 0.1 M NaOH and 100 μl saturated KCl are added to the 0.1 ml reaction mixture and mixed thoroughly. The remaining prodrug and the released galantamine are extracted by 200 μl toluene. The toluene extraction step is repeated twice using 150 μl toluene and the obtained extracts are pooled, dried, dissolved in 50% Methanol and used for subsequent HPLC analysis.
- Investigation of the allosteric modulation effect of drug candidates on nicotinic acetylcholine receptors (nAChRs) expressed in HEK-293 cells by electrophysiology. Results shown as
FIG. 4 . - Single HEK-293 cells expressing either human α4β2, human α3β4, or chimeric chicken α7 (with mouse 5HT3) nAChR were plated on fibronectin-coated cover slips for 3 days before measurement. The selected nAChR containing cells were placed in the recording bath, filled with extracellular buffer (145 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM D-glucose, 10 mM HEPES, pH 7.3, approximately 300 mOsm). Patch-clamp system consisted of an inverted microscope (Zeiss, Germany), computer-controlled patch-clamp amplifier with PatchMaster software (HEKA, Germany), tubing perfusion system (ALA, USA) together with a U-tube applicator (IMM, Germany) and dual micromanipulators. The patch pipettes were pulled from fire-polished, 100 mm long and 1.5 mm width, single borosilicate glass capillaries (WPI, Germany). A programmable puller (Sutter, USA) was used to prepare a twin pair of ready for use pipettes. Each patch pipette (resistance 4-8 MΩ) was used only once. Pipettes were filled with an internal buffer (140 mM CsCl, 11 mM EGTA, 10 mM HEPES, 2 mM MgCl2, pH 7.3, approximately 300 mOsm) and connected to the working electrode. Working and reference electrodes for experiments were made from daily renewed, freshly chlorinated silver wire (40 mm×0.4 mm) and were connected to a headstage circuit of the patch-clamp amplifier. Patching was done using rectangular test pulses with an amplitude of −1 mV and a duration of 20 ms. Immediately after formation of the gigaseal the holding potential of −70 mV was applied to the patch electrode and whole-cell recordings were established by using negative pressure pulses. All necessary compensations for fast and slow membrane capacitance and serial resistance transients were automatically set within the PatchMaster software. Whole-cell currents were evoked by the application of nicotine at the EC50 for each appropriate nAChR subtype (α4β2 and α3β4 EC50=30 μM, chimeric α7 EC50=3 μM). To evaluate an allosteric potentiating ligand (APL) effect of selected compounds on each subtype of nAChR, they were added to stimulating nicotine solutions at the following concentrations: 1, 5, 10, 50, 100, 500, 1,000, 5,000 and 10,000 nM, and solutions were applied to the cell surface during 500 ms pulses through the U-tube, and then corresponding currents, digitized to 10 kHz, were recorded for 10 s. Consecutive current stimulations were done with a 2 min interval to avoid nAChR desensibilisation and to ensure full exchange of stimulating solutions. The averaged peak amplitudes of the currents, measured in the presence of selected compound concentrations, were compared with those determined in the absence of compounds (control) and they were calculated as % of control. The measurements of an APL effect of particular compound were repeated on a minimum of five cells to obtain the mean values +/−SD. Mean values of the observed APL effect, which did not exceed 15% were treated as insignificant. To present a concentration-dependent APL effect of particular compound, the corresponding % of control values +/−SD were plotted against the concentrations used.
- Determination of the pharmacokinetic profiles of Gln-1062 and its cleavage product galantamine in blood and brain. Determine the brain-to-blood concentration ratios of Gln-1062 and its cleavage product galantamine, and assess the blood-brain barrier penetration capacities.
- Analytical method for estimation of Gln-1062 was evaluated for its linearity, precision & accuracy and recovery in SAM blood and brain homogenate using LC/MS/MS.
- The parameters of chromatographic conditions and extraction conditions for the Gln-1062 and Galantamine analysis were
- Chromatographic Parameters:
-
Column Phenomenex Synergi, Polar-RP 80 A, C18, 75 × 2.0 mm, 4μ Mobile Phase Mobile Phase Buffer 40 mM Ammonium Formate, pH 3.5 Aqueous Reservoir (A) 10% Buffer, 90% Water Organic Reservoir (B) 10% Buffer, 90% Acetonitrile Flow rate 0.450 mL/min - Gradient Programme:
-
Gradient Time (min) Curve % A % B 0 1 100 0 1.2 1 60 40 3 1 0 100 3.1 1 100 0 5 1 100 0 - Divert Valve Time Schedule:
-
Divert Valve Time (min) Waste MS 0 x 1.2 x 4.5 x -
Run time 5.0 min Column oven Ambient temperature Auto sampler Ambient temperature Auto sampler Wash Water:acetonitrile:isopropanol with 0.2% formic acid, 1:1:1(v/v/v) Retention time Gln-1062 3.33 ± 0.05 min. Galantamine 2.44 ± 0.05 min Metoprolol 2.80 ± 0.05 min. Mass Parameters (API 3200): Mode MRM Polarity Positive Ion source Turbo spray Analyte Gln-1062 (Q1 Mass 392.4; Q3 Mass 213.2) Galantamine (Q1 Mass 288.3; Q3 Mass 213.1) ISTD Metoprolol (Q1 Mass 268.4; Q3 Mass 116.2) Source/Gas Parameters: Curtain gas (CUR) 10 Collision gas (Collision associated 5 Dissociation) CAD Ion Spray Voltage 5500 V (IS) Temperature (TEM) 575° C. GS1 55 GS2 45 Ihe ON - Compound Parameters:
-
Parameter Galantamine Metoprolol Gln-1062 Declustering Potential (V) 45 35 50 Entrance Potential (V) 10 10 10 Collision Cell Entrance Potential 20 20 20.00 (V) Collision Energy (eV) 32 26 32 Collision Cell Exit Potential (V) 4.5 2 5 Dwell Time (milliSec) 200 200 200 - Extraction Procedure:
-
- A. Preparation of STD, QC and Study Samples
-
- B. Preparation of Calibration Curve Standards for Recovery
- This method was evaluated for linearity, precision & accuracy and recovery of Gln-1062 in SAM blood and brain homogenate.
- A. Linearity, Precision & Accuracy
-
- A single standard curve and six replicates each of three quality control (QC) levels (18 total QCs) were extracted and analyzed. The linearity of the calibration curve was determined by a weighed least square regression analysis.
- Acceptance Criteria
- i. At least six out of nine standards must have an accuracy of ±15% from nominal, except at the lower limit of quantitation (LLOQ) where ±20% is acceptable.
- ii. Two-thirds of the batch QCs and at least half of the QCs at each level must have a calculated accuracy of ±15% from nominal.
- iii. Intra-assay Mean Precision and Accuracy
- 1. Four out of six QCs must be available to determine accuracy and precision.
- 2. The intra-assay coefficient of variation (% CV) of each QC level must not exceed 15% and the accuracy of the mean value for each validation to be accepted.
- Gln-1062 linearity, precision and accuracy in blood and brain homogenate matrices were evaluated.
- B. Recovery
- The recovery of Gln-1062 from the blood and brain homogenate matrices were also evaluated.
- Recovery was determined by quantifying the concentration of the analytes in extracted matrix QC samples with a standard curve prepared in post-extract (blank extracts) sample matrix as described above in section B of the extraction procedure, entitled “Preparation of Calibration Curve Standards for Recovery.”
- Gln-1062 recovery in blood and brain homogenate matrices were evaluated.
-
-
Study design No. of Dose Dose Animals Dose Conc. Volume for each Sample time points Animal Test item (mg/kg) (mg/mL) (mL/kg) Dose route time point (hr) Male SAM Gln-1062 3 0.2 15 i.v, bolus 3 Predose, 0.05, 0.10, 25-33 gm (tail vein) 0.17, 0.33, 0.50, 0.83, 1.33, 2.0 and 4.0 - Blood samples were collected from the retro-orbital plexus. 0.5 ml of blood was collected into a pre-labeled polypropylene micro centrifuge tube containing sodium citrate as the anticoagulant, and kept on ice.
- Blood was mixed gently with anticoagulant and an aliquot of 50 μL of blood sample immediately precipitated as described above in section A of the extraction procedure, entitled “Preparation of STD, QC and Study Samples.” Remaining volume of blood sample at each time point frozen on dry ice.
- All the blood samples were transferred to analytical department and frozen at −80±10° C. until analysis.
- Immediately after blood withdrawal, brain was perfused with phosphate buffer saline (pH 7.4), removed and frozen on dry ice.
- All the brain samples were transferred to analytical department and frozen at −80° C. until analysis.
- Brain samples were thawed on ice and weighed. n appropriate volume ice cold homogenizing media (methanol:water::20:80,v/v) added. n ice, homogenized the brain sample with the polytron homogenizer and make up the volume with homogenizing media to get 1 gm of brain per 4 mL of homogenate. after homogenizing, immediately freezed the brain homogenate samples at −80° C. until analysis.
- Behavioural index for gastro-intestinal side effects in ferrets following application of galantamine and several R1-pro-galantamines, respectively. Results shown in
FIG. 6 . - Fourteen adult male Putoris furo ferrets (Marshall BioResources (North Rose, USA)), weighting 750-1000 grams on the day of experimentation were used in the present study. In agreement with the sponsor four out of the fourteen animals were included in two experimental groups, ferrets # 1, 2, 3 and 4).
- The acclimatization of the animals lasted at least 5 days. At receipt, animals were collectively housed in cages at Syncrosome's premises. They had free access to food and drinking water ad libitum.
- During this study, one reference compound (Galantamine) and one Galantos candidate compound (GLN979) were tested at two doses each. Both compounds were administered I.P. at doses and concentrations.
- Details of the different compound shipments are presented in Table 7.
-
TABLE 7 Receipt Compound November 11th, 2007 November, the 21st, 2007 November, the 29th, 29, 2007 Galantamine 48.0 mg 256.0 mg (One vial) — GLN979 48.0 mg — 262.6 mg 2-Hydroxypropyl- U.I: (One vial) 7.3 g + 7.3 g ≈4.7 g + ≈5.0 g β-cyclodextrin (Two vials) NaCl U.I: (One vial) 3.0 g (One vial) — - As requested by the sponsor, the same vehicle (15% 2-Hydroxypropyl-β-cyclodextrin/96 mM NaCl) was used for both Galantamine and GLN979 preparation. A detailed solubilization protocol was sent by mail by Galantos to Syncrosome and received on Nov. 5, 2007.
-
-
Nature GLN979. Molar mass U.I. Administration dose 20 and 40 mg/kg B.W. Administration route I.P. Vehicle 15% 2-Hydroxypropyl-β-cyclodextrin/96 mM NaCl. -
-
Nature Galantamine Molar mass U.I. Administration dose 3 and 20 mg/kg B.W. Administration route I.P. Vehicle 15% 2-Hydroxypropyl-β-cyclodextrin/96 mM NaCl. - For the 4 experimental groups, the administrations were performed in unanaesthetized animals through the I.P. route at T0.
- After I.P. administration of the compound solution, the animals were continuously observed by a trained technician for four hours. During that period, the number of episodes of vomiting (series of retches leading to the expulsion of part of the gastro-intestinal content) were recorded.
- During the 4 hours-observation period, several side-effects (salivation, shivering, respiratory problems and diarrhea) were also observed. For each of these behaviours, a scoring method was determined with the sponsor. Depending on its severity, each parameter were quantified as:
-
“None” (None) Behaviour not observed. “Moderate” (Mod.) Behaviour observed with a low frequency and/or a low intensity. “Intense” (Int.) Behaviour observed frequently and/or continuously and/or at a high intensity. - All the animals receiving I.P. administration of the reference or the test compound were included in the study regardless of the pattern of both their emetic responses and behaviours.
- Gln 1062, Gln 0979 and galantamine were dissolved in 15%-hydroxypropyl-β-cyclodextrin in 96 mM NaCl (isotonic) supplied by the sponsor. Gln 1062 and
Gln 0979 were used in concentrations of 0.01, 0.03, 0.1 and 0.2 mg/ml, which when given in a volume of 10 ml/kg result in doses of 0.1, 0.3, 1 and 2 mg/kg i.p., respectively. Galantamine was used in concentrations of 0.03, 0.1, 0.2 and 0.5 mg/ml, which when given in a volume of 10 ml/kg result in doses of 0.3, 1, 2 and 5 mg/kg i.p., respectively. - Control animals received 15%-hydroxypropyl-β-cyclodextrin in 96 mM NaCl injection as a vehicle.
- Nicotine ((−)-Nicotine hydrogen tartrate salt, Sigma, France), scopolamine (−(−)scopolamine hydrochloride, Sigma, France) were dissolved in saline (0.9% NaCl, Aguettant, France) at the concentration of 0.04 and 0.1 mg/ml, respectively. They were administrated at a dosage volume of 10 ml/kg to achieve doses of 0.4 and 1 mg/kg, respectively.
- Four to five week old male CD-1 mice (Janvier; Le Genest St Isle—France) were used for the study.
- They were group-housed (10 mice per cage) and maintained in a room with controlled temperature (21-22° C.) and a reversed light-dark cycle (12 h/12 h; lights on: 17:30-05:30; lights off: 05:30-17:30) with food and water available ad libitum.
- The potential cognitive enhancing property of
Gln 1062, Gln 0979 and galantamine were evaluated in scopolamine-treated mice in the T-maze alternation model under the same experimental conditions. BothGln 1062 andGln 0979 were tested in doses of 0.1, 0.3, 1 and 2 mg/kg i.p. Galantamine was tested in doses 0.1, 0.3, 1, 2 and 5 mg/kg i.p. Nicotine was tested in a dose of 0.4 mg/kg i.p. All these compounds were administrated immediately after the injection of 1 mg/kg i.p. scopolamine (20 min prior to the T-maze trial) used to induce memory deficit. - Memory performance was assessed by the percentage of spontaneous alternation in the T-maze. The number of alternation in saline-injected mice was used as the base level of unaltered memory performance.
- Mice were housed 10 per cage. Each mouse in a cage was randomly assigned by a unique number (1 to 10) written on the tail with permanent ink.
- Gln 1062, Gln 0979 and galantamine were tested separately in three set of experiments with different animals. Each set of experiments was divided in series of daily experiments that always comprises at least one representative of each of Saline/vehicle, Scopolamine/vehicle and Scopolamine/Nicotine (0.4 mg/kg) groups.
- The T-maze apparatus was made of gray Plexiglas with a main stem (55 cm long×10 cm wide×20 cm high) and two arms (30 cm long×10 cm wide×20 cm high) positioned at 90 degree angle relative to the left and right of the main stem. A start box (15 cm long×10 cm wide) was separated from the main stem by a guillotine door. Horizontal doors were present to close off specific arms during the force choice alternation task.
- The experimental protocol consists of one single session, which starts with 1 “forced-choice” trial, followed by 14 “free-choice” trials. In the first “forced-choice” trial, the animal is confined 5 s in the start arm and then released while either the left or right goal arm is blocked by a horizontal door. After the mouse is released, it will negotiate the maze and eventually enter the open goal arm, and return to the start position. Immediately after the return of the animal to the start position, the closed goal door is opened and the animal is now free to choose between the left and right goal arm (“free choice trials”). The animal is considered as entered when it places its four paws in the arm. A session is terminated and the animal is removed from the maze as soon as 14 free-choice trials have been performed or 10 min have elapsed, whatever event occurs first. The average duration of a trial is 6 min.
- The apparatus is cleaned between each animal using alcohol (70°). Urine and feces are removed from the maze.
- During the trials, animal handling and the visibility of the operator are minimized as much as possible.
- The percentage of alternation over the 14 free-choice trials was determined for each mouse and was used as an index of working memory performance. This percentage was defined as entry in a different arm of the T-maze over successive trials (i.e., left-right-left-right, etc).
- Analysis of variance (ANOVA) was performed on the result data. Fisher's Protected Least Significant Difference was used for pairwise comparisons. p value≦0.05 were considered significant. The drug induced reversion of scopolamine-induced memory deficit was calculated by setting the respective response of the saline/vehicle group as 100% and the scopolamine/vehicle group as 0% reversion.
- In order to determine the ED50 for each drug, the recovery performance was plotted following a sigmoidal dose-response model (graphpad software). ED50 was read from the curve fitting table and represents the effective dose associated with 50% of response.
- It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of any appended claims. All figures, tables, and appendices, as well as publications, patents, and patent applications, cited herein are hereby incorporated by reference in their entirety for all purposes.
Claims (22)
1. A compound of formula (III):
wherein the bond <1> to >2> is a single or a double bond and the bond between <3> and R1 is a single or a double bond and bond <10> to <11> is a single or no bond and residues are
R1: OH, OCO-(3-pyridyl)(=nicotinic acid residue), OCO-(3-methyl-3-pyridyl), OCO—(C1-C6 alkyl), OCO—(C1-C2, alkenyl), OCO—NH—(C1-C6 alkyl), OCO—(CH2)x—NH—COO—(C1-C6 alkyl), O—CH2—O—(C1-C6 alkyl), O—(CH2)x—OCO—(C1-C6 alkyl), O—(CH2)x—OCO—(CH2)x—N—COO—(C1-C6 alkyl), O—(CH2)x—OCO—(CH2)y-aryl, OCOO—(C1-C6 aminalkyl), OCOO—(CH2)x-tetrahydrofuranyl, or a sugar, preferably glucuronic acid residue, wherein x=1,2, 3 or 4 and y=0, 1, 2, 3 or 4;
wherein if bond <3> to R1 is a double bond, then R1=O, NH, NOH, NOR6, N—CO—NH2, N—CS—NH2, N—C(═NH)—NH2, N—NH-phenyl, N—NHR6, N—N(R6)2, N—N═(CH2)n, with R6=C1-C5 unbranched or branched, saturated or unsaturated (ar)alkyl, phenyl or benzyl and n=2-8; and
wherein if bond <3> to R1 is a single bond, then R1=OH, SH, NH2, NHR6, N(R6)2, OR7, O—CR8R9-O—CO—CHR10-NR11R12, or O—CO—R14,
with R7=C1-C22 unbranched or branched, (poly-)unsaturated or saturated alkyl, optionally containing an additional (ar)alkoxy or di(ar)alkylamino group, a sugar or sugar derivative residue, preferably glucuronic acid residue, a phosphoryl, alkylphosphoryl or arylphosphoryl group, a sulfatyl or alkylsufatyl group, or COR13,
where R13=R6 or R7 or pyridyl or dihydropyridyl or OR6 preferably methyl, 3-pyridyl, 4-pyridyl, 3-dihydropyridyl, 4-dihydropyridyl
R8 and R9 are the same or different and any of H, Me, Ph or they together form a spiro-ring —(CH2)n- with n=4-6
R10=H or the side chain of a natural amino acid including R10, R11 together are forming a proline or hydroxy-proline derivative
R11 either is together with R10 forming a proline or hydroxy-proline derivative or is H
R12 is a carbamate protecting group including t-butoxycarbonyl, benzyloxycarbonyl and other N-protecting groups;
R14 is an aromatic or heteroaromatic 5- or 6-membered ring, selected from substituted benzene with the proviso that it is not 2-fluorobenzene or 3-nitro-4-fluorobenzene, optionally substituted naphthaline, thiophene, pyrrole, imidazole, pyrazole, oxazole, thiazole; or CH(C2H5)CH3, CH2—C(CH3)3, or cyclopropane;
R2: R7, or O—CR8R9-O—CO—CHR10-NR11R12 with the same definitions of R7-R12 as above, H, CH3, CO—(C1-C6 alkyl), CH2—OCO—(CH2)x-aryl, or a sugar, preferably glucuronic acid residue;
R3: H, F, Cl, Br, I, NH2, NO2, CN, CH3;
R4: H, C1-C6 alkyl, preferably CH3, CO—(C1-C6 alkyl), CO-(3-pyridyl)(=nicotinic acid residue), CO-(3-methyl-3-pyridyl), CO—(CH-mercaptoalkyl)-(CH2)x-aryl, (CH2)x—OCO—(CH2)x—N—COO—(C1-C6 alkyl), (CH2)x—OCO—(CH-arylalkyl)-N—COO—(C1-C6 alkyl), wherein x=1, 2, 3 or 4;
R5: if R4=H, then R5 is an electron pair;
if R4=CH3 then R5 is either hydrogen or a C1-C5 (ar)alkyl group, CH2—O—CH3, CH2—O—CO—R6, CH2—O—CR8R9-O—CO—CHR10-NR11R12 with the same definitions of R6 and R8-R12 as above, whereby in all the latter cases the nitrogen has an additional positive charge as well as a counterion, selected from chloride, bromide, iodide, sulphate, nitrate, hydrogensulfate, phosphate, methanesulphonate, tosylate or any other pharmaceutically acceptable anion, with the proviso that the resulting compound is not Galantamine, Norgalantamine, Sanguinine, Norsanguinine, Lycoramine, Norlycoramine, Lycoraminone, Narwedine, Nornarwedine,3-Amino-3-deoxy-galantamine or 3-amino-3-deoxy-1,2-dihydro-galantamine;
or R5=(CH2)x—O—(C1-C6 alkyl), (CH2)x—OCO—(C1-C6 alkyl), (CH2)x—OCO—(CH2)x-aryl, (CH2)x—OCO—(CH2)x—N—COO—(C1-C6 alkyl), wherein x=1, 2, 3 or 4; in case that bond <10> to <11> is a single bond the nitrogen has a positive charge and the counterion is chloride, with the proviso that the compound is not Galantamine, Norgalantamine, Sanguinine, Norsanguinine, Lycoramine, Norlycoramine, Lycoraminone, Narwedine, Nomarwedine,3-Amino-3-deoxy-galantamine or 3-amino-3-deoxy-1,2-dihydro-galantamine as a pro-drug or medicament with improved blood-brain barrier permeability compared to Galantamine.
2. A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof.
3. A pharmaceutical composition according to claim 2 , further comprising a pharmaceutically acceptable carrier.
4. A method for the treatment of a neurodegenerative or psychiatric or neurological disease associated with a cholinergic deficit comprising administering the pharmaceutical composition of claim 2 to a patient in need thereof.
5. The method of claim 4 , wherein the disease is selected from Alzheimer's and Parkinson's disease, other types of dementia, schizophrenia, epilepsy, stroke, poliomyelitis, neuritis, myopathy, oxygen and nutrient deficiencies in the brain after hypoxia, anoxia, asphyxia, cardiac arrest, chronic fatigue syndrome, various types of poisoning, anesthesia, particularly neuroleptic anesthesia, spinal cord disorders, inflammation, particularly central inflammatory disorders, postoperative delirium and/or subsyndronal postoperative delirium, neuropathic pain, subsequences of the abuse of alcohol and drugs, addictive alcohol and nicotine craving, and subsequences of radiotherapy.
6. A method for improvement of blood-brain barrier permeability and/or brain-to-plasma distribution ratio of a cholinergic enhancer molecule, whether a cholinergic agonist or APL and/or a cholinesterase inhibitor and/or a neuroprotective agent, by modification of at least one of the residues R1, R2, R3, R4 and/or R5 of the compound of formula (III) according to claim 1 so as to enhance transport into the brain and compound concentration therein.
7. A compound of formula (III)
wherein the bond <1> to >2> is a double bond and the bond between <3> and R1 is a single bond and bond <10> to <11> is a single or no bond and residues are
R1=OH, OCO-(3-pyridyl)(=nicotinic acid residue), OCO-(3-methyl-3-pyridyl), OCO—(C1-C6 alkyl), OCO—(C1-C21 alkenyl), OCO—NH—(C1-C6 alkyl), OCO—(CH2)x—NH—COO—(C1-C6 alkyl), O—CH2—O—(C1-C6 alkyl), O—(CH2)x—OCO—(C1-C6 alkyl)XO—(CH2)x—OCO—(CH2)x—N—COO—(C1-C6 alkyl), O—(CH2)x—OCO—(CH2)y-aryl, OCOO—(C1-C6 aminalkyl), OCOO—(CH2)X-tetrahydrofuranyl, or a sugar, preferably glucuronic acid residue, wherein x=1, 2, 3 or 4 and y=0, 1, 2, 3 or 4;
R2=H, CH3, CO—(C1-C6 alkyl), CH2—OCO—(CH2)x-aryl, or a sugar, preferably glucuronic acid residue;
R3=H, F or Br;
R4=H, C1-C6 alkyl, preferably CH3, CO—(C1-C6 alkyl), CO-(3-pyridyl)(=nicotinic acid residue), CO-(3-methyl-3-pyridyl), CO—(CH-mercaptoalkyl)-(CH2)x-aryl, (CH2)xOCO—(CH2)x—N—COO—(C1-C6 alkyl), (CH2)x—OCO—(CH-arylalkyl)-N—COO—(C1-C6 alkyl), wherein x=1, 2, 3 or 4;
R5=an electron pair or (CH2)x—O—(C1-C6 alkyl), (CH2)x—OCO—(C1-C6 alkyl), (CH2)x—OCO—(CH2)x-aryl, (CH2)x—OCO—(CH2)x—N—COO—(C1-C6 alkyl), wherein x=1, 2, 3 or 4; in case that bond <10> to <11> is a single bond the nitrogen has a positive charge and the counterion is chloride;
with the proviso that the compound is not Galantamine, Norgalantamine, Sanguinine, Norsanguinine, Lycoramine, Norlycoramine, Lycoraminone, Narwedine, Nomarwedine,3-Amino-3-deoxy-galantamine or 3-amino-3-deoxy-1,2-dihydro-galantamine as a pro-drug or medicament with improved blood-brain barrier permeability compared to Galantamine.
8. A compound according to claim 7 , whereby the derivative is selected from the group provided in Table 4.
9. A pharmaceutical composition comprising a compound according to claim 7 or a pharmaceutically acceptable salt thereof.
10. A pharmaceutical composition according to claim 9 , further comprising a pharmaceutically acceptable carrier.
11. A method for the treatment of a neurodegenerative or psychiatric or neurological disease associated with a cholinergic deficit comprising administering the pharmaceutical composition of claim 9 to a patient in need thereof.
12. The method of claim 11 , wherein the disease is selected from Alzheimer's and Parkinson's disease, other types of dementia, schizophrenia, epilepsy, stroke, poliomyelitis, neuritis, myopathy, oxygen and nutrient deficiencies in the brain after hypoxia, anoxia, asphyxia, cardiac arrest, chronic fatigue syndrome, various types of poisoning, anesthesia, particularly neuroleptic anesthesia, spinal cord disorders, inflammation, particularly central inflammatory disorders, postoperative delirium and/or subsyndronal postoperative delirium, neuropathic pain, subsequences of the abuse of alcohol and drugs, addictive alcohol and nicotine craving, and subsequences of radiotherapy.
13. A method for improvement of blood-brain barrier permeability and/or brain-to-plasma distribution ratio of a cholinergic enhancer molecule, whether a cholinergic agonist or APL and/or a cholinesterase inhibitor and/or a neuroprotective agent, by modification of at least one of the residues R1, R2, R3, R4 and/or R5 of the base structure(s) of formula (III) so as to enhance transport into the brain and compound concentration therein:
wherein the bond between positions <1> and <2> denotes a single- or double bond and the bonds <1> to <2> and <11> to <12> can be either a single or a double bond, and the bond between <10> and <11> is either a single bond or no bond, wherein the modified residues R1-R5 are defined as follows:
R1:
a) if bond <3> to R1 is a double bond, then
R1=O, NH, NOH, NOR6, N—CO—NH2, N—CS—NH2, N—C(═NH)—NH2, N—NH-phenyl, N—NHR6, N—N(R6)2, N—N═(CH2)n,
with R6=C1-C5 unbranched or branched, saturated or unsaturated (ar)alkyl, phenyl or benzyl and n=2-8;
b) if bond <3> to R1 is a single bond, then
R1=OH, SH, NH2, NHR6, N(R6)2, OR7, O—CR8R9-O—CO—CHR10-NR11R12, with R7=C1-C22 unbranched or branched, (poly-)unsaturated or saturated alkyl, optionally containing an additional (ar)alkoxy or di(ar)alkylamino group, a sugar or sugar derivative residue, preferably glucuronic acid residue, a phosphoryl, alkylphosphoryl or arylphosphoryl group, a sulfatyl or alkylsufatyl group, or COR13,
where
R13=R6 or R7 or pyridyl or dihydropyridyl or OR6, preferably methyl, 3-pyridyl, 4-pyridyl, 3-dihydropyridyl, 4-dihydropyridyl, R8 and R9 are the same or different and any of H, Me, Ph or they together form a spiro-ring —(CH2)n- with n=4-6,
R10=H or the side chain of a natural amino acid including R10,R11 together are forming a proline or hydroxy-proline derivative,
R11 either is together with R10 forming a proline or hydroxy-proline derivative or is H,
R12 is a carbamate protecting group including t-butoxycarbonyl, benzyloxycarbonyl and other N-protecting groups;
R2: H, R7, or O—CR8R9-O—CO—CHR10-NR11R12 with the same definitions of R7-R12 as above;
R3: H, F, Cl, Br, I, NH2, NO2, CN, CH3;
R4: H or CH3;
R5: If R4=H, then R5 is an electron pair,
if R4=CH3, then R5 is either hydrogen or a C1-C5 (ar)alkyl group, CH2—O—CH3, CH2—O—CO—R6, CH2—O—CR8R9-O—CO—CHR10-NR11R12 with the same definitions of R6 and R8-R12 as above, whereby in all the latter cases the nitrogen has an additional positive charge as well as a counterion, selected from chloride, bromide, iodide, sulphate, nitrate, hydrogensulfate, phosphate, methanesulphonate, tosylate or any other pharmaceutically acceptable anion,
with the proviso that the resulting compound is not Galantamine, Norgalantamine, Sanguinine, Norsanguinine, Lycoramine, Norlycoramine, Lycoraminone, Narwedine, Nomarwedine,3-Amino-3-deoxy-galantamine or 3-amino-3-deoxy-1,2-dihydro-galantamine.
14. A method according to claim 13 wherein the bond <1> to >2> is a double bond and the bond between <3> and R1 is a single bond and bond <10> to <11> is a single or no bond and residues are
R1=OH, OCO-(3-pyridyl)(=nicotinic acid residue), OCO-(3-methyl-3-pyridyl), OCO—(C1-C6 alkyl), OCO—(C1-C2, alkenyl), OCO—NH—(C1-C6 alkyl), OCO—(CH2)x—NH—COO—(C1-C6 alkyl), O—CH2—O—(C1-C6 alkyl), O—(CH2)x—OCO—(C1-C6 alkyl), O—(CH2)x—OCO—(CH2)x—N—COO—(C1-C6 alkyl), O—(CH2)x—OCO—(CH2)y-aryl, OCOO—(C1-C6 aminalkyl), OCOO—(CH2)X-tetrahydrofuranyl, or a sugar, preferably glucuronic acid residue, wherein x=1, 2, 3 or 4 and y=0, 1, 2, 3 or 4;
R2=H, CH3, CO—(C1-C6 alkyl), CH2—OCO—(CH2)X-aryl, or a sugar, preferably glucuronic acid residue;
R3=H, F or Br;
R4=H, C1-C6 alkyl, preferably CH3, CO—(C1-C6 alkyl), CO-(3-pyridyl)(=nicotinic acid residue), CO-(3-methyl-3-pyridyl), CO—(CH-mercaptoalkyl)-(CH2)x-aryl, (CH2)x—OCO—(CH2)x—N—COO—(C1-C6 alkyl), (CH2)x—OCO—(CH-arylalkyl)-N—COO—(C1-C6 alkyl), wherein x=1, 2, 3 or 4;
R5=an electron pair or (CH2)x—O—(C1-C6 alkyl), (CH2)x—OCO—(C1-C6 alkyl), (CH2)x—OCO—(CH2)X-aryl, (CH2)x—OCO—(CH2)x—N—COO—(C1-C6 alkyl), wherein x=1, 2, 3 or 4; in case that bond <10> to <11> is a single bond the nitrogen has a positive charge and the counterion is chloride.
15. A compound according to formula V
wherein R1=aromatic or heteroaromatic 5- or 6-membered ring, selected from benzene, substituted benzene with the proviso that it is not 2-fluorobenzene or 3-nitro-4-fluorobenzene, optionally substituted naphthaline, thiophene, pyrrole, imidazole, pyrazole, oxazole, thiazole; or CH(C2H5)CH3, CH2—C(CH3)3, or cyclopropane.
16. Compound according to claim 15 , selected from
wherein R2-R6 comprising any substituent selected from H, halogen, optionally substituted C1-C3 alkyl or cyclopropyl, OH, O-alkyl, SH, S-alkyl, NH2, NH-alkyl, N-dialkyl, optionally substituted aryl or heteroaryl, whereby neighbouring substitutents can cooperate to form an additional ring, with the proviso that not all of R2 to R6 are H and substituted benzene is not 2-fluorobenzene or 3-nitro-4-fluorobenzene.
17. A compound according to claim 15 selected from the group consisting of the compounds shown in Table 4.
18. A compound according to claim 15 for use as a pro-drug or medicament.
19. A pharmaceutical composition comprising a compound according to claim 15 .
20. A compound or pharmaceutical composition according to claim 15 , wherein R1 further can be non-substituted benzene or 2-fluorobenzene or 3-nitro-4-fluorobenzene for the treatment of a neurodegenerative or psychiatric or neurological disease associated with a cholinergic deficit.
21. A compound or pharmaceutical composition according to claim 20 wherein the disease is selected from Alzheimer's and Parkinson's disease, other types of dementia, schizophrenia, epilepsy, oxygen and nutrient deficiencies in the brain after hypoxia, anoxia, asphyxia, cardiac arrest, various types of poisoning, anesthesia, particularly neuroleptic anesthesia, autism, postoperative delirium and/or subsyndronal postoperative delirium, subsequences of the abuse of alcohol and drugs, addictive alcohol and nicotine craving, and subsequences of radiotherapy.
22. A compound or pharmaceutical composition according to claim 21 , wherein the neurodegenerative disease is selected from Alzheimer's and Parkinson's disease.
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/422,901 US20090253654A1 (en) | 2005-09-22 | 2009-04-13 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US13/861,134 US9763953B2 (en) | 2005-09-22 | 2013-04-11 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US15/699,626 US10265325B2 (en) | 2005-09-22 | 2017-09-08 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
Applications Claiming Priority (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05020721.6 | 2005-09-22 | ||
EP05020721A EP1777222A1 (en) | 2005-09-22 | 2005-09-22 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US78024306P | 2006-03-07 | 2006-03-07 | |
PCT/EP2006/009220 WO2007039138A1 (en) | 2005-09-22 | 2006-09-22 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US11/683,148 US20070213318A1 (en) | 2006-03-07 | 2007-03-07 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US4668308P | 2008-04-21 | 2008-04-21 | |
US6779908A | 2008-07-02 | 2008-07-02 | |
US12/422,901 US20090253654A1 (en) | 2005-09-22 | 2009-04-13 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
Related Parent Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/067,799 Continuation-In-Part US20080261954A1 (en) | 2005-09-22 | 2006-09-22 | Cholinergic Enhancers with Improved Blood-Brain Barrier permeability for the Treatment of Diseases Accompanied by Cognitive Impairment |
PCT/EP2006/009220 Continuation-In-Part WO2007039138A1 (en) | 2005-09-22 | 2006-09-22 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US11/683,148 Continuation-In-Part US20070213318A1 (en) | 2005-09-22 | 2007-03-07 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US6779908A Continuation-In-Part | 2005-09-22 | 2008-07-02 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/861,134 Division US9763953B2 (en) | 2005-09-22 | 2013-04-11 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090253654A1 true US20090253654A1 (en) | 2009-10-08 |
Family
ID=41133822
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/422,901 Abandoned US20090253654A1 (en) | 2005-09-22 | 2009-04-13 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US13/861,134 Active 2026-12-01 US9763953B2 (en) | 2005-09-22 | 2013-04-11 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US15/699,626 Active US10265325B2 (en) | 2005-09-22 | 2017-09-08 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/861,134 Active 2026-12-01 US9763953B2 (en) | 2005-09-22 | 2013-04-11 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US15/699,626 Active US10265325B2 (en) | 2005-09-22 | 2017-09-08 | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
Country Status (1)
Country | Link |
---|---|
US (3) | US20090253654A1 (en) |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090186832A1 (en) * | 2008-01-18 | 2009-07-23 | Shire Llc | Amino acid peptide pro-drugs of phenolic analgesics and uses thereof |
US20110098278A1 (en) * | 2009-07-23 | 2011-04-28 | Shire Llc | Galantamine amino acid and peptide prodrugs and uses thereof |
WO2014016430A1 (en) * | 2012-07-27 | 2014-01-30 | Neurodyn Life Sciences Inc. | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
WO2015148487A1 (en) * | 2014-03-25 | 2015-10-01 | Synaptec Development Llc | Treatment of autism |
WO2015148480A1 (en) | 2014-03-25 | 2015-10-01 | Emicipi Llc | Treatment of rett syndrome |
US9763953B2 (en) | 2005-09-22 | 2017-09-19 | Neurodyn Life Sciences Inc. | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US20190262352A1 (en) * | 2012-07-27 | 2019-08-29 | Neurodyn Life Sciences Inc. | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
EP4029867A1 (en) | 2021-01-13 | 2022-07-20 | Alpha Cognition Inc. | Solid forms of galantamine benzoate gluconate |
EP4186509A1 (en) | 2021-11-26 | 2023-05-31 | Alpha Cognition Inc. | Alpha-1062 for treating traumatic brain injury |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11344220B2 (en) | 2016-05-13 | 2022-05-31 | Becton, Dickinson And Company | Invasive medical device cover with magnet |
US10032552B2 (en) | 2016-08-30 | 2018-07-24 | Becton, Dickinson And Company | Cover for tissue penetrating device with integrated magnets and magnetic shielding |
US10403016B2 (en) | 2017-06-02 | 2019-09-03 | Apple Inc. | Face syncing in distributed computing environment |
WO2020012245A1 (en) | 2018-07-13 | 2020-01-16 | Alkermes Pharma Ireland Limited | Thienothiophene-naltrexone prodrugs for long-acting injectable compositions |
WO2020012248A1 (en) | 2018-07-13 | 2020-01-16 | Alkermes Pharma Ireland Limited | Novel naphthylenyl compounds for long-acting injectable compositions and related methods |
WO2020094634A1 (en) | 2018-11-05 | 2020-05-14 | Alkermes Pharma Ireland Limited | Thiophene prodrugs of naltroxene for long-acting injectable compositions and related methods |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150354A (en) * | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
US20030162770A1 (en) * | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
US6638925B2 (en) * | 1996-04-19 | 2003-10-28 | Sanochemia Ltd. | Benzazepine derivatives, medicaments containing the same and their use to prepare medicaments |
US20040266659A1 (en) * | 2003-06-27 | 2004-12-30 | Stephen LaBerge | Substances that enhance recall and lucidity during dreaming |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE411026T1 (en) | 1987-05-04 | 2008-10-15 | Bonnie Davis | AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
US4981849A (en) | 1989-02-23 | 1991-01-01 | Smithkline Beecham Corporation | Alpha-adrenergic receptor antagonists |
EP0515301A3 (en) | 1991-05-14 | 1993-06-16 | Ernir Snorrason | Improvements in benzodiazepine treatment by cholinesterterase inhibitors |
IT1248059B (en) * | 1991-06-14 | 1995-01-05 | Miat Spa | MULTI-DOSE INSUFFLATOR FOR POWDER DRUGS |
US6323195B1 (en) | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
US6323196B1 (en) | 1993-10-15 | 2001-11-27 | Aventis Pharmaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
US6316439B1 (en) | 1993-10-15 | 2001-11-13 | Aventis Pharamaceuticals Inc. | Galanthamine derivatives as acetylcholinesterase inhibitors |
AU8742198A (en) | 1997-08-15 | 1999-03-08 | Shire International Licensing B.V. | Use of cholinesterase inhibitor for treating diseases associated with pro teolytic enzyme activity |
AU1282099A (en) | 1997-10-29 | 1999-05-17 | Bonnie M. Davis | Method for treatment of disorders of attention |
WO2000030446A1 (en) | 1998-11-23 | 2000-06-02 | Bonnie Davis | Dosage formulations for acetylcholinesterase inhibitors |
AU1430099A (en) | 1998-12-01 | 2000-06-19 | Sanochemia Pharmazeutika Aktiengesellschaft | Use of galanthamine and galanthamine derivatives in the case of acute functionalbrain damage |
WO2000033840A1 (en) | 1998-12-11 | 2000-06-15 | Bonnie Davis | Use of acetylcholinesterase inhibitors on the modulation of the hypothalamic-pituitary-gonadal axis |
US6670356B2 (en) | 1999-12-10 | 2003-12-30 | Bonnie Davis | Analogs of galanthamine and lycoramine as modulators of nicotinic receptors |
DE50101827D1 (en) | 2000-03-31 | 2004-05-06 | Sanochemia Pharmazeutika Ag Wi | NEW DERIVATIVES AND ANALOGA OF GALANTHAMINE |
JP4721386B2 (en) | 2001-07-10 | 2011-07-13 | 第一三共株式会社 | New galantamine analogs |
DE10235556A1 (en) | 2002-08-03 | 2004-02-19 | Hf Arzneimittelforschung Gmbh | Medicament for treating substance cravings, especially alcohol and/or tobacco abuse, comprising separate dosage forms for continuous release of nicotinic receptor modulator and rapid delivery of galanthamine |
US20050026979A1 (en) * | 2003-07-31 | 2005-02-03 | Maha Ghazzi | Methods for treating inflammation and inflammation-associated diseases with a statin and ether |
GB0322140D0 (en) * | 2003-09-22 | 2003-10-22 | Pfizer Ltd | Combinations |
US7307162B2 (en) | 2003-09-26 | 2007-12-11 | Scinopharm Taiwan, Ltd. | Resolution of a narwedine amide derivative |
CA2506282A1 (en) | 2003-09-29 | 2005-04-07 | Sanochemia Pharmazeutika Ag | Use of galanthamine and the derivatives thereof in the production of medicaments |
AT414125B (en) | 2003-09-29 | 2006-09-15 | Sanochemia Pharmazeutika Ag | NEW DERIVATIVES OF 4A, 5,9,10,11,12-HEXAHYDRO-BENZOFURO (3A, 3,2) (2) BENZAZEPINE, PROCESS FOR THE PRODUCTION THEREOF AND THEIR USE FOR THE PRODUCTION OF MEDICAMENTS |
WO2005041979A1 (en) | 2003-10-30 | 2005-05-12 | University Of South Florida | Modulation of microglial by nicotinic medications |
US20050222123A1 (en) | 2004-01-27 | 2005-10-06 | North Shore-Long Island Jewish Research Institute | Cholinesterase inhibitors for treating inflammation |
WO2005074535A2 (en) | 2004-01-30 | 2005-08-18 | Eisai Co., Ltd. | Cholinesterase inhibitors for spinal cord disorders |
EP1777222A1 (en) | 2005-09-22 | 2007-04-25 | Galantos Pharma GmbH | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US20090253654A1 (en) | 2005-09-22 | 2009-10-08 | Galantos Pharma Gmbh | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
CN104507461A (en) | 2012-07-27 | 2015-04-08 | 神经动力生命科学公司 | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
-
2009
- 2009-04-13 US US12/422,901 patent/US20090253654A1/en not_active Abandoned
-
2013
- 2013-04-11 US US13/861,134 patent/US9763953B2/en active Active
-
2017
- 2017-09-08 US US15/699,626 patent/US10265325B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6150354A (en) * | 1987-01-15 | 2000-11-21 | Bonnie Davis | Compounds for the treatment of Alzheimer's disease |
US6638925B2 (en) * | 1996-04-19 | 2003-10-28 | Sanochemia Ltd. | Benzazepine derivatives, medicaments containing the same and their use to prepare medicaments |
US20030162770A1 (en) * | 2002-02-22 | 2003-08-28 | Davis Bonnie M. | Use of modulators of nicotinic receptors for treatment of cognitive dysfunction |
US20040266659A1 (en) * | 2003-06-27 | 2004-12-30 | Stephen LaBerge | Substances that enhance recall and lucidity during dreaming |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10265325B2 (en) | 2005-09-22 | 2019-04-23 | Neurodyn Life Sciences Inc. | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US9763953B2 (en) | 2005-09-22 | 2017-09-19 | Neurodyn Life Sciences Inc. | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment |
US20090186832A1 (en) * | 2008-01-18 | 2009-07-23 | Shire Llc | Amino acid peptide pro-drugs of phenolic analgesics and uses thereof |
US20090192095A1 (en) * | 2008-01-18 | 2009-07-30 | Shire Llc | Amino acid and peptide prodrugs of opioid analgesics with reduced gi side-effects |
US20110098278A1 (en) * | 2009-07-23 | 2011-04-28 | Shire Llc | Galantamine amino acid and peptide prodrugs and uses thereof |
US20150190401A1 (en) * | 2012-07-27 | 2015-07-09 | Neurodyn Life Sciences Inc. | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
CN108245522A (en) * | 2012-07-27 | 2018-07-06 | 神经动力生命科学公司 | Application of the GLN-1062 salt in drug of the treatment with the relevant cerebral disease of cognitive disorder is prepared |
US11077119B2 (en) | 2012-07-27 | 2021-08-03 | Neurodyn Life Sciences Inc. | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
AU2013294917B2 (en) * | 2012-07-27 | 2016-12-15 | Neurodyn Life Sciences Inc. | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
US20190262352A1 (en) * | 2012-07-27 | 2019-08-29 | Neurodyn Life Sciences Inc. | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
WO2014016430A1 (en) * | 2012-07-27 | 2014-01-30 | Neurodyn Life Sciences Inc. | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
CN104507461A (en) * | 2012-07-27 | 2015-04-08 | 神经动力生命科学公司 | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
EP3417862A1 (en) * | 2012-07-27 | 2018-12-26 | Neurodyn Life Sciences Inc. | Enhanced brain bioavailability of galantamine by selected formulations and transmucosal administration of lipophilic prodrugs |
US20170173038A1 (en) * | 2014-03-25 | 2017-06-22 | Synaptec Development Llc | Treatment of autism |
EP3122187A4 (en) * | 2014-03-25 | 2017-11-15 | Emicipi LLC | Treatment of rett syndrome |
US20170182058A1 (en) * | 2014-03-25 | 2017-06-29 | Emicipi Llc | Treatment of rett syndrome |
WO2015148487A1 (en) * | 2014-03-25 | 2015-10-01 | Synaptec Development Llc | Treatment of autism |
US10561665B2 (en) * | 2014-03-25 | 2020-02-18 | Synaptec Development Llc | Treatment of autism |
WO2015148480A1 (en) | 2014-03-25 | 2015-10-01 | Emicipi Llc | Treatment of rett syndrome |
EP4029867A1 (en) | 2021-01-13 | 2022-07-20 | Alpha Cognition Inc. | Solid forms of galantamine benzoate gluconate |
EP4186509A1 (en) | 2021-11-26 | 2023-05-31 | Alpha Cognition Inc. | Alpha-1062 for treating traumatic brain injury |
Also Published As
Publication number | Publication date |
---|---|
US20180008613A1 (en) | 2018-01-11 |
US20130210808A1 (en) | 2013-08-15 |
US10265325B2 (en) | 2019-04-23 |
US9763953B2 (en) | 2017-09-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10265325B2 (en) | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment | |
EP1940817B1 (en) | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment | |
EP2324002B1 (en) | Processes for the preparation of sglt2 inhibitors | |
KR102072850B1 (en) | Benzimidazole Derivatives as Bromodomain Inhibitors | |
KR101982912B1 (en) | Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof | |
US11358932B2 (en) | N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors | |
CN116075499A (en) | Novel dephosphorylated galectin derivatives with prodrug properties | |
US20220071971A1 (en) | Macrocyclic compounds and their use in the treatment of disease | |
SA05260119B1 (en) | Indole derivative having piperidine ring | |
EP2137192B1 (en) | Derivatives of galantamine as pro-drugs for the treatment of human brain diseases | |
CN111295372A (en) | Nitroxoline prodrugs and uses thereof | |
RU2241001C2 (en) | Derivatives of galanthamine, method for their preparing, medicinal agent based on thereof and method for its preparing | |
US10233175B2 (en) | Pyridinium compounds | |
WO2017031041A1 (en) | Functionalized aminobenzoboroxoles | |
US7112593B2 (en) | N-aryl-substituted cyclic amine derivative and medicine containing the same as active ingredient | |
US8378112B2 (en) | Glycyrrhetinic acid derivative and use thereof | |
US20240043387A1 (en) | Substituted 3-dialkylaminomethyl-piperidin-4-yl-benzamides and methods of making and using same | |
CN111372936A (en) | Mcl-1 selective inhibitors, their preparation and use | |
US20070213318A1 (en) | Cholinergic enhancers with improved blood-brain barrier permeability for the treatment of diseases accompanied by cognitive impairment | |
JP2009508903A (en) | Cholinergic enhancer with improved cerebral blood barrier permeability for use in the treatment of diseases associated with cognitive impairment | |
US20190292150A1 (en) | Ido-tdo dual inhibitor and related methods of use | |
RU2804139C2 (en) | Macrocyclic compounds and their use in the treatment of disease | |
US11766443B2 (en) | Cyclopentathiophene carboxamide derivatives as platelet activating factor receptor antagonists | |
JPS59167598A (en) | C-20- and c-23-modified macrolide derivatives | |
WO2022253316A1 (en) | Quinoxaline derivative, preparation therefor and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GALANTOS PHARMA GMBH, GERMANY Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MAELICKE, ALFRED;REEL/FRAME:023076/0166 Effective date: 20090702 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |